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1. Collagen 
The collagen superfamily is the most considerable group of organic 
macromolecules in the human body, accounting for about 30% of the protein mass. 
These extracellular matrix proteins are present in essentially all tissues and organs, in 
which they fulfill important mechanical functions because of the tensile strength of the 
fibrils, and regulate remodeling during growth, differentiation, and tissue repair by the 
dynamic interaction with the surrounding cells. In addition, collagen regulates cell 
behavior by the entrapment/delivery of growth factors and cytokines. Vertebrates have 
at least 27 collagen types, encoded by 42 genes.(1) On the basis of their mode of 
assembly and structural features the collagen superfamily is subdivided into the following 
subfamilies: fibril-forming collagens, fibril-associated collagens (FACIT), and non-fibril-
forming collagens (Figure 1).  
 
Figure 1. Collagen superfamily. The collagen superfamily is subdivided on the basis of their 
assembly mode and domain structure. This illustration is modified and updated from refs (1;2). 
Chapter 1 
10 
A common characteristic of the collagen molecule is the right-handed triple helix 
composed of three alpha chains, and depending on the collagen type, the collagen 
molecule is either composed of three identical α-chains (homotrimers) or of two or 
three different α-chains (heterotrimers). A structural prerequisite for the formation of 
the triple helix is the presence of the small amino acid glycine (Gly) in every third 
position of the polypeptide chain, resulting in a (Gly-X-Y)n repeat. The X and Y position 
can have any amino acid, but is often occupied by a proline or a hydroxyproline.(2-4)  
About 90% of the total collagen mass is represented by the fibril-forming collagens: 
e.g. type I, II, III, V, XI, XXIV, and XXVII. Collagen type I is the best studied collagen 
type, and has been found to be the major component of most connective tissues, 
including skin, tendon, ligament, cornea, blood vessels, bone, and dentin. In its mature 
form it consists, like the other fibrillar collagens, of three domains: a short amino-
terminal non-triple helical domain (N-telopeptide), a long central uninterrupted triple 
helical domain, and a short carboxy-terminal non-triple helical domain (C-telopeptide; 
Figure 2). Collagen type I is mainly present in a heterotrimeric form composed of two 
α1 chains and one α2 chain [α1(I)]2α2(I), but the homotrimeric form [α1(I)]3 does exist 
in minor amounts.(3;4)  
 
Figure 2. Schematic representation of a fibrillar procollagen molecule. Procollagen is composed 
of an N-propeptide, an N-terminal telopeptide, a helical domain, a C-terminal telopeptide, and 
a C-propeptide. 
2. Biosynthesis of collagen  
The biosynthesis of collagen starts with the transcription of the gene within the cell 
nucleus, followed by translation into pre-pro-α-chains. Collagen type I α1- and α2-
chains are encoded by two separate genes: COL1A1 and COL1A2, which are localized on 
chromosome 17q21.3-q22.1 and 7q22.1, respectively.(5;6) The nascent pre-pro-α-chains 
protrude after translation from the ribosomal-bound collagen mRNA into the lumen of 
the rough endoplasmic reticulum (RER) with the help of signal recognition particles and 
receptors. After removal of the signal peptide by a signal peptidase, the procollagen α-
chains undergo multiple post-translational modifications, including hydroxylation of 
specific proline and lysine residues, and glycosylation of hydroxylysine residues  
(Figure 3). 
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Figure 3. Collagen biosynthesis. Collagen is synthesized as pre-pro-α-chains (1). Following 
translocation into the RER, the signal peptides are removed and the individual procollagen α-
chains will associate through the C-propeptides. After multiple steps of post-translational 
modifications, which include the hydroxylation of specific lysine (Lys) and proline (Pro) residues 
as well as the glycosylation of hydroxylysyl residues (2), the triple helix propagates from the C- 
to N-terminus. The procollagen is excreted and is converted extracellularly into collagen by 
cleaving the propeptides (3). Subsequently, collagen molecules assembly into ordered fibrils (4), 
which are finally stabilized by the formation of inter- and/or intramolecular cross-links (5).  
In the RER the individual α-chains will associate through the C-propeptides and 
during and/or after the various enzymatic modifications the triple helix is propagated 
from the C-terminus to the N-terminus in a zipper-like fashion. The procollagen is 
packaged within the Golgi compartment into secretory vesicles and transported outside 
the cell. In the extracellular space, the procollagen is converted to collagen by removing 
the C- and N-propeptides, a step catalyzed by C- and N-proteinase, respectively  
(EC 3.4.24).(7) The collagen molecule has a marked tendency for self-assembly and after 
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the removal of the propeptides it spontaneously aggregates into ordered fibrillar 
structures. The molecular arrangement into fibrils is finally stabilized by the formation of 
covalent cross-links.(3;4;8;9)  
The highly complex folding and assembly of collagens requires the coordinated 
action of molecular chaperones. A collagen-specific chaperone is heat shock protein 47 
(HSP47), which binds to procollagen α-chains.(10;11) HSP-47 is involved in the translation 
and translocation of the procollagen into the RER, and moreover, it facilitates the 
correct folding of the α-chains into triple helices.(12) Homozygous knockout of HSP47 in 
mice is lethal at the embryonic stage, indicating that this protein is essential for normal 
development.(13)  
3. Enzymes involved in post-translational modifications  
Collagens and a few other proteins with collagen-like amino acid sequences are 
subjected to some unique post-translational modifications which involve specific 
enzymes. Hydroxylation of proline (Pro) residues at the Pro-Y-Gly (3-hydroxyproline) 
and X-Pro-Gly (4-hydroxyproline) position is catalyzed by prolyl 3-hydroxylase (EC 
1.14.11.7) and prolyl 4-hydroxylase (EC 1.14.11.2), respectively.(14-16) It appears that 
different isoenzymes of collagen prolyl 3-hydroxylase and prolyl 4-hydroxylase exist, but 
the exact function of these isoenzymes has not been unraveled.(17;18) 4-Hydroxyproline 
stabilizes the triple helical conformation by providing hydrogen bonds and water bridges 
and the presence of 4-hydroxyproline is needed to render the collagen triple helix 
stable at body temperature. Underhydroxylation of proline residues results in a non-
functional collagen molecule with a weakened triple helix that can easily be 
degraded.(9;19) The function of 3-hydroxyproline has not been deciphered so far. There is 
hardly any variation in the level of prolyl hydroxylation within a specific collagen type: 
the hydroxylation level of each fibrillar collagen appears to be close to maximum.  
The hydroxylation of lysine residues within the triple helix as well as the N- and C-
telopeptides is catalyzed by lysyl hydroxylases (EC 1.14.11.4).(3;9;15) Within the collagen 
triple helix, lysyl hydroxylation occurs exclusively at the Y position in the Gly-X-Y 
repeat: a lysine residue at the X position is not hydroxylated. Collagen telopeptides do 
not have such a repetitive sequence and the hydroxylated lysine residue is embedded in 
an entirely different amino acid sequence. The extent of lysyl hydroxylation in collagen 
type I differs between tissues and is much more variable than hydroxylation of proline 
residues.(20) The presence of hydroxylysine residues within the collagen α-chains has two 
chemical functions: (i) the hydroxyl group acts as the site of attachment of carbohydrate 
units, and (ii) it is a critical determinant for covalent intermolecular cross-linking.  
The formation of hydroxylysine-linked carbohydrate units is catalyzed by two 
specific reactions: the transfer of galactose to some of the hydroxylysine residues and 
the transfer of glucose to some of the galactosylhydroxylysine residues. It was formerly 
believed that these reactions were catalyzed by two different enzymes (hydroxylysyl-
galactosyltransferase and galactosylhydroxylysyl-glucosyltransferase), but recent data 
indicate that a single enzyme is involved (see below). The functions of the hydroxylysine-
linked carbohydrate units are largely unknown. As the units are the most extrusive 
groups on the surface of the collagen molecule, they may regulate the packing of the 
collagen molecules into fibrils.(9)  
General introduction 
13 
3.1. Lysyl hydroxylases 
Lysyl hydroxylase is one of the post-translational modification enzymes in the RER 
and catalyzes the conversion of a lysine residue into a hydroxylysine residue within the 
collagen triple helix and telopeptides. For this reaction lysyl hydroxylase requires Fe2+, 
2-oxoglutarate, O2, and ascorbate.
(9;15) The first isolation and purification of the lysyl 
hydroxylase enzyme was from chick embryo extracts,(21-23) and several years later, 
human lysyl hydroxylase was purified from fetal and placental tissue.(24) Currently, three 
isoforms of lysyl hydroxylase, namely lysyl hydroxylase 1 (LH1), LH2, and LH3, have 
been identified in human,(25-28) mouse,(29;30) and rat,(31;32) which are encoded by 
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1), PLOD2, and PLOD3, 
respectively. Human PLOD genes have been assigned to chromosome 1p36.2-36.3 
(PLOD1),(33) 3q23-24 (PLOD2),(34) and 7q22 (PLOD3),(35) but the exon/intron organization 
has only been described for PLOD1 and PLOD3. The genes have a size of about 40 and 
11.6 kb and consist of 19 exons and 18 introns, respectively.(36;37) The exons of human 
PLOD1 and PLOD3 are well conserved with respect to length. In contrast, the length of 
the introns differs between both genes: the introns of PLOD3 are markedly shorter in 
comparison to the introns of PLOD1. The exon/intron organization of PLOD2 has not 
been described, but analysis of two clones RP11-758I14 and RP11-274H2, together 
comprising the whole PLOD2 gene, demonstrates that PLOD2 consists of 20 exons and 
19 introns. The 19 corresponding exons of PLOD2 are of similar length to the exons of 
PLOD1 and PLOD3.  
So far, very little is known about the promoter regions of the different PLOD 
genes. It appears that the proximal promoter of human PLOD1 and mouse PLOD2 
contains several PITX2 binding elements. PITX2 is a paired-bicoid homeobox gene and 
patients suffering from Rieger syndrome, a connective tissue disease, are found to have 
mutations in PITX2. Mutant PITX2 fail to induce PLOD1 transcription in vitro, showing 
the relevance of PITX2 in regulating PLOD1 transcription.(38)  
PLOD2 mRNA is alternatively spliced, resulting in the splice variants LH2a and 
LH2b. LH2b contains an extra splice insert of 63 bp, corresponding to 21 amino acids. 
This extra insert is encoded by exon 13A, which is located between exon 13 and 
14.(39;40) Alternative splicing has not been found for the other PLOD genes. 
The four human lysyl hydroxylase isoforms LH1, LH2a, LH2b, and LH3 exist as 
homodimers and the processed polypeptides (including the signal peptide) contain 727, 
737, 758, and 738 amino acid residues, respectively (Figure 4).(41-45) The signal peptide of 
each polypeptide is present at the N-terminus and has a respective length of 18 (LH1), 
25 (LH2a and LH2b) or 24 (LH3) amino acids. Lysyl hydroxylase isoforms seem to have 
a novel retention/retrieval mechanism for their localization on the luminal side of the 
RER membrane as they do not contain any of the motifs found in other RER-resident 
proteins. Recent observations suggest that a 40 amino acid sequence at the C-terminus 
of LH1 possesses most of the targeting information needed to localize LH1 in the RER 
lumen.(46;47)  
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LH1 1 M R P L L L L A L L G W L L L A E A K G D A K P E D N L L V L T V A T K E T E
LH2a 1 M G G C T V K P Q L L L L A L V L H P W N P C L G A D S E K P S S I P T D K L L V I T V A T K E S D
LH2b 1 M G G C T V K P Q L L L L A L V L H P W N P C L G A D S E K P S S I P T D K L L V I T V A T K E S D
LH3 1 M T S S G P G P R F L L L L P L L L P P A A S A S D R P R G R D P V N P E K L L V I T V A T A E T E
LH1 40 G F R R F K R S A Q F F N Y K I Q A L G L G E D W N V E K G T S A G G G Q K V R L L K K A L E K H
LH2a 51 G F H R F M Q S A K Y F N Y T V K V L G Q G E E W R G G D G I N S I G G G Q K V R L M K E V M E H Y
LH2b 51 G F H R F M Q S A K Y F N Y T V K V L G Q G E E W R G G D G I N S I G G G Q K V R L M K E V M E H Y
LH3 51 G Y L R F L R S A E F F N Y T V R T L G L G E E W R G G D V A R T V G G G Q K V R W L K K E M E K Y
LH1 89 A D K E D L V I L F T D S Y D V L F A S G P R E L L K K F R Q A R S Q V V F S A E E L I Y P D R R L
LH2a 101 A D Q D D L V V M F T E C F D V I F A G G P E E V L K K F Q K A N H K V V F A A D G I L W P D K R L
LH2b 101 A D Q D D L V V M F T E C F D V I F A G G P E E V L K K F Q K A N H K V V F A A D G I L W P D K R L
LH3 101 A D R E D M I I M F V D S Y D V I L A G S P T E L L K K F V Q S G S R L L F S A E S F C W P E W G L
LH1 139 E T K Y P V V S D G K R F L G S G G F I G Y A P N L S K L V A E W E G Q D S D S D Q L F Y T K I F L
LH2a 151 A D K Y P V V H I G K R Y L N S G G F I G Y A P Y V N R I V Q Q W N L Q D N D D D Q L F Y T K V Y I
LH2b 151 A D K Y P V V H I G K R Y L N S G G F I G Y A P Y V N R I V Q Q W N L Q D N D D D Q L F Y T K V Y I
LH3 151 A E Q Y P E V G T G K R F L N S G G F I G F A T T I H Q I V R Q W K Y K D D D D D Q L F Y T R L Y L
LH1 189 D P E K R E Q I N I T L D H R C R I F Q N L D G A L D E V V L K F E M G H V R A R N L A Y D T L P V
LH2a 201 D P L K R E A I N I T L D H K C K I F Q T L N G A V D E V V L K F E N G K A R A K N T F Y E T L P V
LH2b 201 D P L K R E A I N I T L D H K C K I F Q T L N G A V D E V V L K F E N G K A R A K N T F Y E T L P V
LH3 201 D P G L R E K L S L N L D H K S R I F Q N L N G A L D E V V L K F D R N R V R I R N V A Y D T L P I
LH1 239 L I H G N G P T K L Q L N Y L G N Y I P R F W T F E T G C T V C D E G L R S L K G I G D E A L P T V
LH2a 251 A I N G N G P T K I L L N Y F G N Y V P N S W T Q D N B C T L C E F D T V D L S A V D V H P N V
LH2b 251 A I N G N G P T K I L L N Y F G N Y V P N S W T Q D N B C T L C E F D T V D L S A V D V H P N V
LH3 251 V V H G N G P T K L Q L N Y L G N Y V P N G W T P E G G C G F C N Q D R R T L P G G Q P P P R V
LH1 289 L V G V F I E Q P T P F V S L F F Q R L L R L H Y P Q K H M R L F I H N H E Q H H K A Q V E E F L A
LH2a 299 S I G V F I E Q P T P F L P R F L D I L L T L D Y P K E A L K L F I H N K E V Y H E K D I K V F F D
LH2b 299 S I G V F I E Q P T P F L P R F L D I L L T L D Y P K E A L K L F I H N K E V Y H E K D I K V F F D
LH3 299 F L A V F V E Q P T P F L P R F L Q R L L L L D Y P P D R V T L F L H N N E V F H E P H I A D S W P
LH1 339 Q H G S E Y Q S V K L V G P E V R M A N A D A R N M G A D L C R Q D R S C T Y Y F S V D A D V A L T
LH2a 349 K A K H E I K T I K I V G P E E N L S Q A E A R N M G M D F C R Q D E K C D Y Y F S V D A D V V L T
LH2b 349 K A K H E I K T I K I V G P E E N L S Q A E A R N M G M D F C R Q D E K C D Y Y F S V D A D V V L T
LH3 349 Q L Q D H F S A V K L V G P E E A L S P G E A R D M A M D L C R Q D P E C E F Y F S L D A D A V L T
LH1 389 E P N S L R L L I Q Q N K N V I A P L M T R H G R L W S N F W G A L S A D G Y Y A R S E D Y V D I V
LH2a 399 N P R T L K I L I E Q N R K I I A P L V T R H G K L W S N F W G A L S P D G Y Y A R S E D Y V D I V
LH2b 399 N P R T L K I L I E Q N R K I I A P L V T R H G K L W S N F W G A L S P D G Y Y A R S E D Y V D I V
LH3 399 N L Q T L R I L I E E N R K V I A P M L S R H G K L W S N F W G A L S P D E Y Y A R S E D Y V E L V
LH1 439 Q G R R V G V W N V P Y I S N I Y L I K G S A L R G E L Q S S D L F H H S K L D P D M A F C A N I R
LH2a 449 Q G N R V G V W N V P Y M A N V Y L I K G K T L R S E M N E R N Y F V R D K L D P D M A L C R N A R
LH2b 449 Q G N R V G V W N V P Y M A N V Y L I K G K T L R S E M N E R N Y F V R D K L D P D M A L C R N A R
LH3 449 Q R K R V G V W N V P Y I S Q A Y V I R G D T L R M E L P Q R D V F S G S D T D P D M A F C K S F R
LH1 489 Q Q D V F M F L T N R H T L G H L L S L D S Y R T T H L H
LH2a 499 E M G V F M Y I S N R H E F G R L L S T A N Y N T S H Y N
LH2b 499 E M T L Q R E K D S P T P E T F Q M L S P P K G V F M Y I S N R H E F G R L L S T A N Y N T S H Y N
LH3 499 D K G I F L H L S N Q H E F G R L L A T S R Y D T E H L H
LH1 518 N D L W E V F S N P E D W K E K Y I H Q N Y T K A L A G K L V E T P C P D V Y W F P I F T E V A C
LH2a 528 N D L W Q I F E N P V D W K E K Y I N T D Y S K I F T E N I V E Q P C P D V F W F P I F S E K A C
LH2b 549 N D L W Q I F E N P V D W K E K Y I N T D Y S K I F T E N I V E Q P C P D V F W F P I F S E K A C
LH3 528 P D L W Q I F D N P V D W K E Q Y I H E N Y S R A L E G E G I V E Q P C P D V Y W F P L L S E Q M C
LH1 567 D E L V E E M E H F G Q W S L G N N K D N R I Q G G Y E N V P T I D I H M N Q I G F E R E W H K F L
LH2a 577 D E L V E E M E H Y G K W S G G K H H D S R I S G G Y E N V P T D D I H M K Q V D L E N V W L H F I
LH2b 598 D E L V E E M E H Y G K W S G G K H H D S R I S G G Y E N V P T D D I H M K Q V D L E N V W L H F I
LH3 578 D E L V A E M E H Y G Q W S G G R H E D S R L A G G Y E N V P T V D I H M K Q V G Y E D Q W L Q L L
LH1 617 L E Y I A P M T E K L Y P G Y Y T R A Q F D L A F V V R Y K P D E Q P S L M P H H D A S T F T I N I
LH2a 627 R E F I A P V T L K V F A G Y Y T K G F A L L N F V V K Y S P E R Q R S L R P H H D A S T F T I N I
LH2b 648 R E F I A P V T L K V F A G Y Y T K G F A L L N F V V K Y S P E R Q R S L R P H H D A S T F T I N I
LH3 628 R T Y V G P M T E S L F P G Y H T K A R A V M N F V V R Y R P D E Q P S L R P H H D S S T F T L N V
LH1 667 A L N R V G V D Y E G G G C R F L R Y N C S I R A P R K G W T L M H P G R L T H Y H E G L P T T R G
LH2a 677 A L N N V G E D F Q G G G C K F L R Y N C S I E S P R K G W S F M H P G R L T H L H E G L P V K N G
LH2b 698 A L N N V G E D F Q G G G C K F L R Y N C S I E S P R K G W S F M H P G R L T H L H E G L P V K N G
LH3 678 A L N H K G L D Y E G G G C R F L R Y D C V I S S P R K G W A L L H P G R L T H Y H E G L P T T W G
LH1 717 T R Y I A V S F V D P
LH2a 727 T R Y I A V S F I D P
LH2b 748 T R Y I A V S F I D P
LH3 728 T R Y I M V S F V D P
Figure 4. Amino acid sequences of the four lysyl hydroxylase isoforms LH1, LH2a, LH2b, and 
LH3. The respective polypeptides including signal peptide (shown in boldfaced and italic type) 
contain 727 (LH1), 737 (LH2a), 758 (LH2b), 738 (LH3) amino acids. The gray regions show 
the identity of LH1, LH2 (LH2a and LH2b), and LH3 sequences. Potential asparagine (N)-
glycosylation sites are boxed and shown in boldfaced type. Black letters on a dark gray 
background represent the two conserved histidine (H) and aspartate (D) residues required for 
the binding of Fe2+ to the catalytic site, and the conserved arginine (R) residue that binds the 
C5 carboxyl group of 2-oxoglutarate.  
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Table 1: Expression of lysyl hydroxylase isoforms: LH1, LH2a, LH2b, LH3.(35;48-52) 
 LH1 LH2a LH2b LH3 
Tissues     
Adrenal gland n.d n.d n.d +/- 
Aorta n.d - + n.d 
Bone marrow n.d n.d n.d +/- 
Brain n.d +* +/- 
Cartilage n.d - + n.d 
Chorionic villus n.d +/- + n.d 
Dura n.d - + n.d 
Frontal lobe n.d + + n.d 
Heart n.d ++* ++ 
Kidney n.d ++ + + 
Liver n.d + + + 
Lung n.d - ++ + 
Lymph node n.d n.d n.d +/- 
Pancreas n.d ++* ++ 
Placenta n.d + ++ ++ 
Skeletal muscle n.d +/-* + 
Skin n.d - + n.d 
Spinal cord n.d n.d n.d ++ 
Spleen n.d + + n.d 
Stomach n.d n.d n.d +/- 
Thyroid n.d n.d n.d + 
Trachea n.d n.d n.d +/- 
Cells     
Epitheloid carcinoma: HeLa + +* + 
Fibrosarcoma: HT1080 + ++* + 
Hepatoblastoma: HepG2 ++ ++* + 
JAR727 + +* + 
Lung cells + +* + 
Osteoblasts: MC3T3-E1 + - + + 
Osteosarcoma: MG-63 ++ ++* +/- 
Pancreas adenocarcinoma + +/-* + 
Renal adenocarcinoma + +* + 
Skin fibroblasts ++ +* + 
n.d, not determined; * means LH2 expression, not distinguished between LH2a and LH2b; - not present; +/- expression 
very low; + intermediate expression; ++ strong expression 
A comparison of the lysyl hydroxylase amino acid sequences demonstrates that the 
sequence identity between LH1 and LH2 is 75% and between LH1 and LH3 is 59%. The 
sequences of LH2 and LH3 show 57% similarity (Figure 4).(53;54) The C-terminal region, 
which is important for the catalytic properties of the enzyme, exhibits the highest 
degree of identity between the four lysyl hydroxylase isoforms, whereas the N-terminal 
region shows less identity. It has been suggested that the N-terminal region does not 
serve important functions in the catalytic activity of the enzyme as a mutant LH1 protein 
lacking a 30kDa N-terminal fragment is fully active.(55) Site-directed mutagenesis 
demonstrated that in LH1 an arginine residue at position 718 is the positively charged 
residue that binds the C5 carboxyl group of 2-oxoglutarate.(56) Moreover, two histidine 
residues at position 656 and 708 of LH1 and an aspartate residue at position 658 
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provide the three ligands required for the binding of Fe2+ to the catalytic site.(57) These 
arginine, aspartate, and histidine residues are conserved in the sequences of LH2a, LH2b 
and LH3. It is therefore likely that these residues fulfill similar functions in these lysyl 
hydroxylases.  
All four isoforms have potential attachment sites for asparagine-linked 
oligosaccharide and there is evidence that glycosylation of asparagine residues is 
required for enzymatic activity.(58;59) A conserved glycosylation site within the four 
isoforms has not been observed and the number of putative sites differs between LH1 
(4 sites), LH2a (seven sites), LH2b (seven sites), and LH3 (two sites). Mutation of the 
four asparagine sites within LH1 demonstrates that only two potential glycosylation sites 
(asparagine-197 and asparagine-538) are effectively glycosylated and mutation of only 
one of these two sites (asparagine-197) dramatically diminished enzyme activity.(60) So 
far, it has not been examined in detail which sites of the other lysyl hydroxylase 
isoforms are glycosylated.  
Lysyl hydroxylases are widely expressed throughout the body and the expression 
patterns of the different lysyl hydroxylase isoforms in several tissues and cell lines have 
extensively been studied by Northern Blot or regular PCR. As demonstrated in Table I, 
the expression patterns of the different isoforms vary between tissues and cell lines,(61-65) 
though, a decent quantitative study of LH1, LH2a, LH2b, and LH3 expression levels in 
several connective tissues has not been performed so far.  
Recently, in vitro studies on LH3 function revealed that this enzyme is 
multifunctional. Besides catalyzing lysyl hydroxylation reactions, it has been shown to 
catalyze sugar transfer reactions, enabling consecutive steps in the formation of 
glucosylgalactosylhydroxylysyl residues. The glucosyltransferase and galactosyltrans-
ferase activity, which was observed for LH3, has not been found for the other known 
lysyl hydroxylase isoforms, LH1, LH2a and LH2b.(66;67) 
3.2. Substrate specificity of lysyl hydroxylases 
LH1 was the first lysyl hydroxylase to be isolated, and until very recently, it was 
thought that this enzyme was capable of hydroxylating lysine residues within both the 
telopeptide and triple helical part of all collagen types. However, a close examination of 
two connective tissue diseases (Bruck syndrome and Ehlers-Danlos syndrome type VI), 
revealed that this is unlikely to be the case. Bruck syndrome (OMIM 259450) is an 
autosomal recessive disease, phenotypically characterized by osteopenia, joint 
contractures at birth, fragile bones, and short stature.(68-70) The biochemical defect 
underlying the Bruck syndrome phenotype is an affected collagen cross-linking in bone, 
due to a lack of hydroxylysines in the telopeptides,(71) but the genetic defect was at that 
time unknown. Ehlers-Danlos syndrome type VI (OMIM 225400) is characterized by soft 
hyperextensible skin, severe scoliosis, and joint hypermobility.(72;73) The biochemical 
abnormality of this autosomal recessive disease is a deficiency in lysyl hydroxylase 
activity and patients display mutations in PLOD1.(74;75) 
Interestingly, the hydroxylysine deficiency in Ehlers-Danlos syndrome type VI 
appears to be collagen type-specific: collagen type I and III in most tissues of Ehlers-
Danlos syndrome type VI patients are hydroxylysine-deficient, whereas collagen type II 
and V represent unaffected hydroxylysine levels.(76;77) From this the existence of collagen 
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type-specific lysyl hydroxylases can be deduced. The presence of collagen type-specific 
lysyl hydroxylase was further supported by the finding that lysyl hydroxylases extracted 
from normal fibroblasts preferentially hydroxylated collagen type I, whereas the residual 
lysyl hydroxylase activity of Ehlers-Danlos syndrome type VI fibroblasts preferred type 
VI collagen.(78)  
Further examination of Ehlers-Danlos syndrome type VI revealed differences in the 
hydroxylation state of collagen type I derived from various tissues: collagen type I in skin 
and bone was hydroxylysine-deficient, whereas the hydroxylation state of collagen type I 
in tendon, kidney and lungs was found to be less pronounced.(79) This indicates the 
existence of tissue-specific forms of collagen type-specific lysyl hydroxylases.  
Besides the collagen type-specific lysyl hydroxylases, it appears that the 
hydroxylation of lysine residues within the triple helix and the telopeptides is performed 
by different lysyl hydroxylases as well. This assumption is partially based on findings on 
collagen cross-linking in Bruck syndrome and Ehlers-Danlos syndrome type VI patients. 
The collagen deposited in Bruck syndrome bone has an almost complete absence of 
hydroxyallysine cross-links due to a strong reduction in hydroxylation of the collagen 
telopeptides. The hydroxylation state of the collagen triple helix is normal in Bruck 
syndrome bone.(80) Ehlers-Danlos syndrome type VI patients were found to have 
unaffected total pyridinoline cross-link levels in tissues, however, the cross-links showed 
decreased hydroxylysylpyridinoline and increased lysylpyridinoline levels due to reduced 
triple helical hydroxylysine levels.(81-84) Thus, Ehlers-Danlos syndrome type VI patients 
have, despite a deficiency in triple helical hydroxylysine, unaffected telopeptide 
hydroxylysine levels,(85) and Bruck syndrome patients have affected telopeptide lysyl 
hydroxylation, despite normal triple helical lysyl hydroxylation. Together, Bruck 
syndrome and Ehlers-Danlos syndrome type VI revealed that, in addition to a specific 
helical lysyl hydroxylase (LH1), a specific telopeptide lysyl hydroxylase must exist. The 
activity of such a telopeptide lysyl hydroxylase is affected in Bruck syndrome bone. 
Interestingly, the collagen deposited in cartilage and tendon of Bruck syndrome patients 
demonstrates normal telopeptide lysyl hydroxylation,(86) revealing the existence of 
tissue-specific telopeptide lysyl hydroxylases. 
Further support for the existence of a specific telopeptide lysyl hydroxylase was 
obtained from other studies as well, showing that in a variety of conditions changes in 
triple helical hydroxylation levels are not accompanied by changes in telopeptide lysyl 
hydroxylation and vice versa.(87-91) The most direct evidence was obtained from a study 
which demonstrates that a highly purified lysyl hydroxylase preparation, most likely 
containing LH1, failed to hydroxylate any lysine residues within the non-helical 
telopeptide, despite normal activity towards helical lysine residues.(92)  
Together, the biochemical changes due to a defective LH1 activity in Ehlers-Danlos 
syndrome type VI provide a better insight into the substrate specificity of LH1. It 
predominantly hydroxylates lysine residues within the triple helix of collagen type I and 
III in bone and skin. The substrate specificity of LH2 and LH3 towards lysine residues 
has not been elucidated so far, and diseases associated with LH2 or LH3 defects have 
not yet been discovered. Recently, a disturbed collagen type VI biosynthesis was 
observed in LH3 null mice and these mice appears to be embryonically lethal.(93) A close 
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examination of collagen hydroxylation levels in these null mice will probably give new 
insights into the substrate specificity of LH3 towards lysine residues. 
4. Enzymatic collagen cross-links 
Enzymatic collagen cross-linking is a final step in the biosynthesis of collagen and is 
essential for the physical and mechanical properties of the collagen fibrils. The formation 
of these cross-links starts with the oxidative deamination of the ε-amino group of 
specific lysine or hydroxylysine residues within the C- and N-terminal telopeptides, 
leading to the formation of reactive aldehydes. The conversion of lysine and 
hydroxylysine into the respective aldehydes allysine (Lysald) and hydroxyallysine (Hylald) is 
catalyzed through the action of lysyl oxidase (EC1.4.3.13). Lysyl oxidase is a copper-
dependent enzyme and belongs to the lysyl oxidase family consisting of one lysyl oxidase 
and four lysyl oxidase-like proteins. The function of the four lysyl oxidase-like proteins 
has not been elucidated so far.(94-96) Following the oxidative deamination, the reactive 
aldehyde condensates either with another aldehyde in the same molecule or with lysine, 
hydroxylysine, or histidine residues within the neighboring collagen molecules, in order 
to form intra- and/or intermolecular cross-links.  
The molecular cross-linking sites have been conserved within the fibrillar collagens. 
The collagen type I α1 chain has only four locations, one in each telopeptide: residue 9N 
and 16C, and two within the triple helix: residues 87 and 930. The collagen type I α2 
chain has only three locations: one at the N-telopeptide: residue 5N and two within the 
triple helix: residue 87 and 933. The C-terminal telopeptide of the collagen type I α2 
chain lacks an aldehyde site due to the missing lysine residue.(97;98) The variety of 
enzymatic cross-links in fibrillar collagen can be divided into two classes: (i) cross-links 
formed via the allysine pathway and (ii) cross-links formed via the hydroxyallysine 
pathway.(3;97;99) The crucial factor in defining whether the allysine or hydroxyallysine 
pathway is followed is the hydroxylation state of the telopeptide lysine residues. 
The relative size of the two cross-link pathways varies from tissue to tissue. For 
example, collagen deposited in skin and cornea is mainly cross-linked via the allysine 
pathway and hardly any hydroxyallysine cross-links are observed in these tissues.(100;101) 
In bone, cartilage, tendon, dentin, and ligaments, collagen cross-links are mainly derived 
from the hydroxyallysine pathway.(102)  
4.1. Allysine cross-links 
Allysine cross-links are derived from a lysine residue within the collagen 
telopeptide and basically two types of allysine cross-link reactions occur (Figure 5). One 
leads to the formation of a tetravalent cross-link dehydro-histidinohydroxy-
merodesmosine (deH-HHMD). To form this reducible iminium cross-link, a Lysald 
condenses with another Lysald within the same collagen molecule but within a second α-
chain. The aldol condensation product (ACP) formed reacts then with a histidine and 
finally with a hydroxylysine residue in the neighboring collagen molecules.(103;104) The 
other allysine cross-link reaction leads to the formation of the trivalent cross-link, 
histidinohydroxylysinonorleucine (HHL). 
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Figure 5. Schematic representation of allysine and hydroxyallysine cross-linking pathways. Telo, 
telopeptide; Lysald, allysine; ACP, aldol condensation product; deH-HHMD, dehydro-
histidinohydroxymerodesmosine; HHMD, histidino-hydroxymerodesmosine; deH-HLNL, dehydro-
hydroxylysinorleucine; deH-LNL, dehydro-lysinonorleucine; LNL, lysinonorleucine; HLNL, 
hydroxylysinorleucine; HHL, histidinohydroxylysinonorleucine; Hylald, hydroxyallysine; LKNL, 
lysino-5-keto-norleucine; deH-DHLNL, dehydro-dihydroxylysinonorleucine; DHLNL, 
dihydroxylysinonorleucine; HLKNL, hydroxylysino-5-keto-norleucine; d-Pyr, deoxypyrrole; Pyr, 
pyrrole; LP, lysylpyridinoline; HP, hydroxylysylpyridinoline. The dashed arrows indicate reduction 
by NaBH4. Gray boxes display in vitro reduced cross-links. The square double-lined boxes 
denote reducible cross-links and the oval double-lined boxes denote unreducible cross-links.  
This non-reducible cross-link is the final product of the condensation of a telopeptide 
Lysald with a helical hydroxylysine residue, leading to the reducible iminium 
intermolecular cross-link, dehydro-hydroxylysinorleucine (deH-HLNL), followed by the 
condensation of deH-HLNL with a helical His in the neighboring collagen molecule.(105) 
Lysald can also condense with a helical lysine residue to form dehydrolysinonorleucine 
(deH-LNL). The cross-links deH-HHMD, deH-HLNL, and deH-LNL are unstable in acid 
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conditions, but can be reduced in vitro by e.g. sodiumborohydride (NaBH4) to the more 
stable cross-links histidinohydroxymerodesmosine (HHMD), hydroxylysinorleucine 
(HLNL) and lysinonorleucine (LNL), respectively.(106) 
4.2. Hydroxyallysine cross-links 
If the telopeptide lysine residues are hydroxylated, hydroxyallysine cross-links will 
be formed (Figure 5). The reactive telopeptide Hylald can pair with a helical lysine or 
hydroxylysine residue to form the dehydro-hydroxylysinonorleucine (deH-HLNL) or 
dehydro-dihydroxylysinonorleucine (deH-DHLNL) cross-links, respectively. After 
spontaneous Amadori rearrangement these cross-links are stabilized by forming the 
respective keto-imine cross-links lysino-5-keto-norleucine (LKNL) or hydroxylysino-5-
keto-norleucine (HLKNL). These keto-imines are more stable than the iminium cross-
links.(107) The reducible di-functional cross-links LKNL and HLKNL further mature either 
into the respective lysylpyridinoline (LP) and hydroxylysylpyridinoline (HP) cross-links or 
into the respective deoxypyrrolic and pyrrolic cross-links. Pyridinoline and pyrrolic 
cross-links differ with respect to the hydroxylation state of the second telopeptide 
lysine residue. Pyridinoline cross-links are derived from two telopeptide Hylald residues 
and a helical lysine (LP) or hydroxylysine (HP) residue, whereas pyrrolic cross-links are 
the mature product of a helical lysine or hydroxylysine residue condensed with a 
telopeptide Lysald and Hylald residue (deoxypyrrole or pyrrole, respectively). The di-
functional cross-links deH-HLNL, deH-DHLNL, LKNL, and HLKNL are reduced by 
borohydride to the cross-links HLNL and DHLNL.(3;97;108) 
5. Collagen degradation by matrix metalloproteinases 
Collagen degradation is achieved by the action of various families of proteinases, 
including matrix metalloproteinases (MMPs). MMPs are a family of zinc-dependent 
enzymes that are divided into the following subgroups: collagenases, gelatinases, 
stromelysins and membrane-type MMPs. From the MMP family the collagenases MMP-1, 
MMP-8 and MMP-13, as well as membrane-bound MMP-14 are capable of cleaving native 
fibrillar collagen type I, II and III at specific sites within the triple helix. In addition, native 
fibrillar collagen type I is cleaved by the gelatinases MMP-2 and MMP-9, and native 
fibrillar collagen type III is cleaved by the membrane-bound MMP-16.(109) After cleavage 
the fibrillar collagen fragments denature spontaneously into gelatine. The denatured α-
chains can subsequently be degraded by the gelatinases and a number of other 
enzymes.(110)  
MMPs are secreted as inactive pro-enzymes (pro-MMPs), which are activated by 
proteinases after removal of the propeptides.(111) The proteolytic activity of MMPs is 
controlled by the tight regulation of the activation of pro-MMPs and by the efficient 
inhibition of active MMPs. The latter is achieved by endogenous inhibitors such as tissue 
inhibitors of matrix metalloproteinases (TIMPs) and α2-macroglobulin.(112) The 
importance of an accurate balance between MMP activation and inhibition has been 
shown by several diseases such as arthritis, cancer, aortic aneurysms, and fibrosis where 
a disturbed MMP activity control is seen.(110)  
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6. Fibrosis 
 Fibrosis can be designated as an abnormal healing process, characterized by 
excessive deposition of extracellular matrix proteins, in particular collagen, which 
results in the alteration of the extracellular matrix structure, and finally to the loss in 
function of the particular tissue or organ. Fibrotic processes are a response to a variety 
of insults, including toxic, autoimmune, drug-induced, infectious, or traumatic injuries, 
and occur in several tissues and organs, including the skin (hypertrophic scarring, keloid, 
systemic sclerosis, and lipodermatosclerosis), the liver (parasitic, viral, and alcoholic 
cirrhosis), the lung (infant /adult respiratory distress syndrome and interstitial lung 
disease), the kidney (glomerulosclerosis and interstitial fibrosis), and the palmar fascia 
(Dupuytren’s disease).(113-118) The shared processes in the various fibrotic disorders 
comprise a complex cascade of cellular and biochemical features (Figure 6). 
 
Figure 6. Summary of cellular and biochemical events leading to fibrosis. 
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In the early phase of fibrosis, the accumulation of inflammatory cells, such as 
neutrophils, monocytes, T-lymphocytes and eosinophils is the major event. These cells 
are important sources of the numerous profibrotic cytokines, adhesion molecules, and 
growth hormones which are released at the site of the injury. The released factors 
recruit further inflammatory cells into the site of inflammation and induce fibroblast 
recruitment and proliferation.(119) 
During this inflammatory response fibroblast-like cells do not only proliferate, but 
also differentiate into myofibroblasts, which occurs mainly under the control of 
mechanical tension, TGF-β, and ED-A fibronectin.(120) Myofibroblasts are present during 
normal tissue repair as well, but when the wound is closed they normally differentiate 
into a quiescent form or, alternatively, they disappear selectively through apoptosis.(121) 
During fibrotic processes this does not occur and the myofibroblasts persist.(122) 
Myofibroblasts are distinguished from other fibroblastic cell types by the presence of 
stress fibers, containing α-smooth muscle actin (α-SMA), and by the presence of 
indented nuclei.(123-125)  
In fibrotic lesions myofibroblasts serve important roles in contractile phenomena 
as well as in the production of cytokines.(126) Furthermore, under the control of several 
profibrotic cytokines, myofibroblasts produce increased numbers of several extracellular 
matrix proteins, in particular collagen type I and III, and elevated levels of TIMPs. In 
contrast, the production of MMPs is downregulated in these cells.(114-116;127-129) Thus in 
fibrotic lesions an increase in collagen synthesis is seen in combination with an imbalance 
between TIMP and MMP levels that leads to less collagen degradation. The misbalance 
between collagen synthesis and degradation consequently results in the excessive 
accumulation of collagen. 
6.1. Cytokines involved in fibrotic processes 
During fibrotic processes several cytokines and growth factors are released and 
each of them exerts important functions. Transforming growth factor-β (TGF-β) is 
believed to be the most potent profibrotic cytokine and increased TGF-β levels have 
consistently been found in fibrotic lesions.(130) Furthermore, administration of exogenous 
TGF-β to laboratory animals results in the development of fibrosis.(131;132) TGF-β exists 
in three isoforms, namely TGF-β1, TGF-β2, and TGF-β3.(133) TGF-β1 is generally 
considered to be the major or predominant isoform involved in fibrosis, while the roles 
of TGF-β2 and -β3 are less clear. Interestingly, exogenous addition of TGF-β isoform 
peptides or neutralizing antibodies in an experimental wound healing model 
demonstrates that TGF-β1 and -β2 induce scarring, while TGF-β3 has anti-scarring 
effects.(134) TGF-β is a strong activator of fibroblasts. Via binding to specific receptors 
and activation of a set of intracellular signaling molecules (Smads),(135;136) it induces the 
synthesis of several matrix proteins, including collagen and TIMPs, and reduces the 
synthesis of MMPs.(137) Moreover, TGF-β has chemoattractive effects on fibroblasts and 
stimulates differentiation into myofibroblasts.(138;139)  
Connective tissue growth factor (CTGF, CCN2) is another potent profibrotic 
cytokine and increased CTGF expression has been observed in several fibrotic tissues 
and organs.(140-144) CTGF modulates fibroblast cell growth and extracellular matrix 
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secretion and share many functions with TGF-β. CTGF is upregulated by TGF-β and can 
be indicated as an important downstream mediator of TGF-β.(145-147) Other cytokines 
and growth factors such as tumor necrosis factor α (TNF-α), interleukin 1 (IL-1), IL-4, 
IL-6, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), and 
endothelins can be indicated as profibrotic as well. These cytokines also play important 
roles in stimulating extracellular matrix production, modulating extracellular matrix 
degradation, and fibroblast chemotaxis, proliferation and differentiation.(148;149) 
6.2. Animal models  
A wide variety of animal models mimicking human fibrotic disorders have been 
developed to examine the key mechanisms underlying fibrotic processes. Moreover, 
they are used for in vivo testing of anti-fibrotic therapeutic interventions. A well-
described model is the bleomycin-induced lung fibrosis model. Bleomycin is a cancer 
chemotherapeutic agent and intratracheal inhalation of bleomycin has been found to 
induce fibrosis in lungs of mice, rats, and hamsters with many features similar to those 
seen in human lung fibrotic disorders.(150-152) Repeated cutaneous bleomycin injections in 
mice and rats have toxic effects on the skin as well and result in fibrotic lesions at the 
place of injections. This less-described animal model mimics human systemic sclerosis 
and other fibrotic skin disorders in many histological and biochemical aspects.(153-156). 
Another well-known animal model for systemic sclerosis is the tight skin (Tsk) mouse 
which is characterized by an intragenic duplication of exons 17 to 40 of the fibrillin-1 
gene.(157;158) A wide variety of experimental approaches exists to induce fibrosis in liver 
and kidney, but commonly used animal models for liver fibrosis are the carbon 
tetrachloride- and bile duct ligation-induced cirrhosis model. Unilateral urethral 
obstruction-induced interstitial renal fibrosis is a commonly used animal model to 
examine kidney fibrosis.(159-161)  
6.3. Increased hydroxyallysine cross-linking in fibrotic collagen 
Fibrotic processes are characterized by increased collagen synthesis. Apart from 
that the deposited collagen shows altered cross-link chemistry and in some cases the 
total number of collagen cross-links is increased as well.(162;163) Altered cross-linking in 
fibrotic lesions was first described in hypertrophic scarring. During the course of normal 
wound healing in the skin, the collagen deposited in the early granulation tissue shows 
the reduced di-functional cross-link derived from the hydroxyallysine route (DHLNL). 
But after a few months a normal scar is formed, in which the major collagen cross-links 
are the reduced collagen cross-links HLNL and HHMD, which are derived from the 
allysine route.(164) Thus, during the normal healing process in the skin, there is a change 
in time from the hydroxyallysine cross-links to the cross-links derived from the allysine 
route, and finally mainly allysine cross-links are seen which is typical of normal skin.(165) 
Interestingly, during the course of a disturbed healing process, leading to the formation 
of hypertrophic scars, this change to allysine cross-linking does not occur. The major di-
functional cross-links in hypertrophic scars are the hydroxyallysine cross-links DHLNL 
and HLNL(166) and these di-functional cross-links further mature into the tri-functional 
pyridinoline cross-links. Pyridinolines are hardly detectable in mature normal scars or in 
normal skin.(167) Thus, increased hydroxyallysine cross-linking leading to elevated 
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numbers of the mature tri-functional pyridinoline cross-link is a typical feature of 
hypertrophic scarring. This phenomenon has been observed in other forms of skin 
fibrosis as well, including keloid,(168) systemic sclerosis,(169;170) lipodermatosclerosis,(171) 
and chromomycosis.(172) Moreover, this altered cross-linking is also found in fibrotic 
lesions of other tissues, e.g. lung,(173;174) liver,(175;176) kidney,(177) and palmar fascia.(178;179) 
It appears that the presence of pyridinoline cross-links is related to irreversible 
fibrosis. In a previous study by Ricard-Blum et al., two granulomatous skin diseases were 
compared: chromomycosis, a chronic fungal infection leading to irreversible dermal 
fibrosis, and leishmaniasis, an inflammatory process, which is reversible after treatment. 
It was found that the irreversible chromomycosis was accompanied by the deposition of 
collagen containing increased pyridinoline cross-links, whereas the collagen deposited 
during the course of reversible leishmaniasis displayed pyridinoline cross-link levels 
almost similar to collagen deposited in normal skin.(180) This association between high 
pyridinoline cross-link levels and irreversible fibrosis was also found in two animal 
models: experimental alveolar echinococcosis and murine schistosomiasis.(181;182) The 
above-mentioned observations suggest that the type of collagen cross-linking 
(hydroxyallysine or allysine) is an important factor in determining whether the outcome 
of the fibrotic process is reversible or not.  
6.4. Transglutaminase-mediated cross-linking in fibrosis 
Transglutaminases are a widely distributed group of enzymes which have the 
capacity to cross-link proteins by catalyzing the Ca2+-dependent acyl-transfer reaction 
between the γ–carboxamide group of a peptide-bound glutamine residue and the 
primary amine, including the ε–amino group of peptide-bound lysine. This reaction leads 
to the formation of an ε-(γ-glutamyl) lysine cross-link. Several collagen types (II, V, VII, 
XI, and the N-propeptide of procollagen III) and a number of other extracellular matrix 
proteins are substrates for transglutaminases.(183) Under physiological conditions the 
transglutaminase-mediated cross-links stabilize proteins by increasing their proteolytic 
resistance and facilitate cell adhesion and cell motility.(184) Interestingly, it has been 
observed that elevated transglutaminase expression and ε-(γ-glutamyl) lysine levels are 
correlated with increased extracellular matrix deposition in several fibrotic tissues and 
organs, including lung, liver, heart, and kidney.(185-188) It appears that collagen and 
fibronectin become more resistant to MMP breakdown when previously exposed to 
transglutaminases.(189) Therefore, it is hypothesized that the presence transglutaminase-
mediated cross-linking in fibrotic lesions increases the resistance of extracellular matrix 
proteins towards proteolytic enzymes, and subsequently the extracellular matrix 
proteins will accumulate. However, it should be noted that this postulation has been 
made on the basis of associational observations between increased transglutaminase 
levels, ε-(γ-glutamyl) lysine bonds and collagen deposition. It has never been reported 
whether the number of ε-(γ-glutamyl) lysine cross-links per collagen molecule is 
increased. Only if this is the case, would this increase be expected to play a causative 
role in collagen deposition.  
Another potential link between transglutaminase activity and extracellular matrix 
deposition is the role of transglutaminase in the matrix storage and activation of TGF-β1 
through cross-linking of latent TGF-β1 binding protein to the extracellular matrix.(190;191) 
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6.5. Treatment of fibrotic disorders 
Fibrotic processes result finally in a loss of function of the specific tissues or organs 
and in some fibrotic disorders this can lead to the death of the patient. Over the past 
few years the mechanisms underlying fibrotic processes have been extensively studied in 
order to find specific targets to attenuate fibrosis. The pathogenesis of fibrotic disorders 
has many similar features in the different affected tissues and organs, including 
inflammation, elaboration of cytokines, fibroblasts proliferation and differentiation, 
extensive increase in extracellular matrix synthesis, and loss of degradation control. The 
therapeutic approaches so far developed are based on these features and can be divided 
into the following groups: anti-inflammatory agents, anti-fibrotic cytokines, agents 
inhibiting profibrotic cytokines, agents inhibiting collagen synthesis, agents restoring the 
balance between MMPs and TIMPs, and agents inhibiting the formation of collagen cross-
links. A summary of the literature on some therapeutic strategies is given in Table 2. 
Moreover, this table gives comments on the known effectiveness of each approach in 
fibrotic animal models or human fibrotic diseases. 
7. Hypothesis and outline of the study 
The hallmark of fibrosis is the excessive accumulation of collagen. It is now 
generally accepted that the elevated collagen deposition in fibrotic lesions is the 
consequence of increased collagen synthesis and decreased MMP activity due to an 
imbalance in activity control. Therefore, anti-fibrotic interventions developed so far in 
general interfere with collagen synthesis and MMP activity. However, less attention is 
focused on the fact that the collagen deposited displays altered collagen cross-linking. An 
increased level of hydroxyallysine cross-links per collagen molecule has consistently 
been observed in various fibrotic tissues and organs, and it is postulated that it 
contributes to collagen accumulation by reducing collagen digestibility.(177;192-196) This 
hypothesis is based on the observation that increased hydroxyallysine cross-link levels 
are related to irreversible fibrotic processes.(197-199) However, it has never been 
established that this type of cross-link indeed reduces the susceptibility of the collagen 
network towards degradation by proteinases. The first study described in this thesis has 
been designed to examine the influence of hydroxyallysine cross-linking on in vitro 
collagen degradation by MMPs. Furthermore, this chapter focuses on the impact of 
hydroxyallysine cross-linking on the course of the fibrotic process (reversible or 
irreversible) in bleomycin-induced skin fibrosis in mice (chapter 2).  
Since it turned out that the presence of hydroxyallysine cross-links contributes 
conceivably to the irreversibility of collagen accumulation in fibrosis, anti-fibrotic 
treatment modalities should not only be focused on reducing collagen synthesis or 
inducing MMP activity, but should also address the altered cross-link chemistry. Several 
research groups have focused on inhibiting cross-link formation by developing specific 
lysyl oxidase inhibitors.(200-202) However, inhibition of lysyl oxidase will inhibit both the 
formation of hydroxyallysine and allysine cross-links. Moreover, it will interfere with the 
formation of elastin cross-links as well.(97) Thus, down-regulating lysyl oxidase activity in 
order to reduce the formation of hydroxyallysine cross-links seems not very specific.  
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Table 2: Potential therapeutic approaches to treating fibrotic disorders 
Therapeutic approach Comments 
Anti-inflammatory agents  
 Steroids Widely used as immunosuppressive drugs in fibrosis.(203) 
Anti-fibrotic cytokines/hormones  
 IL-10 Effective on hepatic injury in patients with chronic hepatitis.(204) 
Reduces pulmonary fibrosis in mice.(205) 
 IFN-α Reduces liver fibrosis in Hepatitis D infected patients.(206) Effective 
in treatment of hypertrophic scarring.(207) 
 IFN-γ Reduces human idiopathic pulmonary fibrosis, liver fibrosis in 
hepatitis infected patients,(208-210) and is effective in SSc 
treatment.(211) No human data on kidney fibrosis, but it reduces 
renal fibrosis in rats.(212) 
 TGF-β3 Effective in reducing scarring in cutanous wounds in rats.(213) 
 Relaxin Effective in patients with systemic sclerosis.(214) Reduces renal 
fibrosis in rats.(215) 
Inhibition of cytokines   
 TGF-β inhibition  
Monoclonal TGF-β antibodies Anti-fibrogenic in animal models for kidney, liver, and skin fibrosis, 
and beneficial in preventing scarring after glaucoma filtration 
surgery in human.(216-220) 
Decorin (TGF-β natural inhibitor) Attenuates experimental renal and lung fibrosis, and glial  
scarring.(221-224) 
Latency-associated peptide (LAP) LAP prevents skin fibrosis in murine sclerodermatous graft-versus-
host disease.(225) 
TGF-β soluble receptors Effective in experimental liver, kidney, and lung fibrosis.(226-229) 
TGF-β antisense oligonucleotides 
(ODN) 
Prevent fibrosis in experimental glomerulonephritis and in liver 
fibrosis.(230-232) 
 Inhibition of TGF-β signalling   
Smad7 This natural inhibitor of TGF-β signalling prevents liver and renal 
fibrosis in rats.(233;234) 
Halofuginone Prevents Smad3 DNA binding by inhibiting phosphorylation of 
Smad3. Human trials with halofuginone are successful for SSc and 
cGvHD.(235) It is effective in Tsk mice and in experimental liver 
fibrosis.(236;237) 
Smad4 Inhibition of Smad4 by antisense oligonucleotides attenuates 
experimental liver fibrosis.(238) 
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Table 2: Potential therapeutic approaches to treating fibrotic disorders 
Therapeutic approach Comments 
Inhibition of cytokines  
 CTGF inhibition  
Monoclonal antibody Anti-CTGF antibodies inhibit excessive scarring and fibrosis in 
human (www.fibrogen.com) 
CTGF antisense oligonucleotides Effective in experimental liver fibrosis and in renal interstitial 
fibrosis.(239;240) 
 Endothelin inhibition  
Receptor antagonist Affords protection against experimental glomerulosclerosis and 
experimental liver fibrosis.(241-244) No effect on bleomycin-induced 
lung fibrosis.(245) 
 PDGF inhibition  
Soluble receptor Attenuates experimental liver fibrosis.(246) 
PDGF antisense oligonucleotide Reduces liver fibrosis in rats.(247) 
Inhibition of collagen biosynthesis   
 Inhibition of C-proteinase No specific inhibitor present so far. 
 Inhibition of prolyl-4-hydroxylase Several inhibitors have been successful in preventing fibrosis in 
experimental liver and kidney models and are now tested in 
clinical trials.(248;249) 
The inhibitor HOE-077 has been withdrawn from trials due to the 
side effects found in dogs.(250) 
 Inhibition of HSP47 Antisense oligonucleotides prevent fibrosis in kidney and in 
peritoneum.(251;252)  
 Inhibition of collagen transcription No specific data in animal models or humans. 
Restoring MMP and TIMP balance  
 Induction MMPs Indirect induction of collagenases by urokinase-type plasminogen 
activator reduces cirrhosis in rats. Intravenous injection of MMP-1 
reversed experimental hepatic fibrosis.(253;254) 
 Inhibiting TIMPs  
TIMP-1 antisense oligonucleotides Prevent liver fibrosis in rats.(255) 
TIMP-1 antibody Attenuates experimental liver fibrosis.(256) 
Inhibition of cross-linking   
 Inhibition of lysyl oxidase The inhibitor β-aminopropionitrile (BAPN) is effective as anti-
fibrotic agent in animal models.(257;258) 
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Interventions to specifically reduce the formation of hydroxyallysine cross-link were so 
far not possible, as the mechanism of the formation of this type of cross-links was 
unknown. Therefore, the aim of our other studies was to elucidate the mechanism 
behind the increased formation of hydroxyallysine cross-links in fibrosis in order to find 
a way to interfere specifically with this process.  
Increased formation of hydroxyallysine cross-links is the consequence of an 
overhydroxylation of telopeptide lysine residues. A specific enzyme seems to be 
responsible for the hydroxylation of telopeptide lysine residues (see section “substrate 
specificity of lysyl hydroxylases”), but the gene encoding such a telopeptide lysyl 
hydroxylase has not been found so far. Examination of the biochemical defect in Bruck 
syndrome patients revealed that these patients must have a defective telopeptide lysyl 
hydroxylase.(259) Chapter 3 describes a study in which the genetic defect of Bruck 
syndrome patients was analyzed in order to decipher the gene encoding telopeptide 
lysyl hydroxylase. We found that the Bruck syndrome phenotype is in some cases 
accompanied by mutations in PLOD2, encoding LH2, but Bruck syndrome appears to be 
a heterogenic disease, since in some Bruck syndrome patients we did not observe 
PLOD2 mutations. The following study described in chapter 4, addresses the question 
of whether the reduced telopeptide lysyl hydroxylation in the latter group of Bruck 
syndrome patients is the consequence of a decreased PLOD2 transcription instead of 
PLOD2 mutations. 
We hypothesized that elevated hydroxylation of telopeptide lysine residues in 
collagen deposited in fibrotic lesions is the consequence of increased telopeptide lysyl 
hydroxylase expression. Since we identified LH2 as the putative telopeptide lysyl 
hydroxylase, mRNA expression of the two LH2 splice variants (LH2a and LH2b) was 
studied in myofibroblasts obtained from various fibrotic tissues (chapter 3 and 5). 
Moreover, an examination was made of whether profibrotic cytokines regulate LH2a 
and or LH2b transcription (chapter 6). After establishing that LH2b plays an important 
role in fibrotic processes, by inducing overhydroxylation of the telopeptide lysines, the 
last part of this thesis addresses the search for compounds or methods to specifically 
down-regulate LH2b expression. Minoxidil, an antihypertensive drug, appears to be a 
suitable candidate for reducing LH2b expression as it had been found to down-regulate 
lysyl hydroxylase activity.(260-263) However, it has never been examined whether minoxidil 
has a profound effect on either LH1, LH2a, LH2b, or LH3. Chapter 7 describes a study 
in which the inhibitory effect of minoxidil on lysyl hydroxylase isoforms is dissected. 
Another promising tool to reduce LH2b mRNA expression is RNA interference, 
mediated by small interfering RNA (siRNA) molecules. The last study of this thesis 
addresses the development of specific LH2-siRNA molecules in order to down-regulate 
LH2b expression and the concomitant overhydroxylation of telopeptide lysyl residues 
(chapter 8).  
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Abstract 
Fibrotic processes in humans are characterized by an excessive accumulation of collagen 
containing increased levels of hydroxyallysine-derived cross-links. The occurrence of 
these cross-links appears to be an important criterion in assessing the irreversibility of 
fibrosis. We hypothesize that increased hydroxyallysine cross-linking results in a 
collageneous matrix that is less susceptible to proteolytic degradation and therefore the 
collagen deposition is no longer reversible. In this report, we show that collagen 
matrices with increased hydroxyallysine cross-link levels were less susceptible to matrix 
metalloproteinase 1 degradation than collagen matrices containing low hydroxyallysine 
levels. These data indicate that the type of collagen cross-link influences collagen 
catabolism. In vivo evidence for the importance of the cross-linking type in determining 
the reversibility of the fibrotic process was found using the bleomycin-induced skin 
fibrosis mouse model. Analysis of the accumulated collagen in the fibrotic skin of 
bleomycin-treated mice did not reveal an increase in hydroxyallysine cross-link levels. In 
concurrence with our hypothesis, the collagen accumulation resolved in time when the 
mice were no longer receiving bleomycin treatment, showing the reversibility of the 
fibrosis. In conclusion, our data indicate that the type of collagen cross-linking is an 
important factor in determining whether the outcome of the fibrotic process is 
reversible or not. 
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Introduction 
Fibrosis is a common pathological process characterized by the excessive 
accumulation of extracellular matrix proteins, in particular collagen. The increased 
deposition of collagen is the result of increased collagen synthesis accompanied by 
decreased proteinase activity due to an imbalance between the levels of matrix 
metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs).(1-4) 
Another factor that seems to be involved in the accumulation of collagen is the altered 
mode of collagen cross-linking.  
Collagen cross-linking is the final step in the biosynthesis of collagen fibrils. Two 
related routes are responsible for the formation of these cross-links, namely the allysine 
route, in which a lysine (Lys) residue within the collagen telopeptide is converted by 
lysyl oxidase into the aldehyde allysine, and the hydroxyallysine route, in which a 
hydroxylysine (Hyl) residue in the telopeptide is converted into the aldehyde 
hydroxyallysine. Subsequently, the allysine or the hydroxyallysine reacts with a Lys, Hyl 
or histidine residue in the triple helix to form di-, tri-, or tetra-functional cross-links.(5-8) 
In bone, tendon, ligaments and cartilage, the collagen is cross-linked mainly via the 
hydroxyallysine route, whereas in skin the cross-links are mainly derived from the 
allysine route.(9) Interestingly, during the fibrotic process increased formation of 
hydroxyallysine-derived cross-links such as pyridinolines is observed. Elevated 
hydroxyallysine cross-linking has consistently been found in several human fibrotic 
disorders, pointing to a general fibrotic phenomenon.(10-15)  
It has been noted that the presence of increased enzymatic (allysine and 
hydroxyallysine(16) or non-enzymatic (advanced glycation)(17-19) cross-link levels in 
collagen reduce the digestibility of collagen molecules in vitro. However, it is likely that 
not only the amount, but also the type of cross-link may affect collagen degradation. In 
this context it is of interest that in fibrosis a switch from the allysine to the 
hydroxyallysine route occurs rather than an increase in the total number of enzymatic 
cross-links(20) and this appears to be an important criterion in assessing the irreversibility 
of fibrosis.(10;15;21-23) This observation suggests that collagen containing hydroxyallysine 
cross-links is less susceptible to degradation, and led us to hypothesize that the type of 
enzymatic cross-link influences the reversibility of the fibrotic process due to differences 
in degradability of the accumulated collagen.  
Members of the MMP family are responsible for the degradation of collagen. MMPs 
are a family of zinc-dependent enzymes that together have the capacity to degrade most 
components of the extracellular matrix. This large family of proteolytic enzymes can be 
subdivided into the following subgroups: collagenases, gelatinases, stromelysins and 
membrane-type MMPs. Only the collagenases MMP-1, MMP-8 and MMP-13 as well as 
membrane-bound MMP-14 are capable of cleaving native fibrillar collagens (type I, II and 
III) within the triple helix.(24)  
To gain more insight into whether the type of cross-link regulates collagen 
catabolism, the present study was designed to explore the MMP-1 digestibility of 
collagen containing various pyridinoline cross-link levels. We indeed found that the type 
of cross-linking influences the degradability of collagen by MMP-1 in vitro. Furthermore, 
we examined whether the cross-linking type influences the outcome (reversible or 
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irreversible) of the fibrotic process in vivo. The recently developed bleomycin-induced 
skin fibrosis mouse model(25;26) seems to be an appropriate model for testing the impact 
of the nature of the cross-link on the reversibility of the induced fibrotic process, as the 
fibrotic stimulus, obtained by repeated bleomycin injections, can be easily omitted. This 
mouse model mimics human systemic sclerosis (SSc) both histologically and 
biochemically.(26) So far collagen cross-link levels have never been determined. 
Unexpectedly, we found that the fibrotic skin did not contain elevated levels of 
hydroxyallysine cross-links, as measured by the number of pyridinolines per collagen 
molecule. This absence of increased hydroxyallysine cross-link levels had a profound 
impact on the course of the fibrotic process: the fibrosis turned out to be completely 
reversible.  
Materials and methods 
Animals 
Female C57Bl/6J mice aged 8 to 9 weeks at the start of all experiments were 
purchased from the Centre d’Elevage Janvier (France) and maintained with food and 
water ad libitum.  
Bleomycin-induced skin fibrosis in mice 
To induce skin fibrosis, mice were subcutaneously injected in the shaved neck 3 
times a week for a period of 5 weeks with 200 μl phosphate-buffered saline (PBS) 
containing 0.1 U bleomycin (purchased from Leiden University Medical Center 
pharmacy). The mice were subsequently sacrificed and the lesional skin was used for 
biochemical and histological analyses. Control animals were injected 3 times a week with 
200 μl PBS for the same period. To test the reversibility of the induced fibrosis a second 
group of mice was treated with bleomycin for 5 weeks as described above followed by a 
period of 6 weeks without bleomycin injections. Control mice were treated with PBS 
for 5 weeks followed by a period of 6 weeks without injections. After a total period of 
11 weeks the animals were sacrificed and the skin at the site of the injected neck region 
was used for biochemical and histological analyses. Each group tested contained 10 
animals. The study was performed with the approval of the Animal Ethical Committee 
and in compliance with the Dutch governmental regulations on Animal Experimentation.  
Histology 
Tissue specimens were fixed in 10% formalin solution and embedded in paraffin. 5 
μm sections were stained with hematoxylin-phloxine-saffron (HPS). The thickness of the 
dermal collagen layer was determined throughout the whole section (10 measurements 
per section) at a 10x10 magnification and expressed as arbitrary units. For each mouse 
the average thickness of the collagen layer was measured in two sections. 
Cross-link and amino acid analysis 
The isolated skin samples were hydrolyzed in 6 M HCl and used for amino acid and 
cross-link analysis. Hydroxyproline (Hyp) and Hyl levels were determined in the acid 
hydrolysates after derivatization with 9-fluorenylmethyl chloroformate (FMOC) by 
reverse-phase high-performance liquid chromatography (RP-HPLC).(27) 
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Hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) cross-links were measured in 
the same acid hydrolysates as described previously.(28;29) Pyridinoline and Hyl levels were 
expressed as total amount of residues per collagen molecule, assuming 300 Hyp residues 
per triple helix. 
In vitro extracellular matrix production 
To obtain collageneous matrices for degradation studies, primary human fibroblasts 
obtained from the split skin of a healthy individual were cultured in 25 cm2 flasks for 4 
weeks in Dulbecco’s modified Eagle’s medium (DMEM; BioWhittaker) supplemented 
with 5% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin, 100 U/ml 
streptomycin and 50 μg/ml ascorbic acid in the presence or absence of 1 ng/ml 
recombinant human transforming growth factor β2 (TGF-β2; Sigma). The profibrotic 
cytokine TGF-β2 was added to induce pyridinoline cross-link formation.(30) The medium 
was replenished every 3 days. After 4 weeks of culture, the deposited matrix was 
washed in PBS; the cells present in the matrix were killed by two freeze-thaw cycles. 
Finally, the remaining matrix was incubated in PBS at 37 °C for another week to enable 
cross-link maturation. HP and LP cross-link levels were measured as described above 
and expressed as an amount relative to the total amount of collagen molecules, 
assuming 300 Hyp residues per triple helix. 
 In vitro extracellular matrix degradation by MMP-1 
Extracellular matrix deposited by unstimulated (n = 3) and TGF-β2 (n = 3) 
stimulated fibroblasts was washed 3 times with 1 ml PBS, in order to remove the serum 
used in the culture medium, and incubated for 24 hours at 37ºC in 200 μl 100 mM boric 
acid, 25 mM CaCl2, 750 mM NaCl, 5 μM ZnCl2, 0.1 % NaN3 (w/v), and 0.05 % (v/v) Brij-
35 pH 7.5 in the presence or absence of 100 nM MMP-1, which was activated by ρ-
aminophenyl mercuric acetate (APMA; GlaxoSmithKline) and tested for activity using a 
MMP activity assay.(18) The released collagen (soluble and present in the supernatant) 
was separated from the insoluble collagen matrix by means of centrifugation.  
The amount of collagen in the soluble fraction represents the amount of collagen 
directly released into the medium by MMP-1. It should be realized that not all the 
collagen molecules are directly released by such degradation experiments, and that a 
significant part of cleaved molecules remains attached to other collagen molecules and 
are not released. To examine this part of MMP-1-cleaved collagen molecules we 
measure the amount of degraded molecules present in the collageneous matrix, by 
digesting the insoluble collagen fraction, collected after MMP-1 digestion, with 0.5 mg/ml 
α-chymotrypsin (Sigma) in 200μl PBS containing 0.1 M NaCl for 12 hours. Degraded 
collagen molecules denature at 37°C; α-chymotrypsin digests denatured collagen but 
not the intact triple helix. The released collagen after α-chymotrypsin incubation 
(soluble and present in the supernatant) was separated from the insoluble collagen 
matrix by means of centrifugation. Finally all fractions were hydrolysed in 6 M HCl. Hyp 
levels were determined in acid hydrolysates of matrix samples by RP-HPLC after 
derivatization with FMOC and ο-phtaldialdehyde as described earlier.(31) The amount of 
soluble collagen, collected directly after MMP-1, was expressed as a percentage of total 
collagen using the equation HypsupMMP-1/( HypsupMMP-1 + Hypsupchym + Hypres) x 100%, where 
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HypsupMMP-1 is the amount of Hyp in the supernatant collected directly after MMP-1 
digestion, Hypsupchym is the amount of Hyp in the supernatant collected after α-
chymotrypsin digestion, and Hypres the amount of Hyp in the residual tissue (insoluble 
fraction) collected after α-chymotrypsin. The amount of denatured collagen (soluble 
collagen collected after α-chymotrypsin digestion) was expressed as a percentage of the 
total collagen using the equation Hypsupchym/( HypsupMMP-1 + Hypsupchym + Hypres) x 100%. 
Statistical analysis 
Statistical analysis was performed using SPSS 11.0 software. All data are presented 
as mean ± SEM. Bleomycin- and PBS-treated animals and collagen matrices deposited by 
TGF-β2 stimulated and unstimulated cells were compared by Mann-Whitney’s non-
parametric test. P values less than 0.05 were considered to indicate statistically 
significant differences. 
Results 
Hydroxyallysine cross-links influence the degradability of collagen by MMP-1 
On the basis of the relation between irreversible fibrosis and increased 
hydroxyallysine cross-linking, we hypothesized that the type of cross-link 
(hydroxyallysine or allysine) influences the degradability of collagen. Therefore, the 
effect of hydroxyallysine cross-linking on collagen release by MMP-1 was explored. 
Pyridinolines require two telopeptide hydroxyallysine residues for its formation. The 
presence of pyridinolines is often indicative for the presence of other hydroxyallysine 
cross-links as well, such as dehydro-hydroxylysinonorleucine and dehydro-
dihydroxylysinonorleucine. To induce differences in pyridinoline cross-link levels, 
fibroblasts were cultured in the presence or absence of TGF-β2. Figure 1A shows that 
the collagen matrices deposited by TGF-β2-stimulated cells contain a 4-fold higher 
pyridinoline cross-link level than the matrices deposited by unstimulated cells. 
Moreover, TGF-β2 induced a slight increase in collagen content (Figure 1B). This is 
consistent with previous data.(30) Incubation of the matrices deposited by TGF-β2 
stimulated fibroblasts with MMP-1 resulted in a 2-fold lower collagen release into the 
medium (Figure 1C) in comparison to the matrices deposited by the unstimulated 
fibroblasts (Figure 1C). Hardly any collagen release was detected from matrices that 
were incubated without MMP-1 (0.15 and 0.30% for the matrices deposited by the 
unstimulated and stimulated fibroblasts, respectively).  
The outcome of the experiment above provides the percentage collagen directly 
released into the medium by MMP-1. However, not all the collagen molecules are 
directly released, and a significant part of cleaved molecules remains attached to other 
collagen molecules, thus preventing its release. To get insight into these levels, we also 
measured the amount of denatured collagen present in the residual matrices obtained 
after MMP-1 digestion. Degraded collagen molecules (i.e. molecules with at least one 
cleaved peptide in the triple helix) denature (unwind) at body temperature. Figure 1D 
showed that for the untreated matrices the amount of denatured collagen was around 
3-fold increased after MMP-1 digestion whereas in the TGF-β2 stimulated matrices the 
amount of denatured collagen was only 1.6-fold increased.  
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Figure 1. Collagen matrices with increased hydroxyallysine levels (as measured by pyridinolines) 
are less susceptible to degradation by MMP-1. Total amount of HP + LP cross-links per triple 
helix (A) and collagen (B) in matrices deposited by TGF-β2 stimulated and unstimulated 
healthy skin fibroblasts (n = 3). Amounts of Hyp in the soluble fraction directly after incubation 
with 100 nM MMP-1 (C) and the amount of denatured collagen in the MMP-1 treated 
matrices (D) are lower for matrices with increased pyridinoline cross-linking (matrices deposited 
by TGF-β2 stimulated cells) than for matrices with low pyridinoline cross-link levels (deposited 
by unstimulated cells; calculated as a percentage of the total amount of Hyp in all fractions). 
Data are presented as mean ± SEM. 
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Bleomycin-induced skin fibrosis in mice 
Human SSc is characterized by the deposition of collagen with increased 
pyridinoline cross-link levels.(13;32) In a recently developed experimental SSc model in 
which mice are treated with repeated subcutaneous bleomycin injections, this aspect has 
so far not been investigated.(25;26) The accumulated collagen in the fibrotic skin lesions 
obtained from bleomycin-injected mice showed unaltered pyridinoline cross-link levels 
when compared to collagen deposited in skin obtained from PBS-injected mice (Figure 
2E). In addition, Hyl levels per triple helix were similar as well (Figure 2F). The amount 
of collagen per dry weight demonstrates a 1.6-fold increase in the bleomycin-treated 
skin when compared to control skin (Figure 2D). This increase in collagen content was 
confirmed by histological examination. The fibrotic skin of bleomycin-treated animals 
showed an increased collagen deposition and a distortion of the subcutaneous adipose 
layer (Figure 2A and 2B). Quantitative analysis showed a 2-fold increase in the dermal 
collagen thickness in comparison with the control mice (Figure 2C). These data are 
consistent with previous data.(25;26)  
Reversibility of bleomycin-induced skin fibrosis in mice 
 Our in vitro data showing that pyridinoline cross-links reduce the degradability of 
collagen imply that the accumulation of collagen with increased hydroxyallysine cross-
link levels (as measured by pyridinolines) is refractory to degradation. Since there is no 
increase in the hydroxyallysine cross-link levels in the matrix deposited in fibrotic skin 
lesions of mice subjected to the bleomycin regime, we wondered whether the collagen 
accumulation induced by bleomycin is reversible. To test this hypothesis skin fibrosis 
was induced in mice by subcutaneous injection of bleomycin. Following 5 weeks of 
repeated bleomycin injections the mice were left untreated for another 6 weeks. Skin 
sections indeed revealed that the increase in collagen deposition as found after 5 weeks 
of bleomycin treatment had disappeared after the resting period of 6 weeks (Figure 3A 
and 3B). This was confirmed by quantitative analysis of the skin thickness, showing 
similar values in bleomycin- and PBS-treated mice (Figure 3C). The histological data 
were confirmed by biochemical analysis, which showed that the amount of collagen per 
dry weight was comparable in both groups of mice (Figure 3D). Unexpectedly, the 
amount of pyridinoline cross-links per triple helix of the 6-weeks rested group was 20% 
increased in bleomycin-treated mice when compared to PBS-treated mice (Figure 3E;  
P = 0.03). The number of Hyl residues per collagen molecule was similar in bleomycin- 
and PBS-treated mice (Figure 3F). 
Discussion 
Previous observations of physiological and pathophysiological hydroxyallysine-
cross-link levels indicate that collagen containing increased hydroxyallysine cross-linking 
is less susceptible to degradation. However, direct evidence for the role of these specific 
cross-links in regulating collagen catabolism has never been reported.  
This study demonstrates that collageneous matrices obtained in vitro that differ 
with respect to hydroxyallysine cross-link levels, vary in susceptibility to MMP-1 
degradation. A 2-fold decrease in collagen release from matrices with increased 
hydroxyallysine cross-link levels, deposited by TGF-β2 stimulated fibroblasts, was 
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observed in comparison to matrices with lower hydroxyallysine cross-link levels, 
deposited by unstimulated cells. In addition, a 2-fold decrease was observed in the 
amount of denatured collagen as a result of the MMP-1 incubation in the TGF-β2 
treated matrices in comparison to the untreated matrices. These observations provide 
evidence that the presence of hydroxyallysine cross-linking reduce the capacity of MMP-
1 to degrade collagen. It should be stressed here, that there are more hydroxyallysine 
cross-links than the here measured pyridinolines (HP and LP). A 4-fold increase in 
pyridinolines was seen after TGF-β2 stimulation, resulting in 0.14 pyridinolines per 
collagen molecule. This means that one out of seven collagen molecules has a 
pyridinoline cross-link.  However, the total sum of hydroxyallysine cross-links is likely to 
be higher. Other cross-links, such as dehydro-hydroxylysinonorleucine (deH-HLNL) and 
dehydro-dihydroxylysinonor- 
leucine (deH-DHLNL), show often higher numbers per collagen molecule than the 
pyridinolines,(33) but they are technically more difficult to measure and there are no 
commercially available standards.  
It should be noted that the matrix deposited by the TGF-β2 stimulated fibroblasts 
shows a slight increase in collagen content when compared to the matrix deposited by 
the unstimulated cells. However, since the matrices were incubated with an excess of 
MMP-1, the decrease in collagen release observed for the matrix deposited by TGF-β2 
stimulated cells is unlikely the result of this small difference in collagen/MMP-1 ratios. 
The presence of different levels of TIMPs and/or proteoglycans between the matrices 
deposited by unstimulated and TGF-β2 stimulated cells as a disturbing factor in collagen 
release can also be ruled out, as the collagen network was washed intensively before 
MMP-1 incubation.  
The total number of cross-links (allysine and hydroxyallysine) after TGF-β2 
stimulation is likely to be similar to levels in matrices deposited by unstimulated cells, as 
the expression of lysyl oxidase, the enzyme responsible for the conversion of lysine and 
hydroxylysine into allysine and hydroxyallysine, respectively, is not increased as 
compared to the expression of collagen.(30) Our data thus indicate that not only the 
presence of collagen cross-linking(16) but also the type of cross-link (hydroxyallysine 
versus allysine) plays an important role in regulating collagen catabolism. 
Further circumstantial evidence for the lower degradability of hydroxyallysine 
cross-linked collagen is provided by the physiologically slow turn-over (half-life >100 
years) of collagen type II in healthy adult articular cartilage,(34;35) a collagen type known to 
have high levels of hydroxyallysine-derived cross-links.(36;37) Additional evidence for the 
higher degradability of allysine cross-linked collagen is shown by the common form of 
osteoporosis (i.e. postmenopausal osteoporosis) and the Bruck syndrome (BS), the 
latter being characterized by a severe osteopenic phenotype at an early age due to 
increased bone remodeling. Both conditions exhibit decreased hydroxyallysine cross-
linking in bone.(38-41) 
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Figure 2. Normal pyridinoline cross-link levels in bleomycin-induced skin fibrosis in the mouse. 
HPS stained sections obtained from the lesional skin of PBS- (A) and bleomycin-treated (B) mice 
at 5 weeks shows an increase in dermal thickness in bleomycin-injected skin. The dermal 
thickness was quantitatively determined in 2 sections per animal at 10 randomly selected sites 
throughout the sections (C). A part of the lesional skin was used for biochemical analysis to 
measure collagen per dry weight (D), HP + LP cross-links (E), Hyl levels (F). Data are presented 
as mean ± SEM (n = 10).  
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Figure 3. Bleomycin-induced collagen accumulation in mice is reversible. Representative 
pictures of HPS stained sections at 11 weeks (5 weeks PBS or bleomycin injections followed by 
a resting period of 6 weeks) obtained from PBS- (A) and bleomycin-injected skin (B). 
Quantitative measurement of the dermal thickness (C) and collagen per dry weight (D) 
demonstrate comparable levels in bleomycin- and PBS-injected skin. HP + LP cross-link levels (E) 
was 20% increased but Hyl levels (F) were normal in the bleomycin-injected skin at 11 weeks. 
Data are presented as mean ± SEM (n = 10). 
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In fact, collagen deposited in the bone of BS patients shows an almost complete absence 
of hydroxyallysine-derived cross-links when compared to collagen deposited in healthy 
bone.(38) Pepsin digestion experiments demonstrated that much higher amounts of 
collagen can be released from the bone matrix of BS patients than from healthy controls 
(R.A. Bank unpublished data),(42) indicating that collagen molecules with allysine cross-
links are more prone to degradation than their counterpart with hydroxyallysine cross-
links. These in vitro data are in line with the increased bone remodeling found in BS 
patients leading to the severe osteopenic phenotype (R.A. Bank, unpublished data). 
These findings further subscribe our in vitro data and indicate that the type of collagen 
cross-linking indeed influences the degradability of the collagen matrix. This may explain 
the irreversible accumulation of hydroxyallysine cross-linked collagen in fibrotic 
disorders. 
 Human SSc is characterized by the accumulation of collagen, exhibiting increased 
pyridinoline cross-link levels in skin and other tissues.(13;32) Unexpectedly, elevated 
pyridinoline cross-linking is not observed in the collagen deposited in fibrotic skin 
lesions obtained from bleomycin-treated mice (an experimental SSc model). Our 
biochemical observations of the bleomycin-treated animals thus reveal that experimental 
SSc in mice, although in several aspects reflecting the human situation, differs with 
respect to pyridinoline cross-link levels.  
When the fibrotic stimulus produced by bleomycin was omitted, elevated collagen 
levels disappeared and returned to normal levels, demonstrating that collagen 
accumulation without increased pyridinoline cross-link levels is reversible. This finding is 
similar to previous observations in two experimental liver fibrosis models. These models 
show that moderate pyridinoline cross-link levels in the deposited collagen matrix in 
fibrotic lesions are associated with a reversible fibrotic process (murine schistosomiasis), 
whereas increased pyridinoline cross-link levels result in an irreversible accumulation of 
collagen (alveolar echinococcosis).(43;44) Clearly, the type of collagen cross-link present in 
fibrotic lesions plays an important role in determining whether collagen accumulation in 
the fibrotic lesion is reversible or irreversible. 
 After the resting period without bleomycin injections, the collagen deposited was 
found to have slightly increased pyridinoline cross-link levels (≈ 20%). During this last 
period, collagen degradation in the bleomycin-injected region must have been rather 
high, as the increased collagen levels rapidly returned to normal during the subsequent 
resting period. The small increase in hydroxyallysine-derived cross-link levels reveals 
that the collagen pool containing allysine-derived cross-links is likely to be degraded in 
favor of collagen containing hydroxyallysine-derived cross-links. This finding again 
underlines the importance of the type of cross-linking to collagen catabolism, which is 
consistent with our in vitro findings.  
In conclusion, the present study provides evidence that the irreversible fibrotic 
process is not only the result of an increased collagen synthesis accompanied by a 
decreased collagenase activity, but is most likely also the result of the deposition of less 
degradable hydroxyallysine cross-linked collagen molecules. Treatment modalities 
should therefore not only be focused on the reduction of collagen synthesis and the 
induction of collagenase activity by restoring the balance between MMP and TIMP levels, 
but should also address collagen cross-linking. We hypothesize that the specific 
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inhibition of the formation of the hydroxyallysine cross-links makes the collagen more 
prone to degradation, resulting in a more reversible accumulation. Increased formation 
of pyridinoline cross-link levels in fibrotic lesions is the result of the overhydroxylation 
of lysine residues within the collagen telopeptides. We have recently found that 
increased expression levels of lysyl hydroxylase 2b (LH2b), having telopeptide lysyl 
hydroxylase activity,(45-48) is responsible for this overhydroxylation.(32;48) Specific inhibition 
of hydroxyallysine-derived cross-link formation to attenuate irreversible fibrosis could 
thus be achieved by specific inhibition of LH2b. This enzyme may therefore be a very 
attractive target to interfere with fibrotic processes. 
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Abstract 
The hallmark of fibrotic processes is an excessive accumulation of collagen. The 
deposited collagen shows an increase in pyridinoline cross-links, which are derived from 
hydroxylated lysine residues within the telopeptides. This change in cross-linking is 
related to irreversible accumulation of collagen in fibrotic tissues. The increase in 
pyridinoline cross-links is likely to be the result of increased activity of the enzyme 
responsible for the hydroxylation of the telopeptides (telopeptide lysyl hydroxylase, 
TLH). Although the existence of TLH has been postulated, the gene encoding TLH has 
not been identified. By analyzing the genetic defect of Bruck syndrome, which is 
characterized by a pyridinoline deficiency in bone collagen, we found two missense 
mutations in exon 17 of PLOD2, thereby identifying PLOD2 as a putative TLH gene. 
Subsequently, we investigated fibroblasts derived from fibrotic skin of systemic sclerosis 
(SSc) patients and found that PLOD2 mRNA is highly increased indeed. Furthermore, 
increased pyridinoline cross-link levels were found in the matrix deposited by SSc 
fibroblasts, demonstrating a clear link between mRNA levels of the putative TLH-gene 
(PLOD2) and the hydroxylation of lysine residues within the telopeptides. These data 
underscore the significance of PLOD2 in fibrotic processes.  
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Introduction 
The biosynthesis of collagen molecules involves several intracellular post-
translational modifications, followed by excretion and extracellular aggregation of the 
collagen molecules into fibrils, which are subsequently stabilized by intermolecular 
cross-links.(1;2) Two related routes are responsible for the formation of these collagen 
cross-links: the allysine route, in which a lysine (Lys) residue in the telopeptide is 
converted by lysyl oxidase into the aldehyde allysine (Lysald), and the hydroxyallysine 
route, in which a hydroxylysine (Hyl) residue in the telopeptide is converted into the 
aldehyde hydroxyallysine (Hylald). Subsequently, the Lysald or Hylald react with a Lys or 
Hyl residue in the triple helix to form di-, tri-, or tetra-functional cross-links.(3-6) The 
mature cross-links hydroxylysylpyridinoline (HP) or lysylpyridinoline (LP) are formed via 
the hydroxyallysine route and occur in a variety of connective tissues such as bone, 
tendon, ligaments, and cartilage.(7) In contrast, collagen in the skin is mainly cross-linked 
via the allysine route. Interestingly, in fibrotic skin (lipodermatosclerosis, keloid) and 
organ fibrosis (lung, liver), which is characterized by an excessive accumulation of 
collagen, an increase in cross-links derived from the hydroxyallysine route is found.(8-15) 
It has been shown that the amount of hydroxyallysine-derived cross-links is related to 
the irreversible accumulation of collagen in fibrotic tissues, indicating that collagen 
containing hydroxyallysine-derived cross-links is more difficult to degrade than collagen 
containing allysine-derived cross-links.(10-12;14;15) Inhibition of the formation of 
hydroxyallysine-derived cross-links in fibrosis is therefore likely to result in the 
formation of collagen that is easier to degrade, thereby preventing the unwanted 
collagen accumulation.  
The increase in hydroxyallysine-derived cross-links in fibrosis is the result of an 
overhydroxylation of lysine residues within the collagen telopeptides. The enzyme 
catalyzing the conversion of Lys into Hyl is lysyl hydroxylase (EC1.14.11.4).(16-18) The lysyl 
hydroxylase family consists of lysyl hydroxylase 1 (LH1), LH2 and LH3 encoded by 
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1), PLOD2, and PLOD3, 
respectively.(16;19-21) Alternative RNA splicing has been described for PLOD2 only, 
resulting in the splice variants LH2a and LH2b (LH2b contains an extra exon).(22) The 
Ehlers-Danlos syndrome type VI is characterized by mutations in PLOD1. Collagen of 
these patients shows an absence of hydroxylated lysine residues within the triple helix in 
combination with normal levels of hydroxylated lysine residues within the telopeptides. 
Therefore, it can be concluded that LH1 catalyzes the conversion of triple helical lysine 
residues into hydroxylysines.(23;24) The substrate specificity of LH2 and LH3 has not yet 
been elucidated and so far no disease has been associated with defects in LH2 or LH3.  
Bruck syndrome (BS; OMIM 259450), an autosomal recessive disease, is 
characterized by osteoporosis, joint contractures at birth, fragile bones and short 
stature.(25-28) Biochemical analysis of the bone of BS patients revealed an 
underhydroxylation of Lys residues in the telopeptides of collagen type I, whereas 
hydroxylation of Lys residues in the triple helix is normal.(29) Together, the Ehlers-
Danlos syndrome type VI and the Bruck syndrome imply that a lysyl hydroxylase must 
exist that specifically hydroxylates the telopeptides and that the activity of such a 
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telopeptide lysyl hydroxylase (TLH) is decreased in BS bone. The identity of TLH had 
not yet been discovered.  
Here we show that the gene defect in two BS families is a mutation in PLOD2, 
showing that PLOD2 encodes TLH. The importance of TLH in fibrotic processes is 
demonstrated by the highly increased expression of TLH in fibroblasts cultured from 
fibrotic skin of systemic sclerosis patients (SSc). Furthermore, higher levels of 
pyridinoline cross-links were found in the extracellular matrix deposited by the SSc 
fibroblasts which shows the link between increased TLH expression and the shift to the 
hydroxyallysine cross-linking pathway. 
Materials and methods 
Patients  
In this study three families with children diagnosed as Bruck syndrome patients 
were investigated. Two unrelated Kurdish families (family FH and family PM), both 
consanguineous, were described earlier (case 1, 2, 3 and 7, 8, respectively).(26) The third 
family (family DR) has not yet been described. This Australian family, where the parents 
are not consanguineous, had two affected boys deceased prenatally, one affected girl 
deceased at 2 years, and one surviving unaffected 9-year-old-girl. All these BS patients 
show decreased amounts of pyridinoline cross-links in bone (R.A. Bank, unpublished 
data). 
Genotyping 
Blood samples of the three families were collected and genomic DNA was 
prepared by standard methods. Microsatellite markers, obtained from the Marshfield 
screening set version 6, were amplified as described earlier.(29) Genotypes of the 
previously localized BS locus, which is 17p12,(29) and the chromosomal region of PLOD2, 
which is 3q23-q24,(30) were assigned.  
Mutation analysis  
The exon/intron organization of PLOD2 has not been described. PLOD1 and PLOD3, 
encoding two other members of the lysyl hydroxylase family, both consist of 19 
exons.(31;32) The exon/intron boundaries of both genes are identical. Analysis of clones 
RP11-758I14 and RP11-274H2 showed identical exon/intron boundaries for PLOD2. In 
addition, PLOD2 shows an extra exon,(22) designated as exon 13A, which is not found in 
PLOD1 or PLOD3. To detect DNA sequence variations in exons and exon/intron 
boundaries of PLOD2, primer pairs were designed to amplify the exons, including the 
exon/intron boundaries; in addition a part of the promoter region was amplified  
(Table 1). PCR was carried out on genomic DNA from Bruck syndrome patients, 
unaffected parents and from a pooled healthy population (Roche Diagnostics), using La 
Taq polymerase (TaKaRa). A PCR consisted of a 3-minute interval at 95 ºC, 35 cycles of 
95 ºC for 1 min, a specific annealing temperature as listed in Table 1 for 90 s or 30 s, 
and 68 ºC for 60 s. Finally, an extension step of 10 min at 68 ºC was performed. Purified 
PCR products served as templates for cycle sequencing using the ABI PRISM® BigDye 
Termination Cycle Sequencing Ready Reaction kit (Applied Biosystems) and were 
analyzed on the ABI PRISM® 310 sequencer (Applied Biosystems).  
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Table 1: Primers for mutation analysis 
Exon Forward primer Reverse primer AT 
P 5’CTCCCAAAGCTAAGTGCAGG3’ 5’AGACAGGGATTCCAGGGGT3’ 56°C 30’’ 
1 5’GTCTCTGCGTTCTCGCGAGA3’ 5’AAGGGCTGTTGGATGAATGAAC3’ 56°C 90’’ 
2 5’TGAGGTCTCAATTACTGTAGTGA3’ 5’CTTCCTTGTGAGGATTACAGATT3’ 56°C 90’’ 
3 5’GTACTGTTCAAGTTGATGATGTC3’ 5’GCCACCGTGCCCAACCATATT3’ 56°C 30’’ 
4 5’ATGGTTTATGTGCCTAGATTCTGA3’ 5’GGAACACCAACTCACATAATACA3’ 56°C 90’’ 
5 5’TTCTTTCATGGTGAGCTGTGA3’ 5’TGATATCCAGCCAGGTGACA3’ 56°C 30’’ 
6 5’GCAACTATCGCAGTTTCTACCT3’ 5’CCAAATGGACATAACAAAGGAAAG3’ 56°C 30’’ 
7 5’CACATACACACACAGACACACG3’ 5’AAAGGCTATCACTCTGCTGAGG3’ 64°C 30’’ 
8 5’TAAAGGAATATACCTGCTGCAGA3’ 5’ATTCCACTTACATCTACTGCAGA3’ 56°C 90’’ 
9 5’TTTCAAGTGTTAGAGAACTGCCA3’ 5’CCACTGAACTTAACCCAATGAAT3’ 56°C 90’’ 
10 5’TCTAAGATTTCTAGGCTACAGGC3’ 5’GTTGGCTACTGCATACGCAAAC3’ 60°C 30’’ 
11 5’CAGAAAAGTATGCTAGAGAACCA3’ 5’GTAGAACATAACTAAGTTCCCTC3’ 56°C 90’’ 
12 5’CAGGTTTGTTGAATGAGCTTTCT3’ 5’AGGATTCCAAGTGGTCTTGGG3’ 60°C 90’’ 
13 5’GGGGCAGTGGTTTATCTCCTA3’ 5’CACAGTGACACACCAACTGGT3’ 60°C 90’’ 
13A 5’AGAATACCTGAGAGAGCGGGT3’ 5’ACGCAAACACACAGATGACTGA3’ 60°C 90’’ 
14 5’CAGTTGAGTGTCAGTGCTATCT3’ 5’CTGGTGTGAGACAGTATCTCAT3’ 60°C 90’’ 
15 5’ATAAGCATATTCAGAACCAGGCA3’ 5’CTCCACTTTCACATCTTCTGTG3’ 60°C 90’’ 
16 5’TCATCAATTCTGAGGTGCACCA3’ 5’AGAAACCCGCCCAAACTAAT3’ 56°C 30’’ 
17 5’AGCAGATGATATACCACATTGGA3’ 5’GTTCATGCCAGTCATTCATCCA3’ 60°C 30’’ 
18a 5’AGCAGATGATATACCACATTGGA3’  5’GTTCATGCCAGTCATTCATCCA3’ 60°C 30’’ 
19b 5’AGCAGATGATATACCACATTGGA3’  5’GTTCATGCCAGTCATTCATCCA3’ 60°C 30’’ 
Primers used for sequencing are shown in boldfaced type; P means promoter; AT means annealing temperature 
aSequence primer for exon 18 is 5’GTCTTTGCAGGCTATTATA 3’. 
bSequence primer for exon 19 is 5’GCTCAAATGACATAATTTG 3’. 
Fibroblast cultures  
Primary fibroblast cultures from skin biopsies of 6 patients with diffuse cutaneous 
systemic sclerosis (SSc) were established by routine methods. Control cultures were 
obtained from biopsies taken from 10 healthy controls. Cells were grown in minimal 
essential medium alpha (αMEM; Gibco BRL) supplemented with 10% heat-inactivated 
fetal calf serum (FCS), 100 U/ml penicillin and 100 U/ml streptomycin, until they reached 
subconfluence. Cells were detached using 0.5 ml 0.05% trypsin/0.02% EDTA per 25 cm2 
and used for total RNA isolation. 
Real-time PCR analysis 
Total RNA was isolated using the RNeasy kit (Qiagen). Subsequently, the RNA was 
reverse transcribed into cDNA and subjected to real-time PCR amplification. Real-time 
PCR amplification of cDNA sequences was performed for LH1, LH2b, LH3, the α2 chain 
of collagen type 1 (COL1A2) and lysyl oxidase (LOX). A real-time PCR was performed 
for the constitutively expressed β-2-microglobulin (B2M) to standardize for differences 
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in the total amount of cDNA. Each cDNA was amplified using specific primers and 
specific molecular beacons (Table 2 and Table 3, respectively) in a total reaction volume 
of 25 μl, containing 1x PCR buffer (Applied Biosystems), 0.4 mM of each dNTP, 3.5 mM 
Mg2+, 500 nM of each primer and 1 unit Amplitaq Gold polymerase (Applied 
Biosystems). PCR was performed in an ABI PRISM® 7700 Sequence Detection System 
and consisted of a 5-minute interval at 95 ºC, followed by 40 cycles of 95 ºC for 30 s, 56 
ºC for 40 s and 72 ºC for 30 s. Data were analyzed using sequence detector V1.7 
software.  
Table 2: Primers for real-time PCR 
Name Forward primer Reverse primer 
LH1 5’CAAGCGCTCAGCTCAGTTCTTC3’ 5’CTTCAGCAGCCGGACCTTCT3’ 
LH2b 5’TTAAAGGAAAGACACTCCGATCAGAGATGA3’ 5’AATGTTTCCGGAGTAGGGGAGTCTTTTT3’ 
LH3 5’CTGGGCCTGGGAGAGGAGTG3’ 5’TCACGTCGTAGCTATCCACAAACAT3’ 
COL1A2 5’CAAGGACAAGAAACACGTCTGGCTAGGAGAAA3’ 5’CAGGCGCATGAAGGCAAGTTGGGTAG3’ 
LOX 5’GTGGCCGACCCCTACTACATCC3’ 5’AGCAGCACCCTGTGATCATAATCTC3’  
B2M 5’TCTTGTACTACACTGAATTCACCCCCACTGA3’ 5’ATCCAAATGCGGCATCTTCAAACCTC3’ 
Table 3: Molecular beacons for real-time PCR 
Name Sequence 
LH1 5’ FAM-cgtgcCTAGGGGAGGACTGGAATGTGGAGAAGGgcacg-DABCYL 3’ 
LH2b 5’ FAM-cgtgcgCGTGATAAACTGGATCCTGATATGGCTCTTcgcacg-DABCYL 3’ 
LH3 5’ FAM-cgtgcgTCGAACAGTTGGTGGAGGACAGAAGGTcgcacg-DABCYL 3’ 
LOX 5’ FAM-cgtgccATGCGCGGCGGAGGAAAACTGggcacg- DABCYL 3’ 
COL1A2 5’ FAM-cgtgccGGCAGCCAGTTTGAATATAATGTTGAAGGAggcacg-DABCYL 3’ 
B2M 5’ HEX-cgtgcCCTGCCGTGTGAACCATGTGACTTTGgcacg-DABCYL 3’  
FAM, 6-carboxyfluorescein; DABCYL, 4-(4-dimethylaminophenyl)bezoic acid 
PCR amplification of LH2a and LH2b  
cDNA of human liver tissue, control, and SSc fibroblasts was subjected to LH2a 
and LH2b PCR amplification. LH2a (145 bp) and LH2b (208 bp) were co-amplified using 
a specific forward (5’TTAAAGGAAAGACACTCCGATCAGAGATGA3’) and reverse 
primer (5’TAGCCTTCCAAATTCATGTCTATTAGAAATGTA3’) in a total reaction 
volume of 25 μl, containing 1x PCR buffer (Applied Biosystems), 0.4 mM of each dNTP, 
3.5 mM Mg2+, 500 nM of each primer and 1 unit Amplitaq Gold polymerase (Applied 
Biosystems). PCR was performed in a 9600 thermal cycler (Perkin Elmer) and consisted 
of a 5-minute interval at 95 ºC, followed by 35 cycles of 95 ºC for 30 s, 56 ºC for 40 s 
and 72 ºC for 30 s. Aliquots of 15 μl of each amplified sample were subjected to 
electrophoresis in a 2% agarose gel containing ethidium bromide. 
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Figure 2. Missense mutations in PLOD2 lead to BS phenotype. A, 1823/1886C→T mutation 
(in the cDNA sequence of LH2a and LH2b, respectively) in family DR. A sequence 
chromatogram of exon 17 from a healthy control is shown, aligned with those of a heterozygous 
healthy parent and a homozygous BS patient. This mutation leads to a Thr→Ile substitution at 
position 608(LH2a)/629(LH2b). B, 1802/1865G→T mutation in family PM. The sequence 
chromatograms of exon 17 show the sequence of a healthy control, a heterozygous healthy 
parent and a homozygous BS patient. This mutation results in a Gly601/622→Val substitution 
at position 601 (LH2a) and 622 (LH2b). 
A 
Healthy control Heterozygous parent Homozygous BS patient 
B 
Family PM 
Family DR 
Ser
Gly
Val Gly Tyr
TCTGNTGGTTAT
*
CCAA T T G A T G A T 
* 
Pro Ile Asp Asp ThrPro Ile Asp Asp
AANTGATGAT
*
CC
Ser Gly Gly Tyr
TCTGGTGGTTAT
*
Tyr Gly Val Ser
TCTG TT GG TT A T 
* 
*
Pro Thr Asp Asp
CCAACTGA GATT
 
Figure 1. Haplotype analysis in two BS families, family DR (A) and family PM (B), using 5 
microsatellite markers on 3q23. Black symbols denote affected individuals and striped symbols 
denote carriers of the disease. The haplotypes co-segregating with the disease are indicated by a 
black box. Consanguinity is indicated with a double black line. 
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Cross-link analysis 
Measurements were performed on extracellular matrix obtained from fibroblasts 
cultured for 5 weeks in the presence of ascorbic acid (50 μg/ml). Pyridinoline cross-links 
were measured in acid hydrolysates of unreduced samples by reversed-phase high-
performance liquid chromatography.(33;34) 
Statistical analysis  
Statistical analysis was performed using SPSS 11.0 software. Cross-link analysis and 
real-time PCR data are presented as mean ± standard deviation. Patients and controls 
were compared by Student’s t test (two-tailed). 
Gene bank accession numbers 
Chromosome 3 clone RP11-758I14, AC053539; Chromosome 3 clone RP11-
274H2, AC018369; PLOD1, NM_000302; PLOD2, U84573; PLOD3, XM_051244; COL1A2, 
XM_004658; B2M, XM_007650; LOX, NM_002317. 
Results  
Linkage analysis of BS families 
In order to decipher the gene encoding TLH, the gene defect in BS patients was 
examined. In a previous paper we mapped the BS locus on an 18 cM region on 
chromosome 17p12.(29) At that time only a single family was available for genotyping, due 
to the extreme rarity of the disease. To refine the candidate region, two other 
diagnosed BS families (family DR and family PM) were now screened for linkage to 
chromosome 17p12. Surprisingly, genotype analysis excluded the linkage of both families 
to chromosome 17p12. This implies that in addition to a BS locus on chromosome 
17p12, a BS locus on another chromosomal region exists.  
We reasoned that the candidate region for the second BS locus is chromosome 
3q23-q24, as PLOD2 encoding LH2 is located in that region.(30) This assumption was 
based on the observation of a parallel increase of LH2 expression and hydroxyallysine-
derived cross-links in osteogenic progenitor cells during the course of in vitro 
differentiation,(35) which suggests that LH2 catalyzes the conversion of the telopeptide 
lysine residue into hydroxylysine. Indeed, haplotype analysis of family DR and family PM 
revealed that both families confirm the candidate status of chromosome 3q23  
(Figure 1A and Figure 1B).  
Mutation analysis of BS families 
To verify that the BS phenotype in the patients in family DR and family PM is 
indeed due to mutations in PLOD2, a mutation analysis was performed. In both patients 
of family DR a homozygous missense mutation in exon 17 of C→T was found, resulting 
in a Thr→Ile substitution at position 608 and 629 (LH2a and LH2b, respectively). Both 
parents and the healthy sister were carriers of the mutation (Figure 2A). In the same 
exon a homozygous missense mutation of G→T was observed in both patients of family 
PM resulting in a Gly601/622→Val substitution. The parents were heterozygous for the 
mutation (Figure 2B). Neither mutation was detected in a pool of 250 chromosomes of 
healthy individuals, thereby excluding the possibility that these mutations represent  
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Figure 3. Increased LH2b and COL1A2 mRNA expression in SSc fibroblasts. Shown is mRNA 
expression of LH2b/B2M (A), LH1/B2M (B), LH3/B2M (C), COL1A2/B2M (E) and LOX/B2M 
(F) in control (n = 10) and SSc fibroblasts (n = 6). Expression of LH2a and LH2b in liver (1), 
control fibroblasts (2) and SSc fibroblasts (3) is shown in panel D. NC, negative control; M, 
molecular weight marker. 
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Figure 4. The pyridinoline cross-links hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) in 
the extracellular matrix deposited by SSc fibroblasts (n = 4) are increased compared with 
control fibroblasts (n = 7).  
polymorphisms. Mutation analysis of patients from the BS family (family FH) showing 
linkage to chromosome 17p12(29) did not reveal any mutations in the exons, exon/intron 
boundaries, and the promoter region of PLOD2. 
TLH expression in SSc fibroblasts 
Since BS indicates that the specific substrate of LH2 is the lysine residue within the 
collagen telopeptides, we were interested to find out whether the expression of LH2 is 
increased in cells present in fibrotic lesions, as the collagen deposited in fibrotic lesions 
shows an increased hydroxylation of the telopeptides. Real-time PCR analysis of mRNA 
extracted from SSc skin fibroblasts revealed that the expression of LH2b mRNA was 
highly increased in these fibroblasts compared to controls (Figure 3A; controls 0.02 ± 
0.01; SSc patients 0.15 ± 0.06; P = 0.003). Interestingly, LH1 (Figure 3B; controls 0.61 ± 
0.23; SSc patients 1.08 ± 0.82) and LH3 (Figure 3C; controls 0.05 ± 0.02; SSc patients 
0.09 ± 0.07) expression levels were unchanged. Expression of LH2a mRNA was 
undetectable both in controls and in SSc patients (Figure 3D). In agreement with 
previous data,(36;37) elevated levels of COL1A2 mRNA were found in SSc fibroblasts 
(Figure 3E; controls 3.98 ± 2.01; SSc patients 16.53 ± 7.17; P = 0.007). No changes in the 
expression of LOX mRNA (Figure 3F; controls 0.43 ± 0.31; SSc patients 0.49 ± 0.24) 
were observed. Finally, elevated levels of LH2b mRNA expression relative to COL1A2 
mRNA expression were found in SSc fibroblasts (controls 0.0057 ± 0.0034; SSc patients 
0.0098 ± 0.0021; P = 0.009), whereas LH1 (controls 0.18 ± 0.088; SSc patients 0.06 ± 
0.04; P = 0.002), LH3 (controls 0.015 ± 0.007; SSc patients 0.005 ± 0.004; P = 0.002) 
and LOX (controls 0.12 ± 0.08; SSc patients 0.03 ± 0.005; P = 0.004) mRNA expression 
relative to COL1A2 expression was decreased.  
Analysis of the collagen, deposited by fibroblasts cultured from fibrotic skin of SSc 
patients, showed an increase in hydroxyallysine-derived cross-links, indicating that the 
hydroxylation of the collagen telopeptides is also increased in the fibrotic skin of SSc 
patients (Figure 4; controls 0.041 ± 0.017; SSc patients 0.15 ± 0.049; P = 0.016). This is 
in line with previous in vivo data.(38) 
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Discussion 
Fibrosis is characterized by an excessive accumulation of collagen. Furthermore, a 
change in the collagen cross-link chemistry is found in fibrotic lesions. Therapies to 
reduce collagen accumulation in fibrosis are mostly focused on the reduction of collagen 
synthesis and the induction of proteinase activity. A drawback of these approaches is 
that not only the pathological but also the physiological collagen production and 
degradation in the surrounding tissue is affected. Recently, it has been postulated that 
the change in cross-linking, giving a decrease in the proportion of allysine-derived cross-
links in favor of hydroxyallysine-derived cross-links, is a unique process in fibrosis.(8-15) 
The amount of hydroxyallysine-derived cross-links (such as pyridinolines) is related to 
the irreversible accumulation of collagen in fibrotic tissues.(10-12;14;15) This suggests that 
collagen containing hydroxyallysine-derived cross-links is more difficult to degrade and 
contributes therefore significantly to the accumulation of collagen. The increased 
amount of pyridinolines in fibrosis is the consequence of an overhydroxylation of the 
lysine residues within the telopeptides. Although the existence of a telopeptide lysyl 
hydroxylase (TLH) has been postulated,(24;29) the gene encoding TLH had so far not been 
identified. 
Biochemical analysis of the bone of BS patients revealed that the BS phenotype is 
due to the decreased activity of TLH.(29) Three lysyl hydroxylases are known: LH1, LH2, 
and LH3, encoded by PLOD1, PLOD2, and PLOD3, respectively. LH1 is a helical lysyl 
hydroxylase(23;24) whereas the substrate specificity of LH2 and LH3 is unknown. Here we 
show, by means of mutation analysis, two different missense mutations in exon 17 of 
PLOD2 in BS patients, indicating that LH2 is the putative TLH. These mutations are 
situated in an amino acid sequence showing high homology between the different lysyl 
hydroxylases, LH1, LH2, and LH3 and between the lysyl hydroxylases of species ranging 
from Homo sapiens to Caenorhabditis elegans (Figure 5). Such a strict conservation implies 
that this region is important for the function of the lysyl hydroxylases in general, and 
that of LH2 in particular. 
Homo sapiens  LH1 R I Q G G Y E N V P T I D I H M
Homo sapiens  LH2 R I S G G Y E N V P T D D I H M
Homo sapiens  LH3 R L A G G Y E N V P T V D I H M
Bos taurus  LH1 R I Q G G Y E N V P T I D I H M
Rattus norvegicus  LH1 R I Q G G Y E N V P T I D I H M
Mus musculus  LH1 R I Q G G Y E N V P T I D I H M
Mus musculus  Lh2 R I S G G Y E N V P T I D I H M
Mus musculus  LH3 R L A G G Y E N V P T V D I H M
Gallus gallus  LH1 R I Q G G Y E N V P T I D I H M
Drosophila melanogaster  LH R L E G G Y E A V P T R D I H M
Caenorhabditis elegans  LH R L A G G Y E N V P T R D I H M  
Figure 5. Alignment of the sequence region of human LH2, where both mutations (dark gray 
boxes) are located, shows strong homology (light gray boxes) with the sequence of the different 
human LH isoenzymes and the LH isoenzymes of different species. 
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Mutation analysis of patients from a BS family showing linkage to chromosome 
17p12(29) did not reveal any mutations in the exons, exon/intron-boundaries or the 
promoter region of PLOD2. This suggests that these patients must have another defect. 
Patients linked to chromosome 17 should be called Bruck syndrome type I, whereas 
patients showing mutations in PLOD2 belong to the Bruck syndrome type II. This 
subdivision is solely based on genetic data, as we are not aware of phenotypic 
differences.  
BS provides for the first time insight into the substrate specificity of LH2: it is a 
telopeptide lysyl hydroxylase. As the increased amount of pyridinolines in fibrosis is 
likely to be the results of increased TLH activity, we investigated the expression of LH2 
in fibrotic tissues. Analysis of LH1, LH2a, LH2b, and LH3 mRNA expression in fibrotic 
skin of SSc patients revealed that from the collagen modifying enzymes only the mRNA 
level of LH2b relative to COL1A2 was increased. LH2a was undetectable in both 
control and SSc fibroblasts, indicating that this splice variant is absent in skin fibroblasts 
and therefore plays no role in fibrosis. Furthermore, normal mRNA levels of LOX were 
found, which is the enzyme catalyzing the formation of Lysald and Hylald, a step necessary 
for the formation of cross-links. The increase in pyridinoline cross-links as found in our 
fibroblast cultures of SSc patients is therefore not due to increased aldehyde formation. 
Together, these results imply that only LH2b can be responsible for the 
overhydroxylation of collagen telopeptide lysine residues in SSc skin, leading to the 
increased formation of pyridinolines. It is therefore reasonable to assume that LH2b 
plays an important role in the irreversible accumulation of collagen in fibrosis. 
The type of cross-link provides a mechanism for regulating the rate of collagen 
catabolism.(10-12;14;15) The inhibition of the formation of hydroxyallysine-derived cross-
links by specifically inhibiting TLH, in order to favor the formation of allysine-derived 
cross-links, is likely to make the collagen more susceptible to proteolytic degradation, 
leading to a decrease in collagen accumulation. An additional advantage of this approach 
is that the collagen synthesis needed for normal remodeling of the tissue is not 
compromised, as TLH upregulation is specifically seen in fibrosis. Inhibition of LH2 is 
therefore an attractive way to interfere with fibrotic processes, making LH2 a new and 
promising target for anti-fibrotic therapies.  
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Abstract 
Bruck syndrome (BS), an autosomal recessive disease, is phenotypically characterized by 
osteoporosis, joint contractures at birth, fragile bones, and short stature. The 
biochemical defect underlying the BS phenotype is an affected collagen cross-linking in 
bone. An almost complete absence of hydroxyallysine-derived cross-links has been 
observed in BS bone, which is the consequence of strongly reduced hydroxylated lysine 
levels in the collagen telopeptides. Recently, the underhydroxylation of collagen 
telopeptides has been found to be accompanied by mutations in PLOD2 (BS type II), 
encoding lysyl hydroxylase 2 (LH2), an enzyme predominantly hydroxylating lysine 
residues within collagen telopeptides. However, in one BS family, the BS locus has been 
mapped to chromosome 17p12, and patients of this family do not have mutations in 
PLOD2, located on chromosome 3 (BS type I). In the present study we report three 
additional unrelated BS patients having no sequence variations in PLOD2. Data on LH2a 
and LH2b expression pattern (splice variants of LH2) in differentiated osteoblasts and 
TGF-β stimulated fibroblasts showed an underhydroxylation of collagen telopeptide in 
BS type I patients despite normal LH2a and LH2b mRNA expression levels. The changes 
in collagen telopeptide hydroxylation in BS type I bone thus seem the consequence of 
factors other than mutations in PLOD2 or a reduced PLOD2 transcription. 
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Introduction 
Bruck syndrome (BS; OMIM 259450) is an autosomal recessive disease that 
clinically resembles osteogenesis imperfecta (OI). The phenotype of BS is characterized 
by joint contractures at birth, recurrent bone fractures in infancy and early childhood, 
skeletal deformations, short stature, and the presence of kyphoscoliosis. Unlike OI, BS 
patients do not have blue sclerae or hearing loss and mental development is normal. BS 
is an exceptionally rare disease: in total 26 patients have been described worldwide, 
distributed over 18 families.(1-12) In contrast to OI,(13) the phenotype of BS patients is not 
associated with mutations in the genes encoding collagen type I α1 or α2 (COL1A1 and 
COL1A2, respectively).(5) The biochemical defect in BS patients is an aberration in 
collagen cross-linking in bone. An almost complete absence of hydroxyallysine-derived 
cross-links has been observed in the collagen that is deposited in BS bone, whereas 
normal levels of these cross-links are found in tendon and cartilage.(14) The affected 
collagen cross-linking in BS bone is accompanied by a reduction in mineral content and 
an increase in the size of hydroxyapatite crystals.(3)  
Hydroxyallysine cross-links are derived from the cross-link pathway in which two 
hydroxylated lysine residues within the collagen telopeptide are converted to the 
aldehyde hydroxyallysine, followed by a reaction with a lysine (Lys) or hydroxylysine 
(Hyl) residue within the triple helix in order to form di- and tri-functional cross-links. 
Mature tri-functional hydroxyallysine derived cross-links are lysyl pyridinoline (LP) and 
hydroxylysylpyridinoline (HP).(15-18) The counterparts of the hydroxyallysine cross-links 
are the allysine cross-links. These cross-links are derived from a Lys residue within the 
telopeptides and a Lys, Hyl and/or histidine residue within the triple helix.(15-18) Cross-
links derived from the hydroxyallysine route occur in a variety of connective tissues, 
including bone, cartilage and tendon, whereas collagen in the skin is mainly cross-linked 
via the allysine route.(19) 
The strongly reduced hydroxyallysine cross-link levels in BS bone collagen point to 
a near absence of hydroxylated lysine residues within the telopeptides. Hydroxylation of 
Lys residues within the triple helix appeared to be unaffected, thus implying defective 
telopeptide lysyl hydroxylase (TLH) activity but unaffected helical lysyl hydroxylase 
activity in BS bone.(14) Recently, in three unrelated families (six patients), the BS 
phenotype was found to be associated with mutations in procollagen-lysine, 2-
oxoglutarate 5 dioxygenase 2 (PLOD2).(10;12) PLOD2, encoding lysyl hydroxylase 2 (LH2), 
belongs to the lysyl hydroxylase family (EC 1.14.11.4) which consists of LH1, LH2, and 
LH3 encoded by PLOD1, PLOD2 and PLOD3, respectively.(20-23) Alternative RNA splicing 
has only been described for PLOD2, resulting in the splice variants LH2a and LH2b 
(LH2b contains an extra exon).(24;25) The substrate specificity of the different LH 
becomes clear from studies into pathological matrix cross-linking. Ehlers-Danlos type VI 
syndrome revealed that LH1 predominantly catalyzes hydroxylation of Lys residues 
within the collagen triple helix.(26) The mutations in the gene encoding LH2 found in BS 
patients indicate that LH2 predominantly catalyzes the conversion of telopeptide Lys 
residues into Hyl. In addition, the TLH activity of LH2 was confirmed by several other 
studies.(27-30) The lysine substrate specificity (telopeptides and/or triple helix) of LH3 is 
unknown. 
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Interestingly, three clinically, phenotypically, and biochemically characterized BS 
patients belonging to one large family (family FH), did not show any sequence differences 
in the coding region nor in the promoter region of PLOD2.(10) These results match with 
the finding that the BS locus in this family was mapped on an 18-centimorgan region on 
chromosome 17p12(14) and not on chromosome 3q23-q24 where PLOD2 is located.(31) 
Solely on the basis of genetic data, as no biochemical differences could be observed, BS 
patients were subdivided in BS type I (without PLOD2 mutations) and BS type II patients 
(with PLOD2 mutations). In the present study three additional unrelated BS patients are 
described as belonging to BS type I. Since the biochemical characteristics found in BS 
type I bone cannot be ascribed to mutations in PLOD2, a logical explanation would be 
that the transcription of PLOD2 in osteoblasts is affected. A reduced LH2 expression in 
osteoblasts would explain the underhydroxylation of telopeptide Lys residues in bone 
collagen. Remarkably, LH2a and LH2b expression patterns in cultured osteoblasts were 
found to be normal. In addition, LH2b expression was equally induced in skin fibroblasts 
from BS type I and healthy controls when stimulated with transforming growth factor β1 
(TGF-β1). These findings indicate that the decrease in hydroxyallysine cross-linking in BS 
type I patients is not the consequence of an affected PLOD2 transcription.  
Materials and methods 
BS patients 
Patients used in this study were all clinically diagnosed as BS patients. Patient 
FH505 (BS type I), FH507 (BS type I), PM (BS type II), DB, and RY were previously 
described in the literature (case 2, 3, and 8 of ref 4, and case 1 and 3 of ref 5), 
respectively). Patient BR has not been described so far. This 9-year-old girl is the 
daughter of two related parents. The family with a Turkish origin consists, besides the 
affected girl, of one healthy boy. Tissue collection from the patients was by agreement 
with the patients and their parents and approved by the Local Ethical Committee.  
Table 1: Primers used for sequencing of LH2 cDNA 
Location (LH2b) Sequence 
301-323 5’GCTGATCAAGATGATCTGGTTGT3’ 
420-398 5’TGCTGCAAAGACCACTTTGTGGT3’ 
1008-1030 5’TGATGTCCTTTTCATGATAAACT3’ 
1171-1192 5’GTGGATGCAGATGTTGTTTTGAC3’ 
1864-1886 5’GGTGGTTATGAAAATGTCCCAAC3’ 
2041-2063 5’GTATGAGGACGAAGAGAACGCTG3’ 
Mutation analysis 
Blood samples of two BS patients (patient DB and RY) were collected and genomic 
DNA was prepared by standard methods. To detect DNA sequence variations in 
PLOD2, exons, exon/intron boundaries as well as a part of the promoter region of 
PLOD2 were amplified and sequenced as described earlier.(10) For patient BR, total RNA 
was isolated (Rneasy kit Qiagen) from fibroblasts and mRNA was subsequently reverse 
transcribed into cDNA. The whole coding region of LH2 was amplified using specific 
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primers (5’GGCTATTCTAGACCATGGGGGGATGCACGGTGAAGCCTCAG3’ and 
5’ATGATGATGGGGATCTATAAATGACACTGC3’) using La Taq polymerase 
(TaKaRa). A PCR consisted of a 5-minute interval at 95 ºC, 35 cycles of 95 ºC for 1 min, 
58ºC for 60 s, and 68 ºC for 120 s. Finally, an extension step of 10 min at 68 ºC was 
performed. The purified PCR product served as a template for cycle sequencing using 
the above-mentioned primers and the primers listed in Table I. To detect sequence 
variations in the PLOD2 promoter region, genomic DNA was isolated from cultured 
fibroblasts obtained from patient BR and amplified and sequenced as described 
previously.(10) 
Osteoblastic differentiation culture 
Liquid nitrogen stored Ficoll-separated human bone marrow cells obtained from 
patient FH505, patient PM, and 9 age- and sex-matched healthy children were cultured 
at a density of 107 cells/25 cm2 in minimal essential medium alpha (αMEM; Gibco BRL), 
supplemented with 10% heat inactivated fetal calf serum (FCS), 100 U/ml penicillin and 
100 U/ml streptomycin, until they reached subconfluence. Cells were detached using 0.5 
ml 0.05% trypsin/0.02% EDTA per 25 cm2 and re-seeded. At passage three, cells were 
re-seeded at a plate density of 2.5x104 cells/cm2 in osteogenesis-inducing αMEM medium 
consisting of 10% heat-inactivated FCS, 100 U/ml penicillin, 100 U/ml streptomycin, 50 
μg/ml ascorbic acid and 10-7 M dexamethason. From day 7 onwards, 5 mM β-
glycerophosphate was added to the medium to induce mineralization. Cultures were 
incubated in a humid atmosphere at 5% CO2 at 37 ºC and 3/5 of the medium was 
renewed every 4 days. Cells were collected at days 3, 7, 10, 14, 18, and 21 and used for 
RNA isolation. At day 21 the extracellular matrix deposited was harvested.  
TGF-β1 stimulation of skin fibroblasts 
Primary skin fibroblasts were established by routine methods from four BS patients 
(patient FH505, FH507, BR and PM) and seven healthy individuals, and cultured in 10 
cm2 wells (short culture) or 25 cm2 flasks (long-term culture) in Dulbecco’s modified 
Eagle’s medium (DMEM; BioWhittaker) supplemented with 10% heat-inactivated fetal 
calf serum (FCS), 100 U/ml penicillin and 100 U/ml streptomycin at 37 °C in 5% CO2. 
Fibroblasts that reached subconfluence were used for stimulation experiments. For 
RNA analysis, cells were washed in PBS and starved for 3 hours in DMEM supplemented 
with 0.1% BSA, 100 U/ml penicillin and 100 U/ml streptomycin. Thereafter, fibroblasts 
were cultured for a short period (24 hours) in DMEM supplemented with 0.1% BSA, 
100 U/ml penicillin and 100 U/ml streptomycin in the presence or absence of 1 ng/ml 
recombinant human TGF-β1 (Sigma). For extracellular matrix analysis, long-term 
cultures were performed in which fibroblasts were cultured for 4 weeks in DMEM 
supplemented with 5% FCS, 100 U/ml penicillin, 100 U/ml streptomycin and 50 μg/ml 
ascorbic acid in the presence or absence of 1 ng/ml TGF-β1. After 4 weeks of culture, 
the deposited matrix was washed in PBS; the cells present in the matrix were killed by 
two freeze-thaw cycles. Finally, the remaining matrix was incubated in PBS at 37 °C for 
another week to enable cross-link maturation.(32)  
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Real-time PCR analysis 
Total RNA, obtained from osteoblast cultures and TGF-β1 stimulated fibroblasts, 
was isolated using the RNeasy kit (Qiagen). Subsequently, the RNA was reverse 
transcribed into cDNA and subjected to real-time PCR amplification. Real-time PCR 
amplification of cDNA sequences of LH1, LH2b, LH3 and COL1A2 was performed as 
described previously.(10) LH1, LH2b, LH3, and COL1A2 mRNA expression in each 
sample was corrected for differences in mRNA expression of the constitutively 
expressed β-2-microglobuline (B2M) gene to standardize for differences in the amount 
of total RNA between the samples. LH2a expression was measured using a PCR 
amplifying both LH2a and LH2b.(10) To gain insight into the total expression of the 
different genes over 21 days of osteoblastic differentiation, mRNA expression was 
measured at days 3, 7, 10, 14, 18, and 21 during culture and the area under the curve 
(AUC) was calculated.  
Cross-link and amino acid analysis  
Measurements were performed on the extracellular matrix obtained from long-
term (4 weeks) fibroblast cultures and on the matrix collected at day 21 from 
osteoblastic differentiation cultures. Moreover, cross-links and amino acid levels were 
measured in urine obtained from BS patients and healthy controls. Hydroxyproline 
(Hyp) and Hyl levels in the matrix deposited by skin fibroblasts and osteoblasts were 
determined in acid hydrolysates of matrix samples after derivatization with 9-
fluorenylmethyl chloroformate by reverse-phase high-performance liquid 
chromatography (RP-HPLC).(33) Urinary Hyp levels were determined in urine hydrolyzed 
in 6 M HCl after derivatization with FMOC and ο-phtaldialdehyde by means of RP-
HPLC.(34) Hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) cross-links were 
measured in the same acid hydrolysates.(35;36) Pyridinoline and Hyl levels were expressed 
as the total amount of residues per collagen molecule, assuming 300 Hyp residues per 
triple helix. 
Statistical analysis 
Statistical analysis was performed using SPSS 11.0 software. Statistical differences 
between values were examined by Student’s t test (two-tailed). P values less than 0.05 
were considered to indicate statistically significant differences. 
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Results 
Mutation analysis of biochemically confirmed BS patients 
Strongly reduced pyridinoline cross-link levels have been found to be the 
biochemical defect of BS bone.(14) Recent data revealed that the (HP + LP)/Hyp ratio of 
urinary collagen degradation products is a good diagnostic marker for BS patients (RA 
Bank, unpublished data).(12) Healthy children show an average ratio of 2.80 (range: 1.83-
4.31; Table 2), whereas in all BS patients tested, it is below 1. The (HP+LP)/Hyp ratio 
discriminates between BS and OI as well: the average in children suffering from non-
lethal OI was shown to be 2.67 (range: 1.31-5.10). Patients examined in this study were 
all clinically diagnosed as BS patients,(4;5) and the biochemical analysis of urinary collagen 
degradation products showed that the (HP + LP)/Hyp ratio was below 1 for all patients, 
which confirms that these patients indeed suffer from BS.  
Recently, we found that the BS phenotype is in some cases associated with 
mutations in PLOD2 (BS type II).(10;12) In this study, three additional BS patients (patient 
DB, RY and BR) distributed over 3 families and unrelated to previously studied patients, 
were screened for mutations in PLOD2. Sequence analysis of the coding region and the 
promoter region of PLOD2 did not reveal any sequence differences in the three patients 
when compared to healthy controls and these patients were thus classified as BS type I.  
Table 2: Urinary (HP+LP)/Hyp levels as diagnostic marker for BS. 
 (HP + LP) /Hyp (mean ± sd) 
Controls (n=76) 2.8 (± 0.5; range 1.83-4.31) 
OI patients (n=38 ) 2.67 (± 0.73; range 1.31-5.10) 
BS patient FH505 0.82 
BS patient FH507 0.55 
BS patient PM 0.28 
BS patient DB 0.46 
BS patient RY 0.79 
BS patient BR 0.52 
HP + LP in nM/mM creatinine; Hyp in uM/mM creatinine 
Table 3: LH and COL1A2 mRNA expression during in vitro osteoblastic differentiation 
mRNA expression (AUC 0 - 21 days) 
 Control (mean ± sd; n = 7) BS1 (FH505) BS2 (PM) 
LH1/B2M 2.74 ± 1.50 1.96 2.40 
LH2b/B2M 3.31 ± 2.58 2.81 3.18 
LH3/B2M 0.92 ± 0.79 0.82 0.96 
COL1A2/B2M 62 ± 36 77 81 
LH1/COL1A2 0.046 ± 0.024 0.027 0.030 
LH2b/COL1A2 0.038 ± 0.019 0.026 0.040 
LH3/COL1A2 0.015 ± 0.012 0.009 0.012 
AUC, area under curve; BS1, BS type I; BS2, BS type II 
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LH2b expression in in vitro-differentiated BS osteoblasts  
Apparently, strongly reduced hydroxylated lysine levels within the telopeptides in 
bone of BS type I patients cannot be ascribed to decreased functionality of LH2 due to 
mutations in PLOD2. Therefore, we investigated whether LH2 transcription is affected in 
in vitro differentiated BS type I osteoblasts. Bone marrow stromal cells from a BS type I 
patient (patient FH505), a BS type II patient (patient PM) and healthy controls were 
cultured in osteogenesis-inducing medium and osteoblastic differentiation was confirmed 
by the presence of alkaline phosphatase activity and by the deposition of minerals. Real-
time PCR analysis revealed that total LH2b mRNA expression during 21 days of 
differentiation was similar in patient FH505, patient PM, and healthy controls (Table 3). 
In addition, in comparison to controls, neither BS patients showed differences in LH2b 
expression relative to COL1A2. LH2a was almost undetectable in all cultured 
osteoblasts (BS and controls; data not shown). Analysis of mRNA expression of the 
other lysyl hydroxylases LH1 and LH3 during osteoblastic differentiation revealed 
normal expression levels in both BS patients as well, also when calculated in relation to 
COL1A2 (Table 3).  
A close examination of LH2b expression at the different phases during osteoblastic 
differentiation (proliferation, early differentiation, and mineralization) showed similar 
expression at all phases. This was observed in both healthy control and BS cells (data 
not shown). We did not find increased LH2b expression at the mineralization stage 
which was previously demonstrated by Uzawa et al.(29) 
In line with in vivo data obtained from patient FH505 and patient PM,(14) reduced 
total pyridinoline cross-link levels (HP + LP) were observed in the matrix deposited 
over the 21 days of osteoblastic differentiation (Table 4). Unexpectedly, the in vitro 
cross-linked collagen in both BS patients showed a reduction in HP/LP ratio compared 
to controls, which was not observed in vivo.(14) Triple helical Hyl levels in the BS type I 
patient were similar to the controls, whereas a slight reduction was found in the BS type 
II patient (Table 4).  
Table 4: Pyridinoline cross-linking and lysyl hydroxylation in matrix deposited at day 21 during 
in vitro osteoblastic differentiation. 
Residues per collagen molecule (mol/mol) 
 Control (mean ± sd; n = 9) BS1 (FH505) BS2 (PM) 
HP+LP 0.50 ± 0.13 0.11 0.08 
HP/LP 3.46 ± 1.08 1.69 1.48 
Hyl 59 ± 9 54 38 
BS1, BS type I; BS2, BS type II 
TGF-β stimulation of BS fibroblasts 
We have found that the profibrotic cytokine TGF-β induces LH2b mRNA 
expression in healthy skin fibroblasts which is associated with increased pyridinoline 
cross-link formation in the deposited matrix.(32) Therefore, we investigated whether the 
BS skin fibroblasts were susceptible to TGF-β1 induction with respect to LH2b 
expression and pyridinoline cross-linking. TGF-β stimulation of skin fibroblasts obtained 
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from BS type I patients (patient FH505, FH507 and BR) and a type II patient (patient 
PM), revealed an induction of LH2b mRNA expression in all patients similar to that of 
healthy skin fibroblasts (Figure 1A). In addition, the LH2b/COL1A2 mRNA ratio from 
TGF-β-stimulated BS type I and type II fibroblasts was normal as well (Figure 1B). LH2a 
was undetectable in fibroblasts obtained from healthy individuals and TGF-β1 slightly 
induced LH2a expression. The same LH2a expression pattern was observed in BS 
fibroblasts (data not shown). Both types of BS patients, as well as controls, revealed 
comparable mRNA expression levels of LH1 and LH3 in their TGF-β stimulated 
fibroblasts (Figure 1A), also when calculated in relation to COL1A2 (Figure1B). As 
expected basal pyridinoline cross-link levels were much lower in matrices deposited by 
healthy skin fibroblasts in comparison to the levels found in matrices deposited by 
differentiated osteoblasts (Figure 2A; Table 4). Interestingly, the pyridinoline levels in 
matrices produced by controls and BS patients were similar when unstimulated, but 
TGF-β failed to induce pyridinoline cross-link formation in the matrix deposited by all 
BS fibroblasts. The cross-links formed in the collagen matrix deposited by stimulated 
and unstimulated BS fibroblasts revealed strongly reduced HP/LP ratio (Figure 2B), but 
the number of triple helical Hyl was similar in the matrix deposited by BS fibroblasts and 
healthy controls and was not affected by TGF-β treatment (Figure 2C).  
Discussion 
An almost complete absence of hydroxylated telopeptide Lys residues in bone 
collagen in BS patients has been found to be accompanied by mutations in PLOD2 (BS 
type II).(10;12) However, three BS patients belonging to one family (family FH) were 
biochemically indistinguishable from BS type II, but did not show sequence differences in 
PLOD2 (BS type I).(10) In the present report, we describe three additional children 
biochemically and clinically diagnosed as BS patients, whose phenotype could not be 
ascribed to mutations in PLOD2. The three patients belong to three unrelated families; 
on the basis of the genetic data they should be classified as BS type I. This BS type is 
thus not restricted to one family: BS type I is now known to occur in four unrelated 
families. BS type II is found in three unrelated families. So, it seems that the occurrence 
of both BS types is equally distributed.  
The strongly reduced hydroxylation of telopeptide Lys residues in bone of BS type 
I patients cannot be ascribed to the decreased catalytic properties of LH2 as a result of 
sequence variations in PLOD2. Interestingly, our data revealed that the near absence in 
telopeptide lysyl hydroxylation can neither be explained by reduced LH2 mRNA 
expression. In vitro osteoblastic differentiation experiments demonstrate that normal 
transcriptional regulation of LH2b is accompanied by a 5-fold decrease in pyridinoline 
cross-links. LH2a mRNA levels were nearly undetectable in osteoblasts from both BS 
patients and controls, indicating that this splice variant plays no significant role in 
osteoblasts. Moreover, we found that TGF-β1 induces an elevated LH2a and LH2b 
mRNA expression in BS type I fibroblasts similar to controls, but that TGF-β1 was at 
the same time unable to elevate pyridinoline cross-link levels in matrices deposited by 
BS type I fibroblasts. 
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Figure 1. Similar induction of LH2b mRNA expression by TGF-β1 in control and BS 
fibroblasts. LH1, LH2b, LH3, and COL1A2 mRNA levels in TGF-β1 stimulated skin fibroblasts 
obtained from healthy controls (n = 7), BS type I patients (BS1; n = 3), and BS type II patients 
(BS2; n = 1) are relatively expressed to B2M (A). LH1, LH2b, and LH3 mRNA expression 
relative to COL1A2 is shown in (B). mRNA levels in unstimulated cells were set at 100%. 
Data are presented as mean ± SEM. * indicates P ≤ 0.01 for TGF-β1 stimulated cells versus 
unstimulated cells. 
LH2 transcription in BS type I 
83 
Figure 2. TGF-β1 is not able to induce pyridinoline cross-link formation in matrix deposited by 
BS fibroblasts. HP+LP levels in the collagen matrix deposited by unstimulated and TGF-β1 
stimulated fibroblasts obtained from healthy individuals (n = 5), BS type I patients (BS1; n = 3), 
and BS type II patients (A; BS2; n = 1). Collagen deposited by stimulated and unstimulated BS1 
and BS2 fibroblasts showed reduced HP/LP ratios (B). Triple helical Hyl levels were normal in BS 
collagen matrix (C). Data are presented as mean ± SEM. * indicates P ≤ 0.01 for TGF-β1-
stimulated cells versus unstimulated cells. 
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Both the fibroblasts and osteoblasts data, thus demonstrate a disturbed telopeptide Lys 
hydroxylation in BS type I patients despite normal LH2a and LH2b transcription levels. 
These findings indicate that the biochemical defect in BS type I patients cannot be 
ascribed to an affected transcriptional regulation of LH2a and LH2b. Rather, these data 
indicate that another factor might also be involved in the hydroxylation of Lys residues 
in the telopeptides. 
A clue to this factor can be obtained by linkage analysis. The previously described 
BS type I family (family FH) revealed linkage to an 18-centimorgan region on 
chromosome 17p12.(14) Unfortunately, the BS type I families described in this paper are 
too small to perform homozygosity mapping. Therefore, we were unable to confirm the 
BS locus on chromosome 17p12 in these families, and further delimitation of the BS 
locus on chromosome 17p12 to find a candidate gene for BS type I was therefore not 
possible.  
An interesting observation is that the total level of pyridinoline cross-linking of the 
matrix laid down by osteoblasts from the BS type II patient (with PLOD2 mutation) is 
not entirely zero. This is in agreement with the in vivo data showing that bone of BS type 
II still contains residual levels of pyridinoline cross-links.(14) In addition, total pyridinoline 
levels (HP + LP) in unstimulated fibroblasts of the BS type II patients are similar to 
controls. These findings suggest that basal TLH activity is still present in BS type II cells. 
It is possible that the PLOD2 mutation in this patient does not entirely inhibit the activity 
of LH2. However, this contrasts with the observations (i) that in the TGF-β stimulated 
fibroblasts no increase is seen in pyridinoline cross-linking, despite the upregulation of 
LH2, and (ii) that the basal pyridinoline cross-link level in the unstimulated fibroblasts is 
the same as in the control group. It is more likely that LH1 and/or LH3 is responsible 
for this low basal TLH activity. This explanation is strengthened by the fact that the 
expression of LH1 and LH3 relative to COL1A2 was not increased in TGF-β stimulated 
fibroblasts: neither were the cross-links. In this context, it is of further interest, that 
Mercer et al,(27) found a slight increase in pyridinoline cross-links in cells that 
overexpress LH1, and that Takaluoma et al,(37) demonstrated that LH1 and LH3 are able 
to hydroxylate peptides corresponding to N- and C-telopeptides.  
Basal levels of pyridinoline cross-links (HP + LP) per collagen molecule in the 
matrix deposited by both BS type I and II fibroblasts were similar to controls. 
Nevertheless, pyridinoline cross-linking seems to be affected as HP/LP ratios were 
dramatically decreased in the collagen matrix deposited by the unstimulated and  
TGF-β1-stimulated BS fibroblasts. The matrix deposited by differentiated osteoblasts 
revealed a reduced HP/LP ratio as well. This reduction was not observed in BS type I or 
type II bone.(14) The reduced HP/LP ratios are not the consequence of differences in the 
total hydroxylation levels of the triple helix, as they were found to be normal in the 
collagen matrix deposited by the cultured BS cells. In bone collagen, two-third of the LP 
is distributed at the N-telopeptide to helix site.(38) We cannot rule out that in our 
culture system the N-telopeptide of BS collagen is hydroxylated in favor of the C-
telopeptide with the consequence that the pyridinoline cross-links predominantly 
constitutes LP cross-links. This could explain the low HP/LP ratios. 
In conclusion, our findings reveal that the strongly reduced TLH activity in BS type 
I patients can be explained neither by mutations in PLOD2 nor by disturbed LH2a and 
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LH2b transcription. PLOD1 and PLOD3 are also excluded from being candidate genes, at 
least in family FH, as the BS locus in this family is not situated in the region where 
PLOD1 and PLOD3 are situated (chromosome 1 and 7, respectively).(31;39) As the 
biochemical pattern in BS type I and BS type II is indistinguishable, we postulate that an, 
as yet unknown, factor co-acting with LH2 is involved in catalyzing the conversion of 
telopeptide Lys into Hyl and that this factor is absent or mutated in BS type I 
osteoblasts and TGF-β-stimulated fibroblasts. We assume that the gene encoding this 
factor is situated on chromosome 17p12, the locus that was pinpointed for the BS type I 
family originally described.  
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Abstract 
Fibrosis is characterized by an excessive accumulation of collagen which contains 
increased levels of pyridinoline cross-links. The occurrence of pyridinolines in the matrix 
is an important criterion in assessing the irreversibility of fibrosis, which suggests that 
collagen containing pyridinoline cross-links significantly contributes to the unwanted 
collagen accumulation. Pyridinoline cross-links are derived from hydroxylated lysine 
residues located within the collagen telopeptides (hydroxyallysine pathway). Here, we 
have investigated whether the increase in hydroxyallysine-derived cross-links in fibrotic 
conditions can be ascribed to an increased expression of one of the lysyl hydroxylases 
(LH1, LH2 with its splice variants LH2a and LH2b, or LH3) and/or to an increased 
expression of lysyl oxidase (LOX). In fibroblast cultures of hypertrophic scars, keloid 
and palmar fascia of Dupuytren’s patients, as well as in activated hepatic stellate cells, 
increased levels of LH2b expression were observed. Only minor amounts of LH2a were 
present. In addition, no consistent increase in the mRNA expression levels of LH1, LH3, 
and LOX could be detected, suggesting that LH2b is responsible for the 
overhydroxylation of the collagen telopeptides and the concomitant formation of 
pyridinolines as found in the collagen matrix deposited in long-term cultures by the 
same fibrotic cells. This is consistent with our previous observation that LH2b is a 
telopeptide lysyl hydroxylase. We conclude that the increased expression of LH2b, 
leading to the increased formation of pyridinoline cross-links, is present in a wide variety 
of fibrotic disorders and represents thus a general fibrotic phenomenon.  
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Introduction 
Fibrosis is a common pathophysiological process as a response to chronic damage 
or inappropriate tissue repair. The main characteristic of fibrosis is an excessive 
accumulation of collagen which is the result of increased collagen synthesis and a 
decreased protease activity responsible for collagen degradation.(1) Another factor that 
seems to be involved in the excessive accumulation of collagen is the altered mode of 
collagen cross-linking found in fibrotic lesions.  
Collagen cross-linking is the final step in the biosynthesis of collagen fibrils. Two 
related cross-link routes are responsible for the formation of collagen cross-links, the 
allysine route and the hydroxyallysine route. In the allysine route, a lysine (Lys) residue 
within the telopeptide is converted by lysyl oxidase (LOX) into the aldehyde allysine, 
whereas in the hydroxyallysine route a hydroxylysine (Hyl) residue within the 
telopeptide is converted into the aldehyde hydroxyallysine. In both routes the aldehyde 
subsequently reacts with a Lys, Hyl and/or histidine (His) residue within the triple helix 
to form di-, tri-, or tetra-functional cross-links.(2-5) Cross-links derived from the 
hydroxyallysine route occur in a variety of connective tissues, including bone, cartilage 
and tendon,(6) whereas collagen in the skin is mainly cross-linked via the allysine route. 
Interestingly, during the fibrotic process a switch from the allysine route to the 
hydroxyallysine route occurs(7) which results in the increased formation of pyridinoline 
cross-links derived from the hydroxyallysine route. This switch seems to be a general 
fibrotic phenomenon, as increased formation of hydroxyallysine cross-links (such as 
pyridinolines) has been found in various fibrotic tissues and organs, such as the skin 
(hypertrophic scars, keloid, systemic sclerosis and lipodermatosclerosis),(7-13) the lung 
(infant/adult respiratory distress syndrome and interstitial lung disease),(14;15) the liver 
(parasitic, viral, and alcoholic cirrhosis),(16-18) the kidney (glomerulosclerosis and 
interstitial fibrosis),(19) and the palmar fascia (Dupuytren’s disease).(20;21) The observation 
that the increased formation of hydroxyallysine cross-links is related to the irreversible 
accumulation of collagen in fibrotic lesions suggests that collagen containing these kind 
of cross-links is more difficult to degrade, thereby contributing to the unwanted collagen 
accumulation.(8;12;14;17;22)  
The increased formation of pyridinoline cross-links in fibrotic lesions is the result 
of an overhydroxylation of Lys residues within the collagen telopeptides. Lysyl 
hydroxylase 2 (LH2) has been identified as a telopeptide lysyl hydroxylase (TLH).(23;24) 
LH2 is a member of the lysyl hydroxylase family consisting of LH1, LH2a, LH2b, and LH3 
(EC 1.14.11.4).(25-28) LH2a and LH2b are alternative RNA splice variants of the LH2 gene 
(LH2b contains an extra exon).(29;30) Whereas LH2 hydroxylates telopeptide Lys 
residues, LH1 catalyzes the conversion of triple helical Lys residues into Hyl;(31;32) the 
substrate specificity of LH3 is unknown. We have found in fibroblasts cultured from the 
fibrotic skin of systemic sclerosis patients (SSc) an increased level of LH2b mRNA 
expression; this was associated with elevated levels of pyridinolines in the matrix 
deposited by these fibroblasts.(24) These data indicate that an increased level of LH2b is 
responsible for the overhydroxylation of the collagen telopeptides as found in the 
fibrotic skin of SSc patients. Here we investigate whether an increase in LH2b 
expression is, in concordance with the general increased level of hydroxyallysine cross-
links seen in fibrosis, a general phenomenon. If so, LH2b would be an attractive target 
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with respect to the treatment of fibrosis. In addition, we investigated whether the 
expression of three other collagen-modifying enzymes, namely LH1, LH3, and LOX, is 
generally increased in fibrosis as well. The expression of these genes was studied in 
fibroblasts cultured from hypertrophic scars, keloid, the fibrotic palmar fascia of 
Dupuytren’s disease patients and in activated hepatic stellate cells (HSCs). The latter 
cells are responsible for liver fibrosis.(33) We found an increased LH2b mRNA 
expression in all cultured fibrotic fibroblasts. In contrast, no consistent increase was 
found in the expression levels of LH1, LH3 and LOX, indicating that LH2b is responsible 
for the overhydroxylation of the collagen telopeptides in the extracellular matrices 
deposited by the fibrotic fibroblasts.  
Materials and methods 
Cell cultures 
To obtain primary fibroblast cultures, split skin biopsies of healthy donors, which 
serve as controls in all experiments (n = 10), and specimens of different fibrotic tissues 
(hypertrophic scar, n = 8; keloid, n = 6; and the palmar fascia of Dupuytren’s disease 
patients, n = 4) were collected. Tissues were incubated in serum-free Dulbecco’s 
Modified Eagles Medium (DMEM) containing ultraglutamine I, 0.8 mg/ml collagenase type 
II (CLS2 Worthington Biochemical), 100 units/ml penicillin and 100 units/ml 
streptomycin, for 3 hours at 37 °C under continuously stirring, in order to isolate the 
cells. Subsequently, the suspension was filtered through a nylon gauze and the filtered 
cells were washed and cultured in DMEM containing 10% heat-inactivated fetal calf 
serum (FCS), 100 units/ml penicillin and 100 units/ml streptomycin at 37 °C in 5% CO2. 
Cells were passaged by trypsinization (0.05% trypsin/0.02% EDTA; Gibco) after they 
reached sub-confluence. Primary fibroblasts of one keloid donor were obtained from 
the American Type Culture Collection (ATCC; CRL-1762).  
Hepatic stellate cells (HSCs; n = 3) were obtained either from tumor-free human 
liver tissue obtained during hepatectomy performed to remove a tumor from patients 
with no previous liver disease, or from a healthy donor liver unsuitable for 
transplantation because of the age of the donor. The cells were isolated from livers of 
healthy individuals following the collagenase/pronase method as described earlier,(34) and 
cultured in the same medium as the above mentioned fibroblasts cultures. Quiescent 
HSCs from healthy individuals cultured on plastic spontaneously transform into activated 
HSCs, having a similar phenotype as activated HSCs in vivo in fibrotic livers.(35;36) HSCs 
cultured on plastic provide therefore a good model system to examine the gene 
expression in cells responsible for liver fibrosis. All tissue collection was approved by 
the Local Ethical Committee. 
Real-time PCR analysis 
Fibroblasts obtained from a 25 or 75 cm2 culture flask were used for total RNA 
isolation (RNeasy kit; Qiagen). The mRNA was subsequently reverse transcripted into 
cDNA (Roche). mRNA levels of α-smooth muscle actin (α-SMA), LH1, LH2b, LH3, 
LOX, and collagen type I α2 (COL1A2) were measured using real-time PCR as 
described previously;(24) forward primer α-SMA: 5’CGTGTTGCCCCTGAAGAGCAT3’; 
reverse primer α-SMA: 5’ACCGCCTGGATAGCCACATACA3’; probe α-SMA: 5’FAM-
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cgtcgCCAAGGCCAACCGGGAGAAAATGACgcgacg-DABCYL 3’), and expressed 
relative to β2-microglobulin (B2M) mRNA levels to standardize for differences in the 
total amount of RNA between the samples. LH2a expression was measured using a PCR 
amplifying both LH2a and LH2b.(24)  
Cross-link analysis 
Measurements were performed on the extracellular matrix deposited by the 
fibrotic and control fibroblasts. Cells were cultured for 4 weeks in DMEM containing 
10% FCS, 100 units/ml penicillin, 100 units/ml streptomycin and 50 μg/ml ascorbic acid. 
The culture medium was refreshed twice a week. After 4 weeks of culture, the 
deposited matrix was washed in PBS; the cells present in the matrix were killed by two 
freeze-thaw cycles. Finally, the remaining matrix was incubated in PBS at 37 °C for 
another week. We have found that during the latter incubation the di-functional collagen 
cross-links further mature into the tri-functional pyridinoline cross-link (data not 
shown). By doing so, the level of pyridinoline cross-links per collagen molecule reflects 
more closely the in vivo situation. Hydroxyproline (Hyp) and the cross-links 
hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) were measured in acid 
hydrolysates of unreduced samples by reversed-phase high-performance liquid 
chromatography(37;38) and expressed as total amount of residues per collagen molecule, 
assuming 300 Hyp residues per triple helix. 
Statistical analysis  
Statistical analysis was performed using SPSS 11.0 software. Cross-link analysis and 
real-time PCR data are presented as mean ± SEM. Fibrotic cells and control cells were 
compared by Mann-Whitney’s non-parametric test.  
Figure 1. Increased expression of α-SMA mRNA in fibrotic fibroblasts. Shown is the α-SMA 
mRNA expression relative to B2M mRNA expression in keloid fibroblasts (kel; n = 6), hepatic 
stellate cells (HSC; n = 3), hypertrophic scar (scar, n = 7), Dupuytren (dp; n = 4) and control 
fibroblasts (con; n = 7). * indicates P ≤ 0.01 and # indicates P ≤ 0.05 for fibrotic cells 
compared to controls. Data are presented as mean ± SEM. 
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Results 
To examine whether LH2b mRNA levels are universally increased in fibrotic 
tissues, we investigated LH2b mRNA expression levels in myofibroblasts isolated from 
keloid, hypertrophic scars and the palmar fascia of Dupuytren’s disease patients as well 
as in activated human HSCs. mRNA expression of α-SMA was analyzed to ensure that a 
significant part of the fibroblasts isolated from the different fibrotic tissues exhibits the 
myofibroblasts phenotype: an increased α-SMA expression is the main characteristic of 
myofibroblasts.(39;40) Figure 1 reveals that α-SMA expression was significantly increased in 
all fibrotic cell populations compared to the controls. Therefore, we conclude that a 
significant part of the fibroblasts isolated exhibits a myofibroblast phenotype.  
The next step was to analyze LH2b mRNA expression in the different fibroblast 
cultures. Real-time PCR analysis showed that LH2b mRNA expression was dramatically 
increased in all fibrotic cells compared to normal skin fibroblast populations (Figure 2B). 
Furthermore, we found elevated levels of LH2b mRNA expression relative to COL1A2 
mRNA expression (Figure 3B). This increase was due to the changes in LH2b mRNA 
levels and not due to changes in COL1A2 expression, which was in our culture system 
the same in all fibroblasts except for the Dupuytren fibroblasts. These latter fibroblasts 
showed a 3-fold increase compared to controls (Figure 2E). LH2a, the short splice 
variant of LH2, was slightly elevated in all fibrotic cells, but LH2a expression was still less 
than 5% of the LH2b mRNA expression (Figure 2C). Analysis of the collagen matrix 
deposited by the keloid, hypertrophic scar and Dupuytren fibroblasts as well as the 
activated HSCs revealed increased pyridinoline cross-link levels (Figure 4), indicating 
that the hydroxylation of Lys residues within the collagen telopeptides is increased in all 
fibrotic cells. This is in line with previous in vivo data.(8;11;13;16;17;20;21) 
To ensure that the increased pyridinoline cross-link levels are not the result of 
factors other than the increased expression of LH2b, we measured LH1 (Figure 2A), 
LH3 (Figure 2D), and LOX (Figure 2F) mRNA expression in all fibrotic fibroblasts. 
Furthermore, the expression of LH1 (Figure 3A), LH3 (Figure 3C) and LOX (Figure 3D) 
mRNA expression relative to COL1A2 mRNA expression was calculated.  
Keloid fibroblasts did not reveal differences in LH1, LH3, and LOX mRNA 
expression compared to control levels. However, LH3 mRNA expression relative to 
COL1A2 mRNA expression was slightly decreased in keloid fibroblasts, whereas LH1 
and LOX mRNA expression relative to COL1A2 did not show significant differences. 
HSCs showed a 2-fold increase in LH1 mRNA expression. Furthermore, LH1 mRNA 
expression relative to COL1A2 mRNA expression was 4-fold increased, because 
COL1A2 expression was slightly decreased. There were no differences in mRNA 
expression of LH3 and LOX relative to B2M mRNA expression in HSCs. However, LH3 
expression relative to COL1A2 was significantly increased due to a slight decrease of 
the COL1A2 expression. LOX expression relative to COL1A2 was unchanged.  
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Figure 2. Increased expression of LH2b mRNA in fibrotic fibroblasts. Shown is the mRNA 
expression of LH1/B2M (A), LH2b/B2M (B), LH3/B2M (D), COL1A2/B2M (E) and LOX/B2M 
(F) in keloid fibroblasts (kel; n = 6), hepatic stellate cells (HSC; n = 3), hypertrophic scar 
fibroblasts (scar, n = 7), Dupuytren fibroblasts (dp; n = 4) and controls (con; n = 7). * indicates 
P ≤ 0.01 and # indicates P ≤ 0.05 for fibrotic cells compared to controls. Expression of LH2a 
en LH2b in control (1), keloid (2), HSCs (3), hypertrophics scar (4) Dupuytren (5) and in kidney 
fibroblasts (6) is shown in panel C. M, molecular weight marker; NC, negative control. Data are 
presented as mean ± SEM. 
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Interestingly, hypertrophic scar fibroblasts revealed a dramatic decrease in LH1 and LH3 
expression compared to controls resulting in a 40-fold decrease in LH1 mRNA 
expression relative to COL1A2 mRNA expression and a 20-fold decrease in LH3 
mRNA expression relative to COL1A2. Although LOX expression was slightly 
decreased in hypertrophic scar fibroblasts, the LOX expression relative to COL1A2 
expression was not changed. Dupuytren fibroblasts did not show differences in LH1 
expression or in the LH1 relative to COL1A2 expression. LH3 and LOX expression 
relative to B2M expression was around 2-fold and 3-fold increased in Dupuytren 
fibroblasts, respectively. However, LH3 and LOX expression relative to COL1A2 
expression did not show significant differences. 
Figure 3. Increased expression of LH2b mRNA relative to COL1A2 mRNA in fibrotic 
fibroblasts. Shown is the mRNA expression of LH1/COL2A2 (A), LH2b/COL2A2 (B), 
LH3/COL2A2 (C) and LOX/COL2A2 (D) in keloid fibroblasts (kel; n = 6), hepatic stellate cells 
(HSC; n = 3), hypertrophic scar fibroblasts (scar, n = 7), Dupuytren fibroblasts (dp; n = 4) and 
controls (con; n = 7). * indicates P ≤ 0.01 and # indicates P ≤ 0.05 for fibrotic cells compared 
to controls. Data are presented as mean ± SEM. 
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Discussion 
Fibrosis is characterized by an excessive deposition of collagen as a result of a 
misbalance between collagen synthesis and degradation. Furthermore, the accumulated 
collagen in fibrotic lesions shows an increase in hydroxyallysine cross-link levels.(7-21) The 
increased amount of these cross-links in fibrosis is the result of an overhydroxylation of 
the Lys residues within the telopeptides. The enzyme responsible for this remained for a 
long time unidentified.(41)  
We have recently shown that the overhydroxylation of the collagen telopeptides 
found in the fibrotic skin of SSc patients is associated with increased TLH (LH2b) mRNA 
expression in cells present in fibrotic lesions.(24) Interestingly, the presence of elevated 
hydroxyallysine cross-link levels appears to be a common phenomenon in irreversible 
fibrotic processes. We have therefore analyzed the expression of LH2b in other fibrotic 
tissues, including hypertrophic scars, keloid and the palmar fascia of Dupuytren’s 
patients. In addition, we have examined LH2b expression in activated HSCs which are 
responsible for liver fibrosis.(33) All fibrotic cells evaluated revealed elevated levels of 
LH2b mRNA expression relative to COL1A2 mRNA expression. In addition, the short 
splice variant LH2a was slightly increased in all fibrotic cell cultures. However, the 
expression was less than 5% of the total LH2b expression, suggesting that this splice 
variant does not play a significant role in fibrotic conditions. The other collagen-
modifying enzymes LH1 and LH3 did not show a consistent increase in mRNA 
expression relative to COL1A2 mRNA expression. In fact, in some cases the expression 
was even dramatically decreased. Furthermore, in all fibrotic cell types we found normal 
expression levels of LOX, being the enzyme catalyzing the formation of allysine and 
hydroxyallysine, a step necessary for the formation of cross-links. The increase in 
pyridinoline cross-links that we have found in the collagen matrix deposited in our long-
term cultures is therefore most likely not the result of an increased aldehyde formation. 
Figure 4. Increased pyridinoline cross-links levels in the matrices deposited by the fibrotic 
fibroblasts. Shown is the amount of hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) cross-
links relative to the amount of collagen in the extracellular matrix deposited by keloid fibroblasts 
(kel; n = 6), hepatic stellate cells (HSC; n = 3), hypertrophics scar (scar; n = 8), Dupuytren (dp; 
n = 4) and control fibroblasts (con; n = 10). * indicates P ≤ 0.01 and # indicates P ≤ 0.05 for 
fibrotic cells compared to controls. Data are presented as mean ± SEM. 
 
0
0.07
0.14
0.21
0.28
0.35
0.42
con kel HSC scar dp
H
P
+
L
P
/c
o
lla
ge
n
 (
m
o
l/m
o
l) *
**
#
Chapter 5 
98 
At the expression level, the induction of LH2b exceeds that of COL1A2, indicating that 
the synthesized collagen will become differently modified. LH2b has been previously 
identified as a telopeptide lysyl hydroxylase(23;24) and overexpression will thus lead to 
overhydroxylation of the Lys residues in the telopeptides. Hydroxylation of the 
telopeptide Lys residues is a necessary step in the formation of hydroxyallysine cross-
links. It is therefore plausible that the increased levels of hydroxyallysine cross-links in 
fibrotic disorders are the consequence of induced LH2b expression. Our studies show 
that an induction of LH2b expression, and as a consequence the increased formation of 
pyridinoline cross-links, is a universal process in fibrosis.  
The presence of increased levels of hydroxyallysine cross-links in fibrotic tissues is 
associated with irreversible accumulation of collagen, suggesting that collagen containing 
hydroxyallysine cross-links is more difficult to degrade than its counterpart containing 
allysine derived cross-links.(8;12;14;17;22) It is reasonable to assume that inhibition of TLH 
activity in fibrosis will lead to a decrease in hydroxyallysine cross-links, resulting in a 
decrease in collagen accumulation. We speculate that TLH is an attractive target to 
interfere with the irreversible accumulation of collagen in a wide variety of fibrotic 
disorders.  
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Abstract 
The hallmark of fibrosis is the excessive accumulation of collagen. The deposited 
collagen contains increased pyridinoline cross-link levels due to an overhydroxylation of 
lysine residues within the collagen telopeptides. Lysyl hydroxylase 2b (LH2b) is the only 
lysyl hydroxylase consistently upregulated in several forms of fibrosis, suggesting that an 
enhanced LH2b level is responsible for the overhydroxylation of collagen telopeptides. 
The present paper reports the effect of profibrotic cytokines on the expression of 
collagen, lysyl hydroxylases and lysyl oxidase in normal human skin fibroblasts, as well as 
the effect on pyridinoline formation in the deposited matrix. All three isoforms of TGF-
β induce a substantial increase in LH2b mRNA levels, also when expressed relatively to 
the mRNA levels of collagen type I α2 (COL1A2). The TGF-β isoforms also clearly 
influence the collagen cross-linking pathway, since higher levels of pyridinoline cross-
links were measured. Similar stimulatory effects on LH2b/COL1A2 mRNA expression 
and pyridinoline formation were observed for IL-4, activin A, and TNF-α. An exception 
was BMP-2, which has no effect on LH2b/COL1A2 mRNA levels nor on pyridinoline 
formation. Our data show for the first time that two processes, i.e. upregulation of 
LH2b mRNA levels and increased formation of pyridinoline cross-links, previously 
recognized to be inherent to fibrotic processes, is induced by various profibrotic 
cytokines.  
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Introduction 
Fibrosis is a complex process finally resulting in the excessive deposition of 
extracellular matrix, which is mainly composed of collagen. The collagen deposited in 
the fibrotic lesions contains highly increased pyridinoline cross-link levels.(1-6) 
Pyridinolines are trifunctional cross-links, derived from the hydroxyallysine cross-link 
route. In this pathway, the hydroxylated lysine residue within the telopeptide is 
converted to a hydroxyallysine (Hylald), a reaction catalyzed by lysyl oxidase (LOX). 
Subsequently, the Hylald reacts with a lysine (Lys) or hydroxylysine (Hyl) residue within 
the triple helix to form di- and tri-functional cross-links.(7-10)  
The conversion of Lys into a Hyl in the collagen molecule is catalyzed by lysyl 
hydroxylases (LH; EC1.14.11.4). Three different lysyl hydroxylases have been described: 
LH1, LH2, and LH3.(11-15) Only for LH2 splice variants have been described (LH2a and 
LH2b).(16;17) Mutations in the gene encoding LH1 (Ehlers-Danlos syndrome type VI)(18) 
and LH2 (Bruck syndrome)(19) revealed that LH1 predominantly catalyzes the 
hydroxylation of lysine residues within the triple helix, whereas LH2 predominantly 
catalyzes the formation of Hyl in the telopeptides. Furthermore, compelling evidence 
that LH2 has telopeptide lysyl hydroxylase activity has been shown along various 
research lines.(20-22) The lysine substrate specificity (telopeptides and/or triple helix) of 
LH3 is unknown. Interestingly, LH3 has been found to be a multifunctional enzyme as it 
is able to catalyze the lysyl hydroxylation reaction as well as the sugar transfer reactions, 
enabling consecutive steps in the formation of glucosylgalactosylhydroxylysyl 
residues.(23;24)  
The increased amount of pyridinoline cross-links in fibrosis is the result of an 
overhydroxylation of the lysine residues within the telopeptides. We have recently 
found that LH2b is the only lysyl hydroxylase that is consistently upregulated in several 
forms of fibrosis.(19;25) This suggests that increased LH2b expression is responsible for 
the overhydroxylation and the concomitant formation of pyridinoline cross-links in 
several forms of fibrosis.  
The fibrotic process involves an inflammatory response, and cytokines and growth 
factors constitute a major class of mediators in this process. Transforming growth 
factor-β (TGF-β) has been considered to be one of the key mediators in fibrosis. 
Increased amounts of TGF-β have consistently been found in fibrotic lesions.(26-28) 
Administration of exogenous TGF-β to laboratory animals leads to the development of 
fibrosis,(29;30) whereas administration of anti-TGF-β inhibits experimentally-induced 
fibrosis.(31-34) TGF-β exists in three isoforms, namely TGF-β1, TGF-β2, and TGF-β3.(35) 
Although the biological activities of the three isoforms are highly similar in vitro, their 
difference in function in vivo is shown by the unique isoform-specific phenotypes 
displayed by the different TGF-β knock-out mice.(36-38)  
Fibroblasts stimulated with TGF-β show increased expression levels of various 
extracellular matrix proteins, including collagen. Furthermore, they secrete reduced 
amounts of several matrix metalloproteinases, whereas the production of tissue 
inhibitors of metalloproteinases is increased.(26) These changes are characteristic for 
fibrotic cells. Another general process in fibrosis is the recently observed increased 
expression of LH2b and the formation of pyridinoline cross-links.(25) This prompted us 
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to investigate whether TGF-β is also able to induce LH2b expression and pyridinoline 
cross-link formation. Besides TGF-β, several other cytokines, including interleukin 4 (IL-
4), bone morphogenetic protein–2 (BMP-2), activin A, and tumor necrosis factor-α 
(TNF-α), can be indicated as profibrotic.(39;40) For example, overexpression of activin A 
in the skin of transgenic mice induces fibrosis,(41) BMP-2 induces scar formation,(42) and 
anti-IL-4 or anti-TNF-α treatment prevents collagen deposition in animal models of 
fibrosis.(43;44) So far, the effect of these cytokines on pyridinoline cross-link levels is 
unknown. Therefore we examined whether these cytokines affect LH2b expression and 
pyridinoline cross-link formation as well.  
We found that LH2b mRNA levels in human primary fibroblasts are induced by all 
three TGF-β isoforms. Furthermore, the TGF-β isoforms have considerable effects on 
the cross-linking as the stimulated cells deposit collagen with significantly increased 
pyridinoline levels. These stimulatory effects on LH2b mRNA levels and pyridinoline 
cross-linking of the collagen were also found for the cytokines IL-4, activin A, and  
TNF-α. The observed effects of these profibrotic cytokines is in perfect agreement with 
our previous studies in which we showed that increased LH2b mRNA levels in fibrotic 
cells are associated with elevated pyridinoline cross-linking in the deposited 
matrices(19;25) and indicate that these processes play an important role in fibrosis. 
Materials and methods 
Cytokine stimulation experiments 
Primary cultured human fibroblasts, obtained from the split skin of seven healthy 
individuals, were established by routine methods. Cells were grown in 10 cm2 wells in 
Dulbecco’s modified Eagle’s medium (DMEM; BioWhittaker) supplemented with 10% 
heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin and 100 U/ml streptomycin at 
37 °C in 5% CO2. Fibroblasts that reached subconfluence were used for stimulation 
experiments. Before stimulation, cells were washed in PBS and starved for 3 hours in 
DMEM supplemented with 0.1% bovine serum albumin (BSA), 100 U/ml penicillin and 
100 U/ml streptomycin. Dose- and time-dependent effects of TGF-β1, -β2 or -β3 on 
mRNA expression levels were studied by culturing fibroblasts of one donor in the 
presence or absence of different concentrations recombinant human TGF-β1, -β2 or -
β3 (Sigma) for 24 hours and by culturing cells of one donor in the presence or absence 
of 1 ng/ml TGF-β1, -β2 or -β3 for 6, 12, 24, 48 or 72 hours. Furthermore, fibroblasts of 
seven donors were cultured in DMEM supplemented with 0.1% BSA, 100 U/ml penicillin 
and 100 U/ml streptomycin in the presence or absence of 1 ng/ml TGF-β1, -β2 or -β3 
for 24 hours. Fibroblasts of four donors were stimulated with or without 10 ng/ml 
human recombinant IL-4 (R&D Systems), 10 ng/ml human recombinant BMP-2 (Sigma), 5 
ng/ml human recombinant activin A (Sigma), or 10 ng/ml human recombinant TNF-α 
(R&D Systems) in DMEM supplemented with 0.1% BSA, 100 U/ml penicillin and 100 
U/ml streptomycin for 24 hours. The above-mentioned cultures were used for total 
RNA isolation.  
For extracellular matrix analysis, fibroblasts were cultured for 4 weeks in DMEM 
supplemented with 5% FCS, 100 U/ml penicillin, 100 U/ml streptomycin and 50 μg/ml 
ascorbic acid in the presence or absence of 1 ng/ml TGF-β1, -β2 or -β3 (n = 7) or in the 
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presence or absence of 10 ng/ml IL-4, 10 ng/ml BMP-2, 5 ng/ml activin A, or 10 ng/ml 
TNF-α. Medium was replenished every 3 days. After 4 weeks of culture, the deposited 
matrix was washed in PBS; the cells present in the matrix were killed by two freeze-
thaw cycles. Finally, the remaining matrix was incubated in PBS at 37 °C for another 
week. We have found that at 4 weeks the level of pyridinoline cross-link was 0.0229 ± 
0.0005 mol/mol and this increased to 0.0333 ± 0.0006 mol/mol after the described 
incubation in PBS. In vitro maturation into tri-functional cross-links has been observed by 
others as well.(45) Thus during the latter incubation the di-functional collagen cross-links 
further mature into the tri-functional pyridinoline cross-links, consequently the level of 
pyridinoline cross-links per collagen molecule reflects more closely the in vivo situation, 
because maturation of collagen cross-links is a time-dependent process which is 
facilitated in vivo by the long half-life of collagen.  
Real-time PCR analysis  
Total RNA was isolated from cytokine-stimulated fibroblast cultures using the 
RNeasy kit (Qiagen). Subsequently, the RNA was reverse transcribed into cDNA and 
subjected to real-time PCR amplification. Real-time PCR amplification of cDNA 
sequences was performed for LH1, LH2b, LH3, collagen type I α2 (COL1A2), and LOX. 
To standardize for differences in the total amount of cDNA a real-time PCR was 
performed of β2-microglobulin (B2M), a constitutively expressed gene and which 
expression was not affected by the different stimulations. The expression of the target 
genes was calculated relatively to B2M expression. Each cDNA was amplified using 
specific primers and specific molecular beacons as described earlier.(19) Data were 
analyzed using sequence detector V1.7 software. LH2a expression was measured using a 
PCR amplifying both LH2a and LH2b.(19) 
Cross-link analysis  
Measurements were performed on the extracellular matrix obtained from long-
term (4 weeks) fibroblast cultures. Hydroxyproline (Hyp) and Hyl levels were 
determined in acid hydrolysates of matrix samples after derivatization with 9-
fluorenylmethyl chloroformate by reverse-phase high-performance liquid 
chromatography.(46) Hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) cross-links 
were measured in the same acid hydrolysates as described previously.(47;48) Pyridinoline 
and Hyl levels were expressed as total amount of residues per collagen molecule, 
assuming 300 Hyp residues per triple helix. 
Statistical analysis  
Statistical analysis was performed using SPSS 11.0 software. Differences between 
stimulated and unstimulated cells were analyzed by one-way analysis of variance 
(ANOVA) followed by LSD or Scheffé post-hoc tests. A P-value of ≤ 0.05 was considered 
to indicate statistically significant differences. 
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Figure 1. Concentration- and time-dependent increase in LH2b expression induced by TGF-β1. 
Concentration-dependent upregulation of LH2b mRNA expression in TGF-β1 stimulated skin 
fibroblasts is shown in panel A (after 24 hours). The other panels demonstrate the time-
dependent mRNA expression relative to B2M of LH1 (B), LH2b (C), LH3 (D), LOX (E) and 
COL1A2 (F) in TGF-β1 stimulated cells (1 ng/ml). * indicates P ≤ 0.01 and # indicates P ≤ 0.05 
for TGF-β1 stimulated cells versus unstimulated cells. Data are presented as mean ± SEM. 
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Results 
TGF-β stimulation of skin fibroblasts 
We have recently found that LH2b is increased in cells present in several fibrotic 
tissues.(19;25) Since TGF-β is an important factor for the induction of fibrosis, we 
examined the effect of TGF-β stimulation on LH2b mRNA expression in skin fibroblasts. 
To explore the concentration-dependent effect of TGF-β, fibroblasts of one donor were 
stimulated for 24 hours with different concentrations TGF-β1, -β2, or -β3, rising from 
0.05 ng/ml to 1 ng/ml. Analysis of LH2b mRNA expression demonstrated that TGF-β1 
indeed increase LH2b mRNA expression and that the optimum concentration for TGF-
β1 induced LH2b upregulation is 1 ng/ml (Figure 1A). Similar LH2b expression patterns 
were found for TGF-β2 or -β3 stimulation (data not shown).  
To examine the temporal TGF-β-induced mRNA expression patterns, fibroblasts 
of one donor were cultured for 6, 12, 24, 48 and 72 hours in the presence or absence 
of 1 ng/ml TGF-β1, -β2, or -β3. Real-time PCR analysis revealed that LH2b mRNA 
expression did not show a significant increase until 24 hours after TGF-β stimulation 
and expression was further increased after this time point, reaching high levels (5-fold 
induction) both at 48 and 72 hours (Figure 1C). A significant increase in LH1 mRNA 
expression could only be detected at 72 hours (Figure 1B). LH3 mRNA expression was 
not affected at all by TGF-β1 stimulation (Figure 1D). Induction of LOX and COL1A2 
mRNA expression by TGF-β1 was much faster than LH1 and LH2b, since both genes 
were approximately 1.5-fold upregulated directly after 6 hours and did not further 
increase at later time-points (Figure 1E and Figure 1F, respectively). Equal temporal 
expression patterns of the mentioned genes were found in fibroblasts after stimulation 
with TGF-β2 or -β3 (data not shown). 
To exclude whether the induction of LH2b by TGF-β in skin fibroblasts is a donor 
specific effect, fibroblasts of seven donors were cultured in the presence or absence of 1 
ng/ml TGF-β1, -β2, or -β3 for 24 hours. Real-time PCR analysis revealed highly 
increased LH2b mRNA expression in the fibroblasts of all donors stimulated with either  
TGF-β1, -β2 or -β3 (up to 3.5-fold compared to controls; Figure 2A). The stimulatory 
effect on LH2b mRNA expression was not significantly different between the three 
TGF-β isoforms. In previous experiments, we have found that LH2a is undetectable in 
normal skin fibroblast.(19) However, a PCR amplifying LH2a and LH2b revealed that the 
three TGF-β isoforms slightly induces LH2a expression, although the expression was 
still very low (data not shown). Analysis of LH1 mRNA expression (Figure 2A) in 
fibroblasts stimulated with either TGF-β2 or -β3 showed only a 1.3-fold increase 
compared to controls; TGF-β1 stimulation did not result in a significant increase of LH1. 
Interestingly, in contrast to the donor of the previous experiment, increased LH3 
mRNA expression after TGF-β stimulation was found in the other 6 donors (Figure 2A). 
LOX and COL1A2 mRNA expression was also slightly elevated in TGF-β stimulated 
fibroblasts (up to 1.5-fold compared to controls; Figure 2A). No large differences in 
LH1, LH3, COL1A2, and LOX mRNA expression were found between the three TGF-β 
isoforms. When mRNA expression levels were calculated relative to COL1A2, only 
LH2b was more than 2-fold increased in fibroblasts stimulated with TGF-β (Figure 2B),  
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Figure 2. Increased LH2b expression in TGF-β1, -β2, -β3 stimulated fibroblasts. Expression 
levels of LH1, LH2b, LH3, LOX, and COL1A2 relative to B2M expression in TGF-β1, -β2 
and -β3 stimulated skin fibroblasts (n = 7; 1 ng/ml; 24 hours) is shown in panel A. Expression 
levels of LH1, LH2b, LH3, and LOX relative to COL1A2 expression is depicted in panel B. * 
indicates P ≤ 0.01 and # indicates P ≤ 0.05 for TGF-β stimulated cells versus unstimulated cells. 
Data are presented as mean ± SEM. 
Profibrotic cytokine-induced LH2b expression 
111 
Figure 3. TGF-β1, -β2, and -β3 induce Lys overhydroxylation of the telopeptides, but not of the 
triple helix. Pyridinoline cross-link (HP + LP) levels in the collagen matrix deposited by TGF-β1, 
 -β2, and -β3 stimulated fibroblasts (n = 7; 1 ng/ml) are depicted in panel A. Hyl levels within 
the collagen triple helix are shown in panel B. * indicates P ≤ 0.01 and # indicates P ≤ 0.05 for 
TGF-β stimulated cells versus unstimulated cells. Data are presented as mean ± SEM. 
 
 
whereas no significant increase was found in LH1, LH3, and LOX expression levels 
(Figure 2B).  
To examine whether TGF-β stimulation also results in the induction of pyridinoline 
cross-links formation, the extracellular matrix deposited by fibroblasts stimulated with 
TGF-β1, -β2 or -β3 was analyzed. Indeed, an increase in pyridinoline cross-links levels 
was found in the collagen deposited by TGF-β stimulated cells (Figure 3A). The total 
amount of Hyl residues within the collagen triple helix was unaltered in the matrix 
deposited by TGF-β1, -β2, and -β3 stimulated cells as compared to unstimulated cells 
(Figure 3B).  
IL-4, BMP-2, activin A, and TNF-α stimulation of skin fibroblasts  
In order to examine whether other profibrotic cytokines are able to induce LH2b 
mRNA expression, fibroblasts were cultured in the presence of IL-4, BMP-2, activin A, 
or TNF-α for 24 hours and compared to their unstimulated counterparts. Real-time 
PCR analysis revealed that all tested cytokines increased LH2b mRNA expression 
(Figure 4A). LH2b expression relative to COL1A2 expression showed a 2.5-fold 
increase for IL-4 and activin A, when compared to controls (Figure 4B). This increase 
was due to the changes in LH2b mRNA levels and not due to changes in COL1A2 
expression, which was hardly altered (Figure 4A). TNF-α induced a 4-fold increase in 
LH2b expression relative to COL1A2 (Figure 4B) as a result of increased LH2b 
expression and decreased COL1A2 expression (Figure 4A). Fibroblasts stimulated with 
BMP-2 did not increase LH2b expression relative to COL1A2.  
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Figure 4. Profibrotic cytokines elevate LH2b expression. Expression levels of LH1, LH2b, LH3, 
LOX, and COL1A2 relative to B2M expression in IL-4 (10ng/ml), BMP-2 (10 ng/ml), activin A 
(5 ng/ml), and TNF-α (10 ng/ml) stimulated skin fibroblasts (n = 4) is shown in panel A (after 
24 hours). Expression levels of LH1, LH2b, LH3, and LOX relative to COL1A2 expression is 
depicted in panel B. * indicates P ≤ 0.01 and # indicates P ≤ 0.05 for stimulated cells versus 
unstimulated cells. Data are presented as mean ± SEM. 
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Figure 5. Profibrotic cytokines induce pyridinoline cross-link formation but do not affect triple 
helical Hyl levels. Pyridinoline cross-links (HP + LP) levels in the collagen matrix deposited by  
IL-4 (10 ng/ml), BMP-2 (10 ng/ml), activin A (5 ng/ml), and TNF-α (10 ng/ml) stimulated 
fibroblasts (n = 4) are depicted in panel A. Hyl levels within the collagen triple helix are shown 
in panel B. * indicates P ≤ 0.01 and # indicates P ≤ 0.05 for stimulated cells versus 
unstimulated cells. Data are presented as mean ± SEM. 
LH1 expression (Figure 4A) was only induced in activin A stimulated cells when 
compared to unstimulated cells. However, LH1 expression relative to COL1A2 was not 
changed, due to a slight increase in COL1A2 expression (Figure 4B). All tested cytokines 
did not affect LH3 expression (Figure 4A) nor LH3 expression relative to COL1A2 
(Figure 4B). LOX expression and LOX expression relative to COL1A2 was only 
increased in fibroblasts stimulated with IL-4 (Figure 4A and 4B, respectively), whereas 
activin A and TNF-α did not show any effect. BMP-2 stimulated cells showed a 2-fold 
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increase in LOX expression, however, LOX expression relative to COL1A2 was not 
significantly increased when compared to unstimulated cells (Figure 4A and 4B, 
respectively). 
The effect of IL-4, BMP-2, activin A, and TNF-α on the pyridinoline cross-links 
levels in the deposited matrix is shown in Figure 5A. All tested cytokines, with the 
exception of BMP-2, showed an increase in pyridinoline cross-link levels. Hyl levels 
within the collagen triple helix were unchanged in all stimulated cells when compared to 
unstimulated cells (Figure 5B). 
Discussion 
Fibrosis is characterized by the accumulation of collagen, containing highly 
increased pyridinoline cross-link levels.(1-6) We have recently found that in several forms 
of fibrosis an increased LH2b mRNA expression level is associated with increased 
formation of pyridinoline cross-links, which suggests that LH2b is responsible for the 
overhydroxylation of telopeptide lysine residues and the concomitant increase in 
pyridinoline cross-links in fibrotic lesions.(19;25) The stimulatory effect of the profibrotic 
cytokines TGF-β1, -β2, and -β3 on LH2b gene expression, as shown in this study, 
underline the significant role of LH2b upregulation in fibrotic processes. In contrast to 
LH1 and LH3, LH2b mRNA expression is far more induced by TGF-β than the mRNA 
expression of COL1A2, thus changing the proportion between LH2b and COL1A2 
expression. Analysis of the matrix deposited by fibroblasts stimulated with TGF-β clearly 
showed increased pyridinoline cross-linking, but no increase in overall hydroxylation of 
the lysine residues in the collagen molecule. This means that only the lysine residues 
within the telopeptides are overhydroxylated and not in the triple helical part. Since 
LH2b is the only lysyl hydroxylase which is induced to a greater extent than collagen 
expression by stimulation with TGF-β, it is plausible that telopeptide lysyl hydroxylases 
activity of LH2b is responsible for the increased formation of pyridinoline cross-links in 
the matrix deposited by TGF-β stimulated cells. This is further endorsed by the fact that 
the TGF-β isoforms did not induce the expression of LOX relative to COL1A2 
expression. The increased formation of pyridinolines is therefore most likely not due to 
an increased aldehyde formation (a step necessary for cross-link formation and catalyzed 
by LOX).  
Not only TGF-β isoforms, but also other profibrotic cytokines, including IL-4, 
activin A and TNF-α, appeared to be capable of inducing LH2b expression, whereas the 
expression of the lysyl hydroxylases LH1 and LH3 relative to COL1A2 was unaffected 
by these cytokines. As for TGF-β isoforms, above-mentioned cytokines also stimulated 
the formation of pyridinoline cross-links in the deposited matrix. An exception appeared 
to be BMP-2. This cytokine is clearly not involved in the regulation of LH2b and we can 
perfectly match that with our observation that the amount of pyridinoline cross-links in 
the matrix deposited by BMP-2 stimulated cells was not increased as well. Again the 
obtained results for the profibrotic cytokines activin A and TNF-α point out that it is 
very likely that LH2b is responsible for the overhydroxylation of the lysine residues in 
the telopeptides, leading to increased formation of pyridinoline cross-links. In the case of 
IL-4, the induced formation of pyridinoline cross-links might also be due to increased 
LOX expression or to a combination of induced LH2b and LOX expression. But clearly 
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this was not the case for activin A and TNF-α, since no differences in LOX expression 
relative to COL1A2 was observed in stimulated cells.  
TGF-β time curves of LH1, LH2b, LH3, COL1A2, and LOX mRNA expression 
revealed differences in the induction rate of the TGF-β induced mRNA expression: 
COL1A2 and LOX expression is upregulated to the maximum already after 6 hours, 
whereas LH2b and LH1 expression reach high levels at 48 and 72 hours, respectively. 
The slower induction rate of LH1 and LH2b suggests that the effect of TGF-β on LH1 
and LH2b gene expression is probably not accomplished directly via the intracellular 
pathways downstream the TGF-β receptor. It is most likely a secondary effect. It could 
be that the increased gene expression of LH1 and LH2b is accomplished by profibrotic 
factors that are rapidly upregulated by TGF-β, such as connective tissue growth factor(49) 
or endothelin-1 (ET-1).(50;51) Evidence for such involvement of ET-1 has been obtained by 
microarray analysis studies of lung fibroblasts, showing a 2.5-fold increase in LH2 
expression within 4 hours after ET-1 stimulation.(52) 
 Interestingly, two research groups showed that a hypoxic environment, which 
favors the formation of collagen deposits, induces increased LH2 expression levels.(53;54) 
A hypoxic environment has a significant pathophysiological impact on pulmonary and 
cardiac fibrosis. Our findings together with the above-mentioned observations reveal 
that a broad range of profibrotic cytokines/conditions induce LH2b expression, 
highlighting that upregulation of LH2b is an important general phenomenon in fibrotic 
processes. In addition, our study showed for the first time that in association with 
increased LH2b expression levels, profibrotic cytokines are capable to induce 
pyridinoline cross-link formation. These results provide strong evidence that LH2b is 
responsible for the overhydroxylation of telopeptide lysine and the concomitant 
pyridinoline formation in fibrotic lesions.  
The occurrence of hydroxyallysine-derived cross-links (such as pyridinolines) in the 
matrix deposited in fibrotic lesions is an important criterion in assessing the 
irreversibility of fibrosis.(4;5;55-57) Specific inhibition of LH2b to decrease the formation of 
pyridinoline cross-links is expected to result in a more reversible deposition of collagen. 
Specific compounds inhibiting LH2b enzyme activity or compounds that reduce LH2b 
gene expression, such as antisense molecules,(21) hold promises for future therapies to 
prevent irreversible fibrosis. The differences in induction rate of the different 
extracellular matrix-related genes by TGF-β (this paper),(58) together with the fact that 
from the measured collagen-modifying enzymes TGF-β only induces the expression of 
LH2b relative to COL1A2, suggest that different intracellular pathways are involved in 
the TGF-β-induced gene regulation of LH1, LH2b, LH3, COL1A2, and LOX. Unraveling 
the processes involved in the upregulation of LH2b mRNA expression, may provide 
tools to find new targets enabling interference specifically with LH2b expression in 
order to attenuate fibrosis.  
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Abstract 
Collagen deposits in fibrotic lesions often display elevated levels of hydroxyallysine 
(pyridinoline) cross-links. The relation between the occurrence of pyridinoline cross-
links and the irreversibility of fibrosis suggests that these cross-links contribute to the 
aberrant accumulation of collagen. Based on its inhibitory effect on lysyl hydroxylase 
activity minoxidil has been postulated to possess anti-fibrotic properties by limiting the 
hydroxylysine supply for hydroxyallysine cross-linking. However, to interfere with 
hydroxyallysine cross-linking specifically lysyl hydroxylation of the collagen telopeptide 
should be inhibited, a reaction predominantly catalyzed by lysyl hydroxylase (LH) 2b. In 
this study, we demonstrate that minoxidil treatment of cultured fibroblasts reduces LH1 
>> LH2b > LH3 mRNA levels dose- and time-dependently, but has essentially no effect 
on the total number of pyridinoline cross-links in the collagen matrix. Still the collagen 
produced in the presence of minoxidil displays some remarkable features: hydroxylation 
of triple helical lysine residues is reduced to 50% and lysylpyridinoline cross-linking is 
increased at the expense of hydroxylysylpyridinoline cross-linking. These observations 
can be explained by our finding that LH1 mRNA levels are the most sensitive to 
minoxidil treatment, corroborating that LH1 has a preference for triple helical lysine 
residues as substrate. In addition, the non-proportional increase in cross-links (20-fold) 
with respect to the decrease in lysyl hydroxylation state of the triple helix (2-fold) even 
suggests that LH1 preferentially hydroxylates triple helical lysine residues at the cross-
link positions. We conclude that minoxidil is unlikely to serve as an anti-fibroticum, but 
confer features to the collagen matrix, which provide insight into the substrate 
specificity of LH1. 
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Introduction 
The synthesis of collagen is a multi-step process, involving several unique post-
translational modifications essential for the stabilization of the collagen molecule. The 
assembly of collagen molecules into the functional unit, the collagen fibril, is further 
stabilized by covalent intermolecular cross-links. Hydroxylation of lysine residues is one 
of the key steps in the maturation of collagen, providing specific sites for glycosylation(1) 
and determining the chemical nature of the intermolecular cross-links.(2) A family of lysyl 
hydroxylases (LH; EC 1.14.11.4), consisting of LH1, LH2a, LH2b, and LH3, is responsible 
for the catalytic conversion of lysine into hydroxylysine.(3-9) Mutations in LH1 lead to the 
clinical phenotype of Ehlers-Danlos syndrome type VI (EDS VI; OMIM#225400),(10) 
which is biochemically characterized by a deficiency in triple helical hydroxylysine 
residues.(11) An almost complete lack of hydroxylated lysine residues in the collagen 
telopeptides is seen in Bruck syndrome (BS; OMIM#259450) bone(12) and in a number of 
BS patients LH2 is mutated.(13;14) These connective tissue disorders indicate substrate 
specificity for the different lysyl hydroxylases and their clinical phenotypes show the 
devastating effect of disturbed hydroxylation of triple helical or telopeptide lysine 
residues on tissue performance. The specificity of LH1 is likely directed towards the 
lysine residues in the helical domain of the collagen molecule.(4) There is a growing body 
of evidence that LH2b is involved in the hydroxylation of telopeptide lysine 
residues.(13;15-18) No mutations in LH3 have been identified so far that can be linked to a 
disorder of the extracellular matrix and its lysyl substrate specificity is as yet unknown. 
LH3 is different from the other two lysyl hydroxylases in that it also displays glucosyl 
and galactosyl transferase activity, thereby contributing to the glycosylation of 
hydroxylysine residues in the collagen molecule.(19;20) The embryonic lethality of LH3 
knock-out mice shows that this lysyl hydroxylase provides essential functions in the 
body.(21) 
The hydroxylation status of the cross-linking residue in the collagen telopeptide, 
being either lysine or hydroxylysine, determines the route of intermolecular enzymatic 
cross-linking. In the allysine cross-linking route lysine is converted by lysyl oxidase 
(LOX) into the aldehyde allysine, whereas in the hydroxyallysine route hydroxylysine is 
converted into the aldehyde hydroxyallysine. These aldehydes further react with a 
lysine, hydroxylysine, or histidine in the triple helix to form di-, tri-, or tetra-functional 
cross-links.(22-24) The mature cross-links hydroxylysylpyridinoline (HP) and 
lysylpyridinoline (LP) are formed via the hydroxyallysine route and differ only with 
respect to the triple helical residue involved in the cross-link, hydroxylysine and lysine, 
respectively.(2) These kinds of cross-links occur in a variety of connective tissues such as 
bone, cartilage, tendon, and ligaments. In contrast, skin collagen contains predominantly 
allysine-derived cross-links and only minor amounts of hydroxyallysine-derived cross-
links.(25) In general, the prevalence of a certain type of cross-link appears to be tissue-
specific and is involved in providing tissues with certain properties.(26;27) 
In fibrotic disorders, which are characterized by an accumulation of collagen, an 
increase in hydroxyallysine cross-linking is observed.(28-32) There are strong indications 
that these cross-links diminish the susceptibility of collagen to proteolytic degradation 
and in this way contribute to the unwanted collagen accumulation in fibrosis.(28;31-34) It is 
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therefore plausible that redirecting collagen cross-linking towards the allysine route, by 
reducing the overhydroxylation of telopeptide lysine residues, prevents the irreversible 
deposition of collagen. We have previously shown that an elevated LH2b expression in 
fibrotic cells is associated with an increase in pyridinoline cross-links in the collagen 
deposited by these cells. These data indicate that induction of LH2b expression leads to 
overhydroxylation of telopeptide lysine residues and the concomitant formation of 
hydroxyallysine cross-links.(13;18) Consequently, LH2b becomes a prime target for an anti-
fibrosis therapy based on decreasing hydroxyallysine cross-linking. 
Minoxidil, an antihypertensive drug, has been reported to reduce lysyl hydroxylase 
activity by decreasing the LH1 mRNA level.(35-37) At the time these studies were 
performed it was not known that different isoforms of lysyl hydroxylase existed, but it 
was already postulated that minoxidil would have anti-fibrotic properties by limiting the 
supply of hydroxylysines for hydroxyallysine cross-link formation.(38) In the present study 
we investigated the effect of minoxidil on the gene expression of each individual lysyl 
hydroxylase, in particular LH2b, and on the cross-linking of collagen to examine whether 
minoxidil indeed has the potential to decrease hydroxyallysine cross-link formation.  
Materials and Methods 
Fibroblast cultures 
Primary fibroblasts obtained from healthy dermis, subcutaneous fat, and keloid 
were isolated as described previously.(39) Primary fibroblasts of one keloid donor were 
obtained from the American Type Culture Collection (ATCC; CRL-1762). Cells were 
cultured in Dulbecco’s Modified Eagles Medium (DMEM; BioWhittaker) containing 
ultraglutamine I and supplemented with 10% heat-inactivated fetal calf serum (FCS), 100 
U/ml penicillin and 100 U/ml streptomycin at 37°C in 5% CO2. Upon reaching 
subconfluence cells were detached with 0.5 ml phosphate buffered saline (PBS) 
containing 0.05% (w/v) trypsin and 0.05% (w/v) EDTA (Invitrogen) and re-seeded. 
Medium was replenished twice a week. 
For studying dose- and time-dependent effects of minoxidil on gene expression we 
cultured fibroblasts derived from subcutaneous fat of one donor in 10 cm2 wells until 
subconfluence. Subsequently, these cells were incubated i) in the absence or presence of 
different concentrations of minoxidil (0, 100, 200, 400, 600, 800, and 1000 μM) for 24 
hours or ii) in the presence of 400 μM minoxidil for 2, 4, 6, 8, 10, 12, 24, 32, and 48 
hours.  
Long-term fibroblast cultures from subcutaneous fat (n = 3), dermis (n = 1), and 
keloid (n = 2) were performed to obtain extracellular matrix for amino acid and cross-
link analyses. Cells were cultured until full confluence in 75 cm2 flasks and subsequently 
incubated in DMEM supplemented with 10% FCS, 100 U/ml penicillin, 100 U/ml 
streptomycin, and 50 μg/ml ascorbic acid in the absence or presence of 500 μM 
minoxidil. The relatively large number of fibroblasts used in these cultures was to 
compensate for the anti-proliferative effect of minoxidil.(36;37) In this way sufficient 
amounts of extracellular matrix were obtained to perform amino acid and cross-link 
analyses. After three weeks of culture, the cells present in the extracellular matrix were 
killed by two freeze-thaw cycles and the matrix was incubated in PBS at 37°C for 
another week to enable further maturation into tri-functional cross-links.(40)  
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For all experiments minoxidil was directly dissolved in DMEM supplemented with 
10% FCS, 100 U/ml penicillin, 100 U/ml streptomycin and, if applicable, 50 μg/ml 
ascorbic acid. The medium was filtered through a 0.2 μm filter before use. 
Gene expression analysis 
Total RNA was isolated from fibroblast cultures (10 cm2) using the RNeasy kit 
(Qiagen). Subsequently, mRNA was reverse transcribed into cDNA using the oligo-dT 
primer (Roche). mRNA levels of LH1, LH2b, LH3, collagen type I α2 (COL1A2), and 
LOX were analyzed by quantitative real-time PCR using specific primers and molecular 
beacons as described previously.(13) For quantitative determination of prolyl 4 
hydroxylase α1 (P4HA1) mRNA expression cDNA was amplified using the forward 
primer: 5’TTGCACGGAAAGATGAGCCAGATGCT3’ and the reverse primer:  
5’TGGGCCAAACACTAGCTCCAACTTCAG3’.  
P4HA1 PCR products were measured using the molecular beacon: 5’-FAM-
cgtgccATGAGTGATGTGTCTGCAGGAGGAGCCggcacg-DABCYL-3’. To standardize 
for differences in the total amount of RNA isolated from each sample, expression of the 
different genes was normalized to that of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), a constitutively expressed gene which expression was not affected by 
minoxidil. GAPDH mRNA expression was quantitatively measured using the forward 
primer: 5’CAATGCCTCCTGCACCACCAAC3’, the reverse primer:  
5’AGGGGCCATCCACAGTCTTCT3’, and the molecular beacon: 5’-HEX-
cgctcgCACCCCTGGCCAAGGTCATCCAcgagcg-DABCYL-3’. Data were analyzed 
using sequence detector V1.7 software. Due to the fact that no specific primers 
amplifying only LH2a could be designed for use in real-time PCR, LH2a expression was 
analyzed using a PCR amplifying both LH2a and LH2b.(13)  
Amino acid and cross-link analysis 
Isolated extracellular matrices from long-term fibroblast cultures were hydrolyzed 
in 6 M HCl and used for amino acid and cross-link analysis. The number of 
hydroxyproline and hydroxylysine residues was determined in the acid hydrolysates by 
reverse-phase high-performance liquid chromatography (RP-HPLC) after derivatization 
with 9-fluorenylmethyl chloroformate (FMOC).(41) In the same hydrolysates the number 
of the tri-functional hydroxyallysine-derived cross-links HP and LP was measured by 
HPLC as described previously.(42;43) The number of pyridinoline cross-links and 
hydroxylysine residues were expressed per collagen molecule assuming 300 
hydroxyproline residues per triple helix.    
Statistical analysis 
Statistical analysis was performed using SPSS 11.0 software. Data are presented as 
mean ± standard deviation. Dose- and time-dependent effects of minoxidil were 
analyzed by ANOVA and post-hoc Tukey tests. Normalized data for gene expression, 
collagen hydroxylation, and cross-linking were analyzed by Paired-Samples T-tests. A P 
value of ≤ 0.05 was considered to indicate statistically significant differences. 
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Figure 1. Dose-response relationship for the minoxidil effect on gene expression of collagen 
and its modifying enzymes. Fibroblasts derived from subcutaneous fat were incubated for 24 h 
in the presence of the indicated minoxidil concentrations to assess its effect on gene expression. 
LH1 mRNA level (A) was significantly reduced at ≥ 25 μM minoxidil (p ≤ 0.005, for minoxidil-
treated fibroblasts versus untreated). LH2b mRNA level (B) was significantly reduced at ≥ 100 
μM minoxidil (p ≤ 0.001). LH3 mRNA level (C) was significantly reduced at ≥ 100 μM 
minoxidil (p ≤ 0.01). No dose-dependent effect of minoxidil on mRNA levels of COL1A2 (D), 
LOX (E), or P4HA1 (F) was measured. Statistical analysis was performed using ANOVA and 
post-hoc Tukey tests.  
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Results 
Inhibiting properties of minoxidil on LH gene expression 
To unravel the effect of minoxidil on gene expression of the different lysyl 
hydroxylases, dose- and time-dependent responses were examined in fibroblasts derived 
from subcutaneous fat of one donor. These fibroblasts were used because of their 
elevated levels of LH2b gene expression and hydroxyallysine cross-links compared to 
fibroblasts isolated from dermis.(44) Concentration-dependent effects on the mRNA 
levels of LH1, LH2b, and LH3 after an 24 hours incubation period were studied in a 
range of 0-1000 μM minoxidil (Figure 1). The most pronounced inhibitory effect of 
minoxidil was observed on the expression of LH1, which was almost completely 
inhibited at a concentration of 400 μM (Figure 1A). In addition, minoxidil also affected 
the mRNA levels of LH2b and LH3, although to a much lesser extent than that of LH1. 
Even in the presence of 1000 μM minoxidil a considerable level of LH2b and LH3 mRNA 
was observed (Figure 1B and 1C, respectively). mRNA levels of COL1A2, LOX, and 
P4HA1 were not affected by minoxidil (Figure 1D, 1E, and 1F, respectively). 
To examine time-dependent effects of minoxidil on gene expression of LH1, LH2b, 
and LH3, subcutaneous fat-derived fibroblasts were incubated in the presence of 400 
μM minoxidil for a period of 0-48 hours (Figure 2). The inhibitory effect of minoxidil in 
time on the expression of the different lysyl hydroxylases was quite distinct. Suppression 
of LH1 expression occurred relatively fast, showing an almost complete inhibition after 
8 hours of incubation (Figure 2A), whereas the time-dependent suppression of LH2b 
occurred more gradual (Figure 2B). The time-dependent inhibitory effect of minoxidil on 
LH3 expression was found to be even more delayed: no significant differences compared 
to the mRNA level at t = 0 were found in the first 12 hours of minoxidil incubation 
(Figure 2C). COL1A2 and P4HA1 mRNA levels were not affected by minoxidil (Figure 
2D and 1F, respectively), however, the level of LOX mRNA was significantly reduced to 
73% after 48 hours of exposure to minoxidil (Figure 2E). 
In order to study the universality of the inhibitory profile of minoxidil on the gene 
expression of the different lysyl hydroxylases, fibroblasts derived from subcutaneous fat 
of four different donors were incubated in the presence of 1000 μM minoxidil for a 
period of 24 hours. In all four donors, LH1, LH2b, and LH3 mRNA levels were 
decreased as a consequence of minoxidil treatment (Figure 3A). The maximal reduction 
due to minoxidil treatment again appeared to be different. In the case of LH1, the 
mRNA level is decreased to merely 7% of the level in untreated cells, whereas for LH2b 
and LH3 a significantly higher level of remaining gene expression was found when cells 
were treated with 1000 μM minoxidil (35% and 21%, respectively). 
The effect of minoxidil on LH2a expression, the short splice variant of LH2, was 
qualitatively assessed. In fibroblasts LH2b is the dominant splice variant present, whereas 
LH2a expression constitutes less than 5% of the LH2b expression level. No obvious 
changes in the level of LH2a expression in the four different donors could be observed 
as a consequence of treatment with 1000 μM minoxidil (Figure 3B). 
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Figure 2. Time course of the minoxidil effect on gene expression of collagen and its modifying 
enzymes. Fibroblasts derived from subcutaneous fat were incubated in the presence 400 μM 
minoxidil for the indicated time periods to assess the effect on gene expression. LH1 mRNA 
level (A) was significantly reduced after ≥ 2 h (p ≤ 0.001, for minoxidil-treated fibroblasts 
versus untreated (t = 0). LH2b mRNA level (B) was significantly reduced after ≥ 2 h (p ≤ 0.01). 
LH3 mRNA level (C) was significantly reduced after ≥ 24 h (p ≤ 0.001). LOX mRNA level (E) 
was significantly reduced after 48 h (p = 0.019). No time-dependent effect of minoxidil on 
mRNA levels of COL1A2 (D) or P4HA1 (F) was measured. Statistical analysis was performed 
using ANOVA and post-hoc Tukey tests.  
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Effect of minoxidil on lysyl hydroxylation and hydroxyallysine cross-linking of 
collagen 
The postulated anti-fibrotic effect of minoxidil by reducing the supply of 
hydroxylysine residues for hydroxyallysine cross-linking was further investigated by 
analyzing the collagen deposited by fibroblasts cultured in the presence of 500 μM 
minoxidil for a period of 3 weeks. Fibroblast cultures derived from subcutaneous  
fat (n = 3), dermis (n = 1) and from keloid tissue (n = 2) were used. The keloid 
fibroblasts were chosen for their fibrotic phenotype to show relevance of minoxidil as 
anti-fibroticum. As expected, the lysyl hydroxylation level of the collagen triple helix was 
decreased when the fibroblast cultures were treated with minoxidil (Table 1) to about 
50% of the level found in collagen deposited in the absence of minoxidil (Figure 4).  
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Figure 3. Minoxidil effect on gene expression of collagen and its modifying enzymes in 
different donors of subcutaneous fat-derived fibroblasts. Fibroblasts derived from four different 
donors were incubated in the absence and presence of 1000 μM minoxidil to assess the 
universality of the effect on gene expression. (A) mRNA levels in minoxidil-treated fibroblasts 
were normalised against levels in untreated fibroblasts. Statistical analysis was performed using 
Paired-Samples T tests. *, #, + indicate p < 0.001, p < 0.01, and p < 0.05, respectively, for 
minoxidil-treated versus untreated fibroblasts. (B) LH2a mRNA levels in the absence (1, 3, 5, 
7) and presence of 1000 μM minoxidil (2, 4, 6, 8) in (1, 2) donor #1, (3, 4) donor #2, (5, 6) 
donor #3, and (7, 8) donor #4. M, molecular weight marker.   
Chapter 7 
130 
Figure 4. Minoxidil effect on the lysyl hydroxylation and pyridinoline cross-linking of collagen. 
Fibroblasts derived from subcutaneous fat (n = 3), dermis (n = 1), and keloid (n = 2) were 
incubated in the absence or presence of 500 μM minoxidil for a period of three weeks. 
Extracellular matrix was collected and analysed by HPLC. Data obtained for each donor are 
shown in Table 1. To compare data from different fibroblast populations, lysyl hydroxylation 
and cross-linking levels in collagen deposited by minoxidil-treated fibroblasts were normalised 
against levels found in collagen deposited by untreated fibroblasts. Statistical analysis was 
performed using Paired-Samples T tests. *, #, + indicate p < 0.001, p < 0.01, and p < 0.05, 
respectively, for minoxidil-treated versus untreated fibroblasts. 
To assess the effect of minoxidil on hydroxyallysine cross-linking, the tri-functional 
cross-links HP and LP were measured. In all donors pyridinoline cross-linking was 
affected by minoxidil treatment (Table 1), resulting in a decrease in the number of HP 
cross-links per collagen molecules to 31% of HP cross-link levels in collagen produced 
under normal conditions (Figure 4). The number of LP cross-links increased, 2.5 to 37-
fold, dependent on the donor (Figure 4, Table 1). The change in the number of HP or LP 
cross-links is also reflected in the HP/LP ratio (Table 1), which decreased dramatically to 
5% of what is normally found in collagen deposited by dermal fibroblasts (Figure 4). In all 
cases the number of LP cross-links present in the matrix was higher than that of HP 
after minoxidil incubation, whereas the opposite is seen in the collageneous matrix 
deposited by fibroblasts cultured in the absence of minoxidil (Figure 5). No general 
effect of minoxidil treatment on the total number of pyridinoline cross-links (sum of HP 
and LP) was observed (Figure 4). Collagen deposited by keloid (n = 2) and dermis (n = 
1) fibroblasts showed an increase in pyridinoline cross-linking. No consistent increase or 
decrease in the total number of pyridinoline cross-links was found in collagen produced 
by subcutaneous fat-derived fibroblasts (Table 1).  
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Table 1: Lysyl hydroxylation and cross-linking of collagen 
 
 
FBa  
donor 
 
Hyl/collagen 
(mol/mol) 
 
 
HP/collagen 
(mmol/mol) 
 
LP/collagen 
(mmol/mol) 
 
HP+LP/collagen 
(mmol/mol) 
 
HP/LP 
(mol/mol) 
 - MXLb + MXL - MXL + MXL - MXL + MXL - MXL + MXL - MXL + MXL 
s.c. fat  
#1c 
38.4 ± 5.0 14.3 ± 0.8 81 ± 5 22 ± 8 4 ± 1 92 ± 22 85 ± 5 114 ± 30 19.1 ± 
3.8 
0.23 ± 
0.04 
s.c. fat 
#2 
48.8 26.8 190 ± 46 88 ± 38 54 ± 11 162 ± 66 244 ±  
55 
250 ± 105 3.6 ±  
0.6 
0.44 ± 
0.07 
s.c. fat 
#3 
56.1 ± 1.4 31 ± 3.0 249 ± 32 61 ±16 48 ± 9 117 ± 11 297 ±  
23 
178 ± 5 4.4 ±  
0.2 
0.53 ± 
0.19 
keloid 
#1 
37.7 ± 3.3 17.1± 0.3 220 ± 4 51 ±5 13 ± 1 256 ± 2 233 ±  
5 
307 ± 6 17.7 ± 
1.3 
0.21 ± 
0.00 
keloid 
#2 
47.0 ± 0.2 31.2 ± 0.1 93 ± 1 42 ± 1 7 ± 2 193 ± 34 99 ± 33 236 ± 32 26.1 ± 
6.0 
0.22 ± 
0.05 
dermis 
#1 
36.9 ± 0.5 14.6 ± 0.2 52 ± 4 11 ± 1 2 ± 0.3 73 ± 53 54 ± 4 83 ± 5 24.5 ± 
5.1 
0.15 ± 
0.02 
a FB,  fibroblast; b MXL, minoxidil; c s.c., subcutaneous 
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Figure 5. Minoxidil effect on the formation of HP and LP cross-links. Representative 
chromatograms of reverse-phase HPLC analysis, showing HP and LP cross-links present in 
collagen deposited by fibroblasts in the  absence (A) and  presence (B) of minoxidil. In panel C 
schematic representations of the trifunctional cross-links HP and LP are given. Note that the only 
difference between these two mature cross-links is the nature of the triple helical residue involved 
in the cross-link. HylTH, hydroxylysine residue in triple helix; HylTP, hydroxylysine residue in 
telopeptide; LysTH, lysine residue in triple helix. 
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Discussion 
Collagen deposition in human fibrotic tissues often displays an increase in 
hydroxyallysine-derived cross-links,(18) which most likely contributes to the unwanted 
accumulation of collagen by conferring increased resistance to proteolytic 
degradation.(28;31-34) After the discovery of the inhibitory action on lysyl hydroxylase gene 
expression, minoxidil was postulated to possess anti-fibrotic properties by reducing the 
total number of hydroxylysine residues in the collagen molecule and consequently the  
formation of hydroxyallysine cross-links.(37;38) However, this statement needs to be 
further nuanced to diminution of the number of telopeptide hydroxylysine residues, 
since only these residues are prerequisites for the formation of hydroxyallysine cross-
links. With the present knowledge that four different lysyl hydroxylases exist,(3-9) each 
with its preference for a certain substrate (telopeptide or triple helical lysine), it is 
important to understand the inhibitory effect of minoxidil on gene expression of the 
individual lysyl hydroxylases. 
Recent studies indicate that LH2b exhibits telopeptide lysyl hydroxylase 
activity.(13;15-18) Minoxidil appeared to be able to decrease the LH2b mRNA level, but 
remarkably no consistent decrease in the total number of pyridinoline cross-links was 
found in the matrix deposited by fibroblasts. Since minoxidil does not completely inhibit 
LH2b gene expression at a concentration of 500 μM (used in long-term cultures for 
obtaining extracellular matrix), an explanation could be that residual gene expression is 
sufficient for hydroxylating telopeptide lysine residues to a level normally found in 
collagen produced by fibroblasts. Another explanation could be that the observed levels 
of pyridinoline cross-links are due to a concerted action of LH2b and LH3 in 
hydroxylating telopeptide lysine. LH3 is able to hydroxylate lysine residues in synthetic 
peptides corresponding to N- and C-telopeptides.(45) We observed that 50% of the LH3 
mRNA level remains at a minoxidil concentration of 500 μM and moreover, the 
inhibitory response shows a strong delay in time. The fourth lysyl hydroxylase LH2a, an 
enzyme with unknown specificity, does not seem to play a significant role in fibroblasts 
given its low expression levels. A qualitative assessment showed that minoxidil did not 
induce changes in the already minimal mRNA LH2a expression, thus excluding the 
possibility that LH2a expression contributes to the observed formation of pyridinoline 
cross-links. Finally, a necessary step in the pyridinoline cross-linking pathway is the 
formation of the aldehyde hydroxyallysine, a reaction catalyzed by lysyl oxidase. A 
stimulatory effect of minoxidil on lysyl oxidase gene expression has been described(46) 
and in principle this could compensate for a decrease in telopeptide hydroxylysines due 
to reduced LH2b mRNA levels. This might explain why no difference in the total 
number of pyridinoline cross-links was observed between matrices deposited by 
minoxidil-treated and untreated fibroblasts. However, we were unable to confirm this 
stimulatory effect of minoxidil on lysyl oxidase gene expression. So no conclusive 
answer to the question what is causing the essentially unchanged pyridinoline cross-link 
level in collagen after minoxidil treatment can be given.  
Prolyl 4-hydroxylase α1 gene expression was found to be unaffected or only 
slightly stimulated by minoxidil in the different donors and this corresponds to previous 
data showing that gene expression, prolyl hydroxylase activity, and hydroxyproline to 
proline ratio in collagen are normal in minoxidil-treated skin fibroblasts.(35-38;47) The 
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unaffected level of collagen mRNA that we observed in fibroblasts after minoxidil 
treatment also corroborates with previous findings.(48)  
Minoxidil appeared to have the most profound effect on LH1 expression, the lysyl 
hydroxylase involved in the hydroxylation of triple helical lysine, and this is reflected in 
the decreased lysyl hydroxylation state of the collagen molecule. Similar reduction in the 
number of hydroxylysine residues due to minoxidil treatment has been reported,(38;49) 
but the consequence for pyridinoline cross-linking has never been examined before. The 
triple helical residues involved in the tri-functional hydroxyallysine cross-links, lysine or 
hydroxylysine, are located at specific positions in the collagen type I α1 molecule 
(residues 87 and 930) and determine the type of pyridinoline cross-link, LP or HP, 
respectively.(50) The observed decrease in HP and increase in LP cross-links can thus 
perfectly be explained by the hypothesis that the lysine residues at these two positions 
in the triple helix are less hydroxylated. However, it is remarkable that in every single 
donor the number of LP cross-links formed is much higher than expected based on the 
effect of minoxidil on lysyl hydroxylation (20-fold increase in LP cross-links versus 2-fold 
reduction in lysyl hydroxylation), suggesting that LH1 preferentially hydroxylates lysine 
residues at the cross-linking positions (residues 87 and 930).  
Striking similarities between the effect of minoxidil on collagen hydroxylation and 
cross-linking and the biochemical defects of EDS VI exist, which is understandable from 
the dominant effect of minoxidil on LH1 gene expression, being the lysyl hydroxylase 
that is mutated in EDS VI. A switch from HP to LP cross-linking, as seen in collagen 
deposited by minoxidil-treated fibroblasts, occurs in several tissues of EDS VI patients as 
well, including skin, bone, and tendon and is reflected in the substantial decrease in the 
HP:LP ratio.(51) When examining previously described lysyl hydroxylation levels and HP 
and LP cross-linking of collagen deposited by EDS VI fibroblasts,(4;52;53) again it strikes that 
the increase in LP cross-links is not proportional to the decrease in the number of 
hydroxylysines. Thus the suggestion that LH1 preferentially hydroxylates triple helical 
lysine residues involved in enzymatic cross-linking is corroborated by the pyridinoline 
cross-link characteristics found in EDS VI.(54) In this context, it is also interesting to 
notice that the amino acids surrounding the cross-linking positions in human collagen 
type I α1 almost all correspond to amino acids that has been described to promote LH1 
binding.(6) In contrast, Ala-Lys-Gly containing sequences appears to be poor substrates 
for LH1.(6;55) In collagen type I α1 ten out of twenty potential lysyl hydroxylation sites in 
the triple helical part (excluding the cross-linking sites) are imbedded in a Ala-Lys-Gly 
sequence. In collagen type I α2, however, this is less dramatic: three out of nineteen 
potential lysyl hydroxylation sites are imbedded in such a sequence.   
In conclusion, the proposed anti-fibrotic property of minoxidil,(38) i.e. reduction of 
hydroxyallysine cross-linking, could not be supported by our findings. However, it is 
worthwhile to investigate whether modifying the minoxidil structure offers possibilities 
to obtain derivatives that are more potent in inhibiting the LH2b expression. The ideal 
minoxidil derivative should lack the effect on LH1 gene expression and should be active 
in a nanomolar range. A number of structural analogs of minoxidil has been described in 
literature(38;47;56) and it would be of relevance to study their effect on gene expression of 
the four lysyl hydroxylases and hydroxyallysine cross-linking of collagen. 
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Abstract 
The hallmark of fibrotic processes is an excessive accumulation of collagen. The 
deposited collagen contains increased hydroxyallysine cross-link levels due to an 
overhydroxylation of lysine residues within collagen telopeptides. The occurrence of 
elevated hydroxyallysine levels is related to irreversible fibrotic processes, suggesting 
that collagen containing this type of cross-link significantly contributes to the unwanted 
collagen accumulation. We reasoned that specific inhibition of hydroxyallysine cross-link 
formation will result in increased collagen degradation. Recently, we have found that 
elevated lysyl hydroxylase 2b (LH2b) mRNA expression is responsible for the 
overhydroxylation of collagen telopeptides in fibrotic lesions. Therefore LH2b is a 
promising target to interfere with hydroxyallysine cross-linking in fibrosis. The present 
study demonstrates that four different synthetic LH2-silencing RNA (LH2-siRNA) 
molecules reduce LH2b mRNA expression levels in cultured fibroblasts without 
interfering with mRNA expression of the other lysyl hydroxylase: LH1 and LH3, nor 
with mRNA expression of collagen type I α2 chain and lysyl oxidase. However, the 
silencing effect of the synthetic LH2-siRNAs was found to be short-term. The 
persistence of the LH2-siRNA effect on LH2b expression was extended by adenoviral-
mediated expression of LH2-siRNA. Unfortunately, the adenoviruses had dramatic 
effects on cell survival, and due to extreme cell death, we were not able to investigate 
the effect of siRNA-mediated LH2b down-regulation on hydroxyallysine cross-linking. 
Together, siRNA based LH2b silencing appears a promising tool and it would be 
interesting to develop strategies to obtain long-term silencing in order to examine the 
effects of LH2b silencing on hydroxyallysine cross-linking. 
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Introduction 
Fibrosis is an abnormal healing process characterized by excessive accumulation of 
extracellular matrix proteins, in particular collagen. It is now generally accepted that the 
elevated collagen deposition in fibrotic lesions is the consequence of increased collagen 
synthesis and decreased matrix metalloproteinase (MMP) activity due to an imbalance 
between MMP and tissue inhibitor of matrix metalloproteinase (TIMP) levels.(1-4) 
Therefore, anti-fibrotic interventions are in general interfering with collagen synthesis 
and MMP activity. Interestingly, in addition to increased collagen synthesis, altered cross-
link chemistry is seen in collagen that is deposited in fibrotic lesions. Elevated 
hydroxyallysine cross-link levels (such as pyridinolines) have consistently been observed 
in various fibrotic tissues and organs, pointing to a general fibrotic phenomenon.(5-10) 
Moreover, the presence of increased hydroxyallysine cross-link levels is related to 
irreversible fibrotic processes, indicating that it significantly contributes to collagen 
accumulation, conceivably by conferring collagen resistance to proteolytic digestion.(11-14) 
We speculate that specific inhibition of hydroxyallysine cross-link formation during 
fibrotic processes results in the deposition of collagen which is more susceptible 
towards degradation, and subsequently less collagen accumulation is expected. It is 
therefore worthwhile to search for specific inhibitors of hydroxyallysine cross-link 
formation. 
Hydroxyallysine cross-links are derived from hydroxylated lysine residues within 
collagen telopeptides, which are converted by lysyl oxidase (LOX) to the reactive 
aldehyde hydroxyallysine. Subsequently, the hydroxyallysine reacts with a lysine or 
hydroxylysine residue within the collagen triple helix in order to form di- and tri-
functional cross-links. Mature tri-functional hydroxyallysine cross-links are 
lysylpyridinoline (LP) and hydroxylysylpyridinoline (HP) and,(15-18) under physiological 
conditions, hydroxyallysine cross-links exist in e.g. bone, cartilage, and tendon.(19)  
The increased formation of hydroxyallysine cross-links in fibrotic lesions is the 
consequence of an overhydroxylation of telopeptide lysine residues. We have shown 
that an increase in mRNA expression of the telopeptide lysyl hydroxylase, lysyl 
hydroxylase 2b (LH2b), in various fibrotic fibroblasts is associated with increased 
pyridinoline levels in the deposited matrix. These findings imply that LH2b is responsible 
for the increased formation of hydroxyallysine cross-link formation in fibrosis.(20;21) LH2b 
is a member of the lysyl hydroxylase family (EC1.14.11.4) consisting of four isoforms: 
LH1, LH2a, LH2b, and LH3.(22-26) LH2a and LH2b are two splice variants of the LH2 gene 
(LH2b contains an extra insert).(27;28) LH2 predominantly hydroxylates telopeptide lysine 
residues, whereas LH1 predominantly catalyzes the conversion of helical lysines into 
hydroxylysine residues.(20;29-32) The substrate specificity of LH3 towards lysine residues 
has not been unraveled.  
As LH2b is responsible for the overhydroxylation of telopeptide lysine residues 
within collagen deposited in fibrotic lesions, LH2b appears an interesting target to 
interfere with hydroxyallysine cross-linking during fibrotic processes. Therefore we 
searched for a way to specifically reduce LH2b mRNA expression. 
 A powerful technology, allowing the silencing of mammalian genes in cells lines and 
whole organisms with great specificity, is RNA interference mediated by small 
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interfering RNAs (siRNAs). SiRNA molecules are 21-23-nucleotides duplex RNA 
molecules, which assemble within a nuclease complex called RNA-inducing silencing 
complex (RISC). After the incorporation of the siRNA molecule into the RISC, the 
duplex siRNA molecule is unwound, and subsequently the single antisense strand guides 
the RISC to its complementary target mRNA, finally leading to endonucleolytic cleavage 
of the target mRNA. Under physiological conditions, RNA interference mediated by 
siRNA molecules is now recognized as a naturally occurring strategy for silencing genes 
during development in plants, invertebrates, and vertebrates.(33;34) In mammalian cell 
cultures, siRNA mediated reduction of mRNA expression has either been accomplished 
by transfection of synthetic siRNA oligonucleotides(35;36) or by expression systems, that 
produce siRNA or hairpin-siRNA molecules under the control of RNA polymerase III. 
The latter siRNA molecule consists of two complementary sequences: the sense and 
antisense with a few nucleotides in-between, which form a loop.(37-45)  
SiRNA-mediated RNA interference seems a very promising technique to 
specifically reduce LH2b mRNA expression in fibrotic cells in order to down-regulate 
hydroxyallysine cross-linking in fibrotic lesions. The present study was designed to 
explore the effect of specific LH2-siRNA sequences on LH2b mRNA expression. We 
demonstrate that four different synthetic LH2-siRNAs are able to achieve 75% LH2b 
silencing without interfering with LH1, LH3, collagen type I α2 (COL1A2), and LOX 
mRNA expression. Unfortunately, the approaches we used did not induce long-term 
LH2b silencing. Therefore we were not able to investigate the effect of siRNA-mediated 
LH2b down-regulation on hydroxyallysine cross-linking.  
Material and Methods 
Transfection of fibroblasts with synthetic LH2-siRNAs 
Primary cultured human fibroblasts, obtained from subcutaneous fat of one donor, 
were established by routine methods.(46) Subcutaneous fat-derived fibroblasts were used 
for these studies, because of their elevated levels of LH2b gene expression and 
hydroxyallysine cross-links compared to fibroblasts isolated from split skin.(47) Cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM; BioWhittaker) 
supplemented with 10% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin and 
100 U/ml streptomycin at 37 °C in 5% CO2. Fibroblasts were detached using 1 ml 0.05% 
trypsin/0.02% EDTA per 75 cm2 and transfected with four different synthetic LH2-
siRNA molecules which were designed and provided by Qiagen-Xeragon (4-for-silencing 
siRNA duplex program; for target sequences see Table 1). A transfection without 
siRNA served as a negative control. Transfection was performed by electroporation 
using the Amaxa nucleofector technology. Cells were resuspended in 100 μl human 
dermal fibroblast nucleofector solution (VPD-1001; Amaxa) at a final concentration of 
0.5x106 cells/100μl. The cell suspension was mixed with 2 μg siRNA or 2 μl phosphate 
buffered saline (PBS) and transferred into an Amaxa certified electroporation cuvette. 
The cuvette was placed into the nucleofector system and cells were electroporated 
using program U-23. To avoid damage to the cells, the cell suspension was immediately 
removed from the cuvette, resuspended in 2 ml pre-warmed culture medium, and 
transferred to 10 cm2 wells. Finally, cells were cultured for 48 hours before they were 
harvested and used for gene expression analysis.  
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Table 1: DNA target sequences of synthetic LH2-siRNAs 
Name DNA target sequence Position (sequence LH2b) 
siRNA1 5’ GACTCCCCTACTCCGGAAACA 3’ 1519-1539 
siRNA2 5’ CGGGAGTTCATTGCACCAGTT 3’  1879-1900 
siRNA3 5’ AAGGTCCTTGGTCAAGGAGAA 3’  199-219 
siRNA4 5’ TCCTGGGAGACTCACACATTT 3’ 2130-2150 
Table 2: Oligonucleotide sequences used for construction of siRNA3 and siSCRAM expressing 
adenoviruses 
Name Sequence 
siRNA3 5’ GAAGGTCCTTGGTCAAGGAGAATTCAAGAGATTCTCCTTGACCAAGGACCTTCTTTTTT 3’ 
siSCRAM 5’ GTGTACTGACCATGCTAGTCGATTCAAGAGATCGACTAGCATGGTCAGTACACTTTTTT 3’ 
Hairpin loop sequence and extra overhang are shown in boldfaced type; Terminator sequence is shown in italics. 
Construction of LH2-siRNA expressing adenovirus 
To obtain an adenovirus expressing LH2-siRNA duplexes, we first inserted double 
strand oligonucleotides, containing the sense sequence of siRNA3 or a scrambled 
sequence (siSCRAM; same GC and AT content as siRNA3), a 9-nucleotide loop, and the 
antisense sequence of siRNA3 or siSCRAM, in the RNAi-ready pSIREN shuttle vector, 
in which expression is driven by the pU6 promoter (BD Biosciences-Clontech; for 
sequences of oligonucleotides see Table 2). The constructed pSIRENsiRNA3 and 
pSIRENsiSCRAM vectors were digested with I-Ceu-I and PI-Sce-I restriction enzymes, 
and the fragments comprising the pU6 promoter, the siRNA sense, the loop, and 
antisense sequences were inserted into the I-Ceu-I and PI-Sce-I sites of an adapted Ad-5 
adenoviral shuttle vector (pAdapt). This adenoviral shuttle vector was originally a CMV 
consisting vector which did not contain I-Ceu-I and PI-Sce-I restriction sites. Therefore, 
we adapted this vector by replacing the CMV promoter region with a fragment 
comprising these two restriction sites. For the generation of recombinant adenovirus, 
the constructed pAdapt.pU6.siRNA3 or pAdapt.pU6.siSCRAM vectors were 
cotransfected with pJM17 in HER9.11 cells by standard procedures.(48) The viable clones 
were selected using standard plaque isolation and after amplification and purification the 
respective ad-siRNA3 and ad-siSCRAM viral stocks were used for further experiments. 
Adenoviruses carrying no insert (ad-Mock) were generated as described previously.(49)  
Transfection of fibroblasts with LH2-siRNA expressing adenovirus 
Primary fibroblasts obtained from skin biopsies of one patient with diffuse 
cutaneous systemic sclerosis were established by routine methods. Cells were cultured 
in DMEM supplemented with 10% heat-inactivated FCS, 100 U/ml penicillin and 100 
U/ml streptomycin at 37 °C in 5% CO2 until reaching subconfluence. To explore the 
effect of LH2-siRNA on LH2b mRNA expression, fibroblasts cultured in 10 cm2 wells 
were transfected with ad-siRNA3. In addition, cells were transfected either with ad-
siSCRAM and ad-Mock, which served as negative controls in addition to non-transfected 
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fibroblasts. Transfection was performed by incubating the cells for 3 hours in 0.5 ml 
DMEM supplemented with 0.1% bovine serum albumin (BSA), 100 U/ml penicillin and 
100 U/ml streptomycin at 37 °C in the presence of the respective adenovirus at a 
concentration of approximately 2x108 pfu/ml. After 3 hours, cells were washed with PBS 
and cultured in DMEM supplemented with 10% FCS, 100 U/ml penicillin and 100 U/ml 
streptomycin at 37 °C in 5% CO2. At days 3, 7, and 14 cells were harvested and used 
for gene expression analysis.  
To explore the effect of LH2-siRNA expression on hydroxyallysine cross-linking, 
systemic sclerosis fibroblasts were cultured in 75 cm2 until reaching 100% confluence. 
Fibroblasts were infected either with ad-siRNA3, ad-siSCRAM, or ad-Mock at 37 °C in 4 
ml DMEM supplemented with 0.1% BSA 100 U/ml penicillin and 100 U/ml streptomycin 
at a concentration of approximately 2x108 pfu/ml. After 3 hours of incubation, cells 
were washed with PBS and cultured for 2 weeks in DMEM supplemented with 10% FCS, 
50μg/ml ascorbic acid, 100 U/ml penicillin and 100 U/ml streptomycin. Medium was 
replenished every 3 days. After 2 weeks of culture, the cells present in the extracellular 
matrix were killed by two freeze-thaw cycles and the matrix was incubated in PBS at 
37°C for another 10 days to enable further maturation into tri-functional cross-links.(50) 
Matrices were harvested and used for amino acid and pyridinoline cross-link analysis. 
Gene expression analysis 
Total RNA was isolated from transfected and untransfected fibroblasts using the 
RNeasy kit (Qiagen). Subsequently, the RNA was reverse transcribed into cDNA using 
the oligo-dT primer (Roche) and subjected to real-time PCR amplification. Real-time 
PCR amplification of cDNA sequences was performed for LH1, LH2b, LH3, COL1A2, 
and LOX using specific primers and specific molecular beacons as described 
previously.(20) To standardize for differences in the total amount of cDNA, a real-time 
PCR was performed for β-2-microglobulin (B2M), a constitutively expressed gene which 
expression was not affected by the various transfections. Data were analyzed using 
sequence detector V1.7 software and the mRNA expression of the target genes was 
calculated relatively to B2M expression. LH2a mRNA expression was measured using a 
PCR amplifying both LH2a and LH2b, as no specific primers amplifying only LH2a could 
be designed for use in real-time PCR.(20)  
Amino acid and pyridinoline cross-link analysis 
Measurements were performed on the extracellular matrix obtained from long-
term (2 weeks) fibroblast cultures. Hydroxyproline (Hyp) and hydroxylysine (Hyl) levels 
were determined in acid hydrolysates of matrix samples after derivatization with 9-
fluorenylmethyl chloroformate by reverse-phase high-performance liquid 
chromatography.(51) Hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) cross-links 
were measured in the same acid hydrolysates as described previously.(52;53) Pyridinoline 
and Hyl levels were expressed as total amount of residues per collagen molecule, 
assuming 300 Hyp residues per triple helix. 
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Figure 1. LH2b mRNA expression is strongly diminished by synthetic LH2-siRNA. 
Subcutaneous fat-derived fibroblasts (n = 2) were transfected with four different synthetic LH2-
siRNA molecules e.g. siRNA1 (si 1), siRNA2 (si 2), siRNA3 (si 3) and siRNA4 (si 4). 
Untransfected fibroblasts served as a control (con). LH2b/B2M (A) and LH2b/COL1A2 (B) 
mRNA expression was reduced by the various LH2-siRNAs, whereas LH1 (C), LH3 (D), 
COL1A2 (E), and LOX (F) mRNA expression was not affected by synthetic LH2-siRNAs. Data 
are presented as mean ± sd.  
0
2
4
6
8
con si 1 si 2 si 3 si 4
ra
ti
o
 o
f m
R
N
A
 L
O
X
/B
2M
0
1
2
3
4
con si 1 si 2 si 3 si 4
ra
ti
o
 o
f m
R
N
A
 C
O
L
1A
2/
B
2M
0.00
0.05
0.10
0.15
0.20
con si 1 si 2 si 3 si 4
ra
ti
o
 o
f 
m
R
N
A
 L
H
3/
B
2M
       0.00
0.20
0.40
0.60
0.80
con si 1 si 2 si 3 si 4
ra
ti
o
 o
f 
m
R
N
A
 L
H
1/
B
2M
        
0.00
0.04
0.08
0.12
0.16
con si 1 si 2 si 3 si 4
ra
ti
o
 o
f 
m
R
N
A
 L
H
2b
/C
O
L
1A
2
       0.00
0.05
0.10
0.15
0.20
con si 1 si 2 si 3 si 4
ra
ti
o
 o
f 
m
R
N
A
 L
H
2b
/B
2M
        
A
C
B
E F
D
ra
ti
o
 o
f m
R
N
A
 L
O
X
/B
2M
ra
ti
o
 o
f m
R
N
A
 C
O
L
1A
2/
B
2M
ra
ti
o
 o
f 
m
R
N
A
 L
H
3/
B
2M
ra
ti
o
 o
f 
m
R
N
A
 L
H
1/
B
2M
ra
ti
o
 o
f 
m
R
N
A
 L
H
2b
/C
O
L
1A
2
ra
ti
o
 o
f 
m
R
N
A
 L
H
2b
/B
2M
Chapter 8 
146 
Figure 2. Synthetic LH2-siRNA induced short-term LH2b RNA interference. Subcutaneous fat-
derived fibroblasts were transfected with synthetic siRNA2 molecules (n = 2). To explore 
temporal effects of siRNA2 on LH2b mRNA expression, LH2b mRNA expression was measured 
at day 1, 2, 3, 7, 10, 14, 17, 21, and 24. Data are presented as mean ± sd.  
Results 
Transfection of fibroblasts with synthetic LH2-siRNAs 
As LH2b is responsible for the overhydroxylation of collagen telopeptides and the 
concomitant increased formation of hydroxyallysine cross-links in fibrosis, we searched 
for a way to specifically inhibit LH2b. SiRNA-mediated RNA interference appears a 
promising tool to specifically down-regulate LH2b mRNA expression. Therefore, 
subcutaneous fat-derived fibroblasts, expressing high levels of LH2b mRNA,(47) were 
transfected with 4 synthetic LH2-siRNA molecules (for target locations see Table 1). At 
48 hours after transfection LH2b mRNA expression was analyzed. All different LH2-
siRNAs, e.g. siRNA1, siRNA2, siRNA3 and siRNA4 strongly reduced LH2b mRNA 
expression and in all transfected fibroblasts LH2b mRNA expression was approximately 
25% of the level in untransfected cells (Figure 1A). Expression of LH2b mRNA 
expression relative to COL1A2 mRNA expression was also reduced in the LH2-siRNA 
transfected fibroblasts in comparison to untransfected cells (Figure 1B). This decrease 
could be ascribed to changes in LH2b mRNA expression and not to changes in COL1A2 
mRNA expression, as COL1A2 mRNA expression was not affected by the different 
siRNA molecules (Figure 1E). In fibroblasts LH2b is the dominant splice variant, whereas 
LH2a mRNA constitutes less than 5% of the LH2b expression level.(54) No obvious 
changes in the level of LH2a expression could be observed in LH2-siRNA transfected 
cells when compared to untransfected cells (data not shown). Moreover, LH1, LH3, and 
LOX mRNA expression were similar in LH2-siRNA tranfected cells and untransfected 
controls as well, showing the specificity of the siRNA approach (Figure 1C, 1D, and 1F, 
respectively).  
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To explore the temporal silencing effect of LH2-siRNA, subcutaneous fat-derived 
fibroblasts were transfected with siRNA2, and at day 1, 2, 3, 7, 10, 14, 17, 21, and 24 
after transfection, LH2b mRNA expression was analyzed. Figure 2 demonstrates that 
LH2b mRNA expression was dramatically reduced until day 3. After day 7 the reducing 
effect of siRNA2 on LH2b mRNA expression slowly disappeared and from day 17 
onwards LH2b expression levels were similar to the expression level measured directly 
after transfection (t = 0).  
Transfection of fibroblasts with an adenovirus expressing siRNA3 
To investigate the effects of LH2-siRNA on hydroxyallysine cross-linking, long-
term cell cultures (4 weeks) should be performed in order to obtain a sufficient collagen 
matrix for cross-link analysis. As synthetic LH2-siRNA molecules produce a short-term 
silencing effect, an adenoviral-mediated delivery system expressing siRNA3 sequences 
was constructed to obtain long-term silencing effects. Fibroblasts isolated from the 
fibrotic skin of systemic sclerosis patients, which express high levels of LH2b,(20) were 
transfected with adenovirus expressing siRNA3 (ad-siRNA3). As controls, fibroblasts 
were transfected either with an adenovirus without an insert (ad-Mock) or with a 
scrambled siRNA sequence (ad-siSCRAM). At day 3, 7, and 14, LH2b mRNA expression 
was analyzed in the transfected cells (Figure 3A). Moreover, LH1, LH3, COL1A2, and 
LOX mRNA levels were measured at the same time-points (Figure 3C, D, E, and F, 
respectively). Unfortunately, we were not able to investigate LH2b mRNA expression at 
later time-points than day 14, as the adenoviral transfection had dramatic effects on cell 
survival. At day 14, only 30% of the total cell population was still alive. Figure 3A 
demonstrates that ad-siRNA3 reduced LH2b mRNA expression to 30% of the level of 
untransfected cells. This effect was observed at all time-points. Ad-siSCRAM and ad-
Mock transfection did not result in a diminution of LH2b mRNA expression. In fact 
LH2b mRNA expression was dramatically elevated by ad-siSCRAM and an increase of 
around 300% of the level of untransfected cells was found at day 14. LH2b expression 
relative to COL1A2 expression was reduced by ad-siRNA3 as well (Figure 3B). Ad-
Mock and ad-siSCRAM also reduced LH2b/COL1A2 expression at day 3 and 7, whereas 
it elevated the expression at day 14 (Figure 3B). 
Ad-siRNA3 transfection did not show strong reducing effects on LH1, LH3, 
COL1A2, and LOX mRNA expression when compared to untransfected cells. SiSCRAM 
did not affect LH1 and LH3 expression, whereas it increased both COL1A2 and LOX 
expression. Fibroblasts transfected with ad-Mock did not show dramatic changes in LH1 
and COL1A2 mRNA expression. LH3 mRNA expression was increased by ad-Mock 
only at day 3 and LOX expression was upregulated by ad-Mock at all time-points.  
To explore the effect of siRNA-mediated LH2b interference on hydroxyallysine 
cross-linking, we cultured systemic sclerosis fibroblasts for two weeks in the absence or 
presence of ad-siRNA3, ad-siSCRAM, and ad-Mock. Unfortunately, due to massive cell 
death, the transfected cells did not produce a suitable amount of collagen and 
pyridinoline cross-link levels were below the detection limit.  
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Figure 3. LH2b mRNA expression is decreased during two weeks after transfection with LH2-
siRNA expressing adenoviruses. Fibroblasts obtained from the fibrotic skin of systemic sclerosis 
patients were transfected with ad-siRNA3, ad-siSCRAM, and ad-siMock (n = 1). At day 3, 7, 
and 14 after transfection LH2b mRNA (A), LH2b/COL1A2 (B), LH1 (C), LH3 (D), COL1A2 
(E), and LOX (F) mRNA expression was analyzed and expressed as percentage of 
untransfected cells. mRNA expression in untransfected cells was set at 100%. 
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Discussion 
Collagen accumulation in fibrotic lesions is the consequence of increased collagen 
synthesis and decreased proteinase activity. Moreover, the collagen deposited shows 
increased hydroxyallysine cross-link levels.(5-10) We reasoned that the deposition of 
hydroxyallysine cross-linked collagen contributes to the collagen accumulation as well, 
most likely by decreasing the susceptibility of the collagen molecules towards 
degradation.(11-14) Specific inhibition of hydroxyallysine cross-link formation is expected 
to result in less collagen accumulation as a consequence of collagen deposition that is 
more prone to collagen degradation. We therefore searched for a way to interfere with 
hydroxyallysine cross-link formation. 
LH2b appears a promising target to interfere with hydroxyallysine cross-linking 
during fibrotic processes, as increased LH2b mRNA expression is likely to be 
responsible for the overhydroxylation of collagen telopeptides and the concomitant 
increase in hydroxyallysine cross-link levels in fibrosis.(20;21) Here we show that 
fibroblasts transfected with synthetic LH2-siRNA molecules display a 75% reduction in 
LH2b mRNA expression levels. The effect of LH2-siRNAs turned out to be highly 
specific as mRNA expression levels of the other lysyl hydroxylase isoforms: LH1 and 
LH3 as well as the expression levels of COL1A2 and LOX were not affected by LH2-
siRNAs (the latter being an enzyme involved in aldehyde formation during cross-linking). 
Unfortunately, the silencing effect of the synthetic LH2-siRNAs appears to be short-
term, most likely because of the instability of the synthetic siRNA molecules. It can be 
ruled out that the disappearance of the silencing effect can be ascribed to dilution of the 
present intracellular siRNAs as a consequence of cell proliferation, since the fibroblasts 
were seeded in an extreme high density after transfection. Recently, it has been found 
that some chemical modifications in siRNA molecules increase the persistence of the 
activity of synthetic siRNA,(55;56) but it has never proved whether the effect of modified 
synthetic siRNA molecules persists for more than 5 days.  
Interestingly, the duration of LH2b interference mediated by LH2-siRNA could be 
extended using an adenoviral-mediated system with siRNA expression driven by the 
specific pU6 promoter. Two weeks after transfection with ad-siRNA3, LH2b mRNA 
expression was still reduced to 30% of the level of untransfected cells. Moreover, LH2b 
expression relative to COL1A2 was still decreased as well at this time-point. It should 
be noted, however, that ad-siSCRAM and ad-siMock, which served as negative controls, 
also reduced LH2b/COL1A2 mRNA expression, although this reduction was less 
evident. Unfortunately, the adenoviruses had dramatic effects on cell survival. At two 
weeks after transfection with either ad-siRNA3, ad-siSCRAM, or ad-Mock, only 30% of 
the total cell population was still alive. Therefore, we were not able to investigate the 
effect of siRNA-mediated LH2b RNA interference on hydroxyallysine cross-linking, 
since we need to culture cells for at least four weeks to obtain a sufficient amount of 
collagen to measure hydroxyallysine cross-link levels.  
To overcome the dramatic effect of the adenoviruses on cell survival, the 
adenoviral concentration could be decreased. However, an experiment, in which we 
examined different ad-siRNA3 concentrations on LH2b mRNA expression, 
demonstrated that lower ad-siRNA3 concentrations had a less reducing effect on LH2b 
expression (data not shown). Thus, by decreasing viral concentrations to diminish 
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negative effects on cell survival, the LH2-siRNA-mediated silencing effect on LH2b RNA 
disappears as well. Therefore, lower viral concentrations appear not very useful to 
perform long-term silencing effect in order to investigate the siRNA-mediated effects on 
hydroxyallysine cross-linking. 
In conclusion, siRNA mediated LH2b RNA interference appears to be a suitable 
approach to specifically reduce LH2b mRNA expression without interfering with 
expression of COL1A2 or with expression of other collagen modifying enzymes. 
Unfortunately, the methods we used to express siRNAs had several limitations and 
were not applicable in generating a long-term silencing effect. Therefore we could not 
investigate whether LH2b RNA interference by siRNA affected hydroxyallysine cross-
linking. As the effect of siRNA molecules on LH2b expression turned out to be very 
specific, siRNA based gene-silencing still remains very promising and it would be 
interesting to develop strategies to overcome the limitations we experienced with our 
approaches.  
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Hydroxyallysine cross-links play an important role in fibrosis 
Fibrotic disorders are widely prevalent, debilitating and often life-threatening. As 
there is currently no effective treatment available, the only alternative in the case of 
major organ failure may be organ replacement or transplantation. To discover and 
develop new treatment strategies, the mechanism behind the excessive collagen 
accumulation in fibrotic lesions has been studied extensively over the past decades, and 
several experimental drugs have now entered clinical trials.  
In general, anti-fibrotic interventions are either based on interfering with the 
chronic immune response or on restoring the balance between collagen synthesis and 
degradation by down-regulating collagen synthesis and up-regulating MMP activity. Less 
attention has been given to the altered cross-linking mode of the collagen deposited. In 
fibrotic lesions, a shift is seen towards the hydroxyallysine cross-link route at the 
expense of allysine cross-links,(1) which results in increased formation of the mature tri-
functional pyridinoline cross-links. This altered cross-link formation has consistently 
been found in various fibrotic tissues and organs, pointing to a general fibrotic 
phenomenon.(2-7) Interestingly, the presence of increased hydroxyallysine cross-link 
levels appears to be related to irreversible collagen accumulation, suggesting that 
collagen molecules containing this type of cross-link are more resistant towards collagen 
degradation. Our in vitro study, described in chapter 2, provides for the first time 
direct evidence that hydroxyallysine cross-links reduce the degradability of collagen 
molecules towards MMPs. Furthermore, we found that the absence of increased 
pyridinoline levels has a profound impact on the course of bleomycin-induced fibrotic 
processes in the skin of mice: the fibrosis turned out to be completely reversible. The 
relation that we found between hydroxyallysine cross-linking and the reversibility of the 
fibrotic process was in line with the findings by Ricard-Blum et al. in human skin fibrosis 
and in experimental liver fibrosis.(8-10) Our findings, together with the previous 
observations, provide evidence that irreversible collagen accumulation in fibrotic lesions 
is the consequence of the deposition of less degradable collagen molecules due to 
increased hydroxyallysine cross-linking. Specific inhibition of hydroxyallysine cross-
linking is therefore expected to result in less collagen accumulation, and it is thus 
worthwhile that anti-fibrotic interventions also pay attention to drugs that are able to 
interfere with this type of cross-linking.  
Compounds that specifically inhibit hydroxyallysine cross-link formation without 
interfering with allysine cross-link formation or with cross-linking of other extracellular 
proteins (such as elastin), have not been described so far. Therefore, we searched for a 
way to specifically reduce hydroxyallysine cross-link levels.  
Hydroxyallysine cross-links are derived from hydroxylated lysine residues within 
collagen telopeptides and increased formation of these cross-links in fibrosis is therefore 
the result of an overhydroxylation of telopeptide lysine residues. As the enzyme 
responsible for the conversion of telopeptide lysine into hydroxylysine is telopeptide 
lysyl hydroxylase, we assumed that the overhydroxylation of telopeptides is the 
consequence of increased telopeptide lysyl hydroxylase activity. Although the existence 
of a telopeptide lysyl hydroxylase has been postulated, the gene encoding such an 
enzyme has not been identified.  
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Bruck syndrome: the identification of LH2b as a telopeptide lysyl 
hydroxylase 
As early as 1974 it was postulated that telopeptide and helical lysyl hydroxylation 
are under separate enzymatic control.(11) In the years thereafter, this postulation was 
widely neglected, but some 20 years later it was confirmed by several other 
investigators.(12-15) The connective tissue disorder, Ehlers-Danlos syndrome type VI, is 
characterized by a deficiency in triple helical hydroxylysine levels but normal telopeptide 
hydroxylysine levels in association with mutations in LH1. This disease thus revealed 
that LH1 is a helical lysyl hydroxylase.(16;17) The identity of a telopeptide lysyl hydroxylase 
had at that time not been discovered and the substrate specificity towards lysine 
residues of the other identified lysyl hydroxylases isoforms, LH2 and LH3, remained 
obscure. The finding that the Bruck syndrome phenotype is associated with a near 
absence of telopeptide lysyl hydroxylation, but normal triple helical lysyl hydroxylation 
levels, demonstrates that these patients have defective telopeptide lysyl hydroxylase 
activity, but normal helical lysyl hydroxylase activity. This finding provided a major step 
forward in identifying the enzyme responsible for telopeptide lysyl hydroxylation.(18) 
Since the Bruck syndrome locus of one large Bruck syndrome family was situated on 
chromosome 17p12, we assumed that the gene encoding telopeptide lysyl hydroxylase is 
situated on chromosome 17p12. Unexpectedly, the Bruck syndrome locus of two other 
Bruck syndrome families was found to be situated on chromosome 3q23-q24, where 
PLOD2 is situated, and we showed that the biochemical defect in these patients is 
accompanied by mutations in PLOD2 (chapter 3). In four unrelated Bruck syndrome 
families, the Bruck syndrome phenotype is not the consequence of mutations in PLOD2, 
whereas the biochemical defect is highly similar to that of the patients with PLOD2 
mutations (chapter 3 and 4). Thus, Bruck syndrome appears to be a heterogeneous 
disease, and we classified patients without PLOD2 mutations as Bruck syndrome type I 
patients, and patients with PLOD2 mutations as Bruck syndrome type II patients. 
PLOD2 encodes two different splice variants LH2a and LH2b (LH2b contains an 
extra insert). LH2b is expressed in a wide variety of tissues and organs, including bone, 
cartilage and skin, whereas LH2a is only present in the frontal lobe, spleen, kidney, liver, 
and placenta.(19;20) The biochemical and genetic defect in Bruck syndrome type II patients 
revealed that LH2b serve important functions in telopeptide lysyl hydroxylation in bone. 
The telopeptide lysyl hydroxylase activity of LH2b was recently confirmed by others as 
well.(19;21) It appears that LH2a does not have telopeptide lysyl hydroxylase activity, as 
overexpression of LH2a does not induce pyridinoline cross-link formation in vitro.(21) The 
exact function of LH2a is not yet clear, and Bruck syndrome type II patients in which 
both LH2a and LH2b are affected, do not show severe problems in tissues where LH2a 
is expressed, suggesting that the function of LH2a, if any, can be taken over by other 
enzymes.  
LH2b mRNA expression is consistently increased in fibrotic 
conditions 
As we traced down the gene encoding telopeptide lysyl hydroxylase, the next step 
was to investigate whether myofibroblasts present in fibrotic lesions exhibit increased 
telopeptide lysyl hydroxylase (LH2) expression. Myofibroblasts are the cells that are 
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thought to be responsible for the unwanted collagen accumulation in fibrosis.(22;23) We 
indeed found that myofibroblasts obtained from various fibrotic lesions show increased 
mRNA expression of the splice variant LH2b which exceeds COL1A2 mRNA induction 
(chapter 3 and 5). The other splice variant LH2a was slightly increased in all fibrotic 
fibroblasts, but the expression was still very low, suggesting that this splice variant does 
not play a significant role in fibrotic conditions. The increased LH2b mRNA expression 
in the myofibroblasts was associated with increased formation of the mature 
hydroxyallysine-derived pyridinoline cross-link in the collagen matrix deposited by the 
same cells. Interestingly, mRNA expression of the other lysyl hydroxylase isoforms: 
LH1, LH3, as well as the expression of lysyl oxidase, catalyzing the formation of reactive 
aldehydes during cross-link formation, did not show a consistent increase in fibrotic 
cells. These results imply that only LH2b is responsible for the overhydroxylation of 
telopeptide lysine residues within fibrotic collagen, and as the LH2b upregulation is 
present in a wide variety of fibrotic disorders it represents a general fibrotic 
phenomenon. Unfortunately, we could only obtain expression data from cultured cells, 
but Brinckmann et al. showed a similar expression pattern to the one we found in 
fibrotic skin from systemic sclerosis patients, demonstrating the in vivo relevance of our 
findings (personal communication). 
The fibrotic process involves an inflammatory response, and cytokines and growth 
factors constitute a major class of mediators in this process. TGF-β is believed to be 
one of the major profibrotic cytokines and has been found to induce the deposition of 
extracellular matrix proteins, including collagen, and the production of tissue inhibitors 
of metalloproteinases (TIMPs). In contrast, this profibrotic cytokine reduces matrix 
metalloproteinase expression.(24) In chapter 6 we showed that TGF-β increases LH2b 
mRNA expression as well, and in contrast to LH1 and LH3, LH2b mRNA expression is 
far more induced by TGF-β than the mRNA expression of COL1A2, thus changing the 
proportion between LH2b and COL1A2 expression. The elevated LH2b/COL1A2 
mRNA levels were associated with an overhydroxylation of collagen telopeptides as 
shown by the increased pyridinoline cross-link levels. Moreover, similar stimulatory 
effects on LH2b mRNA levels and pyridinoline cross-linking of the collagen were found 
for other profibrotic cytokines, including IL-4, activin A, and TNF-α.  
In the context of our findings, it is of interest that other research groups have also 
shown very recently that profibrotic cytokines and/or other profibrotic conditions affect 
LH2 expression and hydroxyallysine cross-linking. For example, microarray analysis 
studies of lung fibroblasts stimulated with endothelin-1, assigned as profibrotic, showed 
a 2.5-fold increase in LH2 expression compared to unstimulated cells.(25) Moreover, a 
hypoxic environment, which favors the formation of collagen deposits and has significant 
pathophysiological impact on pulmonary and cardiac fibrosis, induces increased LH2 
expression levels as well.(26;27) Brinckmann et al. showed that fibroblasts stimulated with 
IL-4 deposit a collagen matrix with increased hydroxyallysine cross-link levels (personal 
communication). Thus our findings, together with the above-mentioned observations, 
reveal that a broad range of profibrotic cytokines/conditions induce LH2b expression 
and hydroxyallysine cross-link formation, again highlighting that upregulation of LH2b is 
an important general phenomenon in fibrotic processes.  
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The data described in chapters 3, 5, and 6 imply that LH2b is responsible for the 
overhydroxylation of collagen telopeptides in fibrotic collagen. Unfortunately, we did 
not obtain direct evidence for this as we were not able to investigate whether specific 
down-regulation of LH2b mRNA expression in myofibroblasts results in a reduction of 
hydroxyallysine cross-linking in the matrix deposited by these cells. But our findings are 
strengthened by recent data obtained by Pornprasertsuk et al., showing that in vitro 
overexpression of LH2b results in the deposition of collagen with increased 
hydroxyallysine cross-link levels.(19)  
Inhibition of LH2b to combat collagen accumulation in fibrosis 
Since LH2b expression appears to be responsible for increased formation of 
hydroxyallysine cross-links in fibrotic collagen, LH2b is a very interesting target for 
interfering with hydroxyallysine cross-linking in order to attenuate collagen 
accumulation in fibrosis. Specific LH2b inhibitors are unknown; therefore we searched 
for tools to specifically down-regulate LH2b activity/expression. Minoxidil seemed a very 
interesting tool, as this antihypertensive drug was found to reduce LH gene 
expression.(28-31) So far, no examination has been made of whether minoxidil acts on 
LH1, LH2a, LH2b, and/or LH3. If the inhibitory effect of minoxidil is more profound on 
LH2 gene expression than on LH1 and LH3, it might be suitable as an anti-fibrotic drug. 
Unfortunately, we found that the most pronounced inhibitory effect of minoxidil is on 
LH1 expression rather than on LH2a, LH2b or LH3 expression and in addition, it does 
not reduce hydroxyallysine cross-linking (chapter 7). Thus, minoxidil appears to be an 
inappropriate drug for interfering with LH2b activity in order to reduce hydroxyallysine 
cross-linking.  
Although minoxidil did not affect hydroxyallysine cross-linking, it strongly reduces 
triple helical hydroxylation, which was in line with the effects on LH1 expression. 
Interestingly, the effects of minoxidil show striking similarities to Ehlers-Danlos 
syndrome type VI, a disease characterized by defective triple helical lysine hydroxylation 
due to LH1 mutations.(32) The phenotypic characteristics of Ehlers-Danlos type VI skin, 
namely a soft and hyperextensible skin, demonstrates that strong reduction in triple 
helical hydroxylysine levels in skin collagen seems to induce the elasticity of the skin. As 
the collagen matrix deposited by minoxidil-treated skin fibroblasts shows many 
similarities to the collagen matrix deposited in Ehlers-Danlos type VI skin, we 
hypothesize that minoxidil may have similar effects on skin elasticity. The skin in 
systemic sclerosis patients lacks any elasticity, and the armoured skin throughout the 
body severely impairs the normal functioning of the limbs. Although minoxidil is an 
inappropriate drug to interfere with collagen accumulation in fibrosis, minoxidil might 
have beneficial effects in systemic sclerosis patients due to its possible elasticity-inducing 
effect on the skin.  
Instead of minoxidil, a very promising approach to interfering specifically with 
pyridinoline cross-linking is LH2b gene-silencing by using small interfering RNA (siRNA) 
molecules. In chapter 8 we demonstrate that specific siRNA molecules diminish LH2b 
mRNA expression without affecting the expression of other collagen-modifying 
enzymes. Unfortunately, the methods we used to express siRNAs had several limitations 
and were not applicable in generating a long-term silencing effect. Therefore, we could 
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not investigate whether LH2b RNA interference by siRNA affects hydroxyallysine cross-
linking. As the effect of siRNA molecules on LH2b expression is very specific, siRNA-
based gene-silencing appears very promising, and it would be interesting to develop 
other strategies to overcome the limitations we experienced with our approaches. For 
example, instead of using an adenoviral system to express siRNA molecules, as we did in 
our studies, a lentiviral system could be used. Preliminary data revealed that lentiviral-
mediated transfection of green fluorescence protein did not affect cell survival, and the 
transfected fibroblasts were expressing the green fluorescent protein for up to three 
weeks (unpublished data). The lentiviral system appears thus very promising to examine 
the effect of LH2-siRNA on hydroxyallysine cross-linking. 
Another tool for affecting LH2b mRNA expression specifically is the use of 
antisense molecules. Recently, Pornprasertsuk et al. has demonstrated that LH2b 
antisense molecules reduce in vitro LH2b mRNA expression without disturbing LH1 or 
LH3 expression. The specific diminution in LH2b mRNA expression has profound 
effects on hydroxyallysine cross-linking, as the levels of pyridinoline cross-links were 
strongly diminished.(19) Thus, siRNA- and antisense-induced LH2b gene-silencing seems 
very promising agents for reducing hydroxyallysine cross-linking in fibrosis. 
Advantage of LH2b inhibition in attenuating collagen accumulation in 
fibrosis 
Anti-fibrotic therapeutic interventions developed so far, interfere either with the 
chronic immune response or with collagen synthesis or with proteinase activity. A 
drawback of all these approaches is that they do not only tackle the fibrotic process but 
also interfere with normal healing. Additionally, such interventions will disrupt other 
physiological processes in the body. For example, TGF-β is involved in immuno- and 
tumor suppression in addition to its profibrotic actions.(33) Thus, suppressing TGF-β 
action might have deleterious consequences for the patients as such a treatment is used 
chronically in fibrotic disorders. Another example is reducing collagen synthesis: chronic 
inhibition of collagen synthesis affects also physiological collagen synthesis in the 
surrounding tissues, thus interfering with the strength, integrity and structure of the 
normal tissue. Chronic inhibition of collagen synthesis may therefore have harmful side-
effects. Interestingly, up-regulation of pyridinoline cross-link formation is specifically 
seen in fibrosis, and is not observed during normal wound healing. Thus, an advantage of 
our approach in comparison to other anti-fibrotic interventions to attenuate collagen 
accumulation is that it does not interfere with normal wound healing. Moreover, specific 
down-regulation of hydroxyallysine cross-links in order to attenuate skin fibrosis, such 
as systemic sclerosis, hypertrophic scarring or keloid, does not interfere with 
physiological cross-linking: in normal skin collagen cross-links are mainly derived from 
the allysine pathway with only very low hydroxyallysine cross-link levels.(32;34) But it 
should be noted that under physiological conditions hydroxyallysine cross-links are 
present in e.g. bone, cartilage, and tendon. The phenotype of patients with the common 
form of osteoporosis (i.e. postmenopausal osteoporosis), a disease in which 
hydroxyallysine cross-link levels are decreased in bone,(35-37) demonstrates that these 
cross-links serve important roles in bone. Systemic use of LH2b inhibitors for a 
prolonged time (>1 year) is expected to have harmful side effects. Therefore it is 
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preferable that LH2b inhibitors, when used for a prolonged time, will be specifically 
targeted to the affected tissue or organ in order to minimize possible side effects. 
Telopeptide lysyl hydroxylation is a complex process 
An interesting observation in Bruck syndrome is that these patients show a 
strongly reduced telopeptide lysyl hydroxylation in bone, whereas in cartilage and 
tendon hydroxyallysine cross-linking is not affected. This indicates that although 
telopeptide lysyl hydroxylase activity is disturbed in bone, in cartilage and tendon 
telopeptide lysyl hydroxylase activity is still present. Thus, it appears that LH2b is 
probably not responsible for telopeptide lysyl hydroxylation in cartilage and tendon. 
Since the whole human genome has been sequenced, it seems very unlikely that other 
lysyl hydroxylases showing sequence homology with LH1, LH2a, LH2b, and LH3 will 
turn up. An obvious explanation is that either LH1 or LH3 is responsible for telopeptide 
lysyl hydroxylase activity in these tissues. An in vitro study demonstrates that 
overexpression of rat LH1 in CHO-K1 cells induces pyridinoline cross-linking,(21) 
indicating that LH1 has in vitro telopeptide lysyl hydroxylase activity. However, total 
pyridinoline cross-link levels appears to be normal in tendons of Ehlers-Danlos 
syndrome type VI patients showing a complete lack of LH1 activity.(32) Moreover, 
although total hydroxyallysine cross-link levels in cartilage have never been compared in 
Ehlers-Danlos syndrome type VI and in healthy control cartilage, cross-links derived 
from the hydroxyallysine pathway are present in Ehlers-Danlos syndrome type VI 
cartilage, suggesting that telopeptide lysine residues are normally hydroxylated.(38;39) 
Thus, the observations in Ehlers-Danlos syndrome type VI do not support the in vivo 
telopeptide lysyl hydroxylase activity of LH1 in cartilage and tendon. Contradictory 
observations have been described with respect to the telopeptide lysyl hydroxylase 
activity of LH3. Peptides corresponding to N- and C-telopeptides are in vitro 
hydroxylated by LH3 as effectively as LH2,(40) whereas overexpression of LH3 in CHO-
K1 cells is associated with a pyridinoline cross-link level similar to that of untransfected 
cells, showing that LH3 overexpression does not influence telopeptide lysyl 
hydroxylation.(21) Very recently Rautavuoma et al. has been successful in generating LH3 
null mice.(41) It would be very interesting to analyze hydroxyallysine cross-linking in these 
mice in order to examine whether LH3 has in vivo telopeptide lysyl hydroxylase activity. 
The biochemical phenotype in Bruck syndrome type I patients is not accompanied 
by mutations in PLOD2. Interestingly, LH2b expression studies in osteoblasts and 
fibroblasts obtained from Bruck syndrome type I patients demonstrate that the reduced 
telopeptide lysyl hydroxylation in Bruck syndrome type I collagen is not the 
consequence of reduced transcription as well (chapter 4). Thus, the biochemical defect 
in Bruck syndrome type I patients can neither be ascribed to mutations in LH2b nor to a 
disturbed LH2b transcription. Since the biochemical phenotype is highly similar between 
Bruck syndrome type I and Bruck syndrome type II patients, we postulate that together 
with LH2b, a co-factor is involved in telopeptide lysyl hydroxylation in bone, and that 
the function of this co-factor is affected in Bruck syndrome type I patients. To gain more 
insight into the genetic defect in Bruck syndrome type I patients, it is of interest to 
further delimitate the BS locus on chromosome 17p12. This will ultimately elucidate 
additional processes involved in telopeptide lysyl hydroxylation in bone. Unfortunately, 
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several large BS families are required for such an approach, which is the limiting factor 
because of the extreme rarity of the disease.  
The presence of co-factors involved in telopeptide lysyl hydroxylase would also 
provide an explanation for the fact that mutations in LH2b have severe effects on 
hydroxyallysine cross-linking in bone but not in cartilage and tendon. It is possible that 
bone, cartilage and tendon have tissue specific co-factors involved in LH2b activity, and 
that the LH2b mutations we found in Bruck syndrome impairs the function of bone-
specific co-factors but does not interfere with the function of cartilage and tendon co-
factors.  
Conclusion 
This thesis describes the identification of the enzyme LH2b as the telopeptide lysyl 
hydroxylase that is specifically involved in hydroxyallysine cross-link formation in fibrotic 
processes. In addition to providing a step forward in elucidating the fibrotic process, this 
identification paves the way for the development of drugs aimed specifically at inhibiting 
hydroxyallysine cross-linking in order to combat collagen accumulation in a wide variety 
of fibrotic disorders. 
References
1. Brinckmann, J., Neess, C.M., Gaber, 
Y., Sobhi, H., Notbohm, H., 
Hunzelmann, N., Fietzek, P.P., Muller, 
P.K., Risteli, J., Gebker, R., 
Scharffetter-Kochanek, K. (2001) 
Different pattern of collagen cross-links in 
two sclerotic skin diseases: 
lipodermatosclerosis and circumscribed 
scleroderma. J. Invest. Dermatol. 117:269-
273. 
2.  Bailey, A.J., Bazin, S., Sims, T.J., Le 
Lous, M., Nicoletis, C., and Delaunay, 
A. (1975) Characterization of the collagen 
of human hypertrophic and normal scars. 
Biochim. Biophys. Acta. 405:412-421. 
3.  Di Donato, A., Ghiggeri, G.M., Di 
Duca, M., Jivotenko, E., Acinni, R., 
Campolo, J., Ginevri, F., and 
Gusmano, R. (1997) Lysyl oxidase 
expression and collagen cross-linking during 
chronic adriamycin nephropathy. Nephron 
76:192-200. 
4.  Gelberman, R.H., Amiel, D., Rudolph, 
R.M., and Vance, R.M. (1980) 
Dupuytren's contracture. An electron 
microscopic, biochemical, and clinical 
correlative study. J. Bone Joint Surg. Am. 
62:425-432. 
5.  Istok, R., Bely, M., Stancikova, M., and 
Rovensky, J. (2001) Evidence for increased 
pyridinoline concentration in fibrotic tissues 
in diffuse systemic sclerosis. Clin. Exp. 
Dermatol. 26:545-547. 
6.  Reiser, K.M. and Last, J.A. (1987) A 
molecular marker for fibrotic collagen in 
lungs of infants with respiratory distress 
syndrome. Biochem. Med. Metab. Biol. 37:16-
21. 
7.  Ricard-Blum, S., Bresson-Hadni, S., 
Vuitton, D.A., Ville, G., and Grimaud, 
J.A. (1992) Hydroxypyridinium collagen 
cross-links in human liver fibrosis: study of 
alveolar echinococcosis. Hepatology 15:599-
602. 
8.  Ricard-Blum, S., Ville, G., and 
Grimaud, J.A. (1992) Pyridinoline, a 
mature collagen cross-link, in fibrotic livers 
from Schistosoma mansoni-infected mice. 
Am. J. Trop. Med. Hyg. 47:816-820. 
9.  Ricard-Blum, S., Esterre, P., and 
Grimaud, J.A. (1993) Collagen cross-
linking by pyridinoline occurs in non-
reversible skin fibrosis. Cell. Mol. Biol. (Noisy-
le-grand) 39:723-727. 
10.  Ricard-Blum, S., Liance, M., Houin, R., 
Grimaud, J.A., and Vuitton, D.A. 
(1995) Covalent cross-linking of liver 
collagen by pyridinoline increases in the 
course of experimental alveolar 
echinococcosis. Parasite 2:113-118. 
Chapter 9 
164 
11.  Barnes, M.J., Constable, B.J., Morton, 
L.F., and Royce, P.M. (1974) Age-related 
variations in hydroxylation of lysine and 
proline in collagen. Biochem. J. 139:461-468. 
12.  Gerriets, J.E., Curwin, S.L., and Last, 
J.A. (1993) Tendon hypertrophy is 
associated with increased hydroxylation of 
nonhelical lysine residues at two specific 
cross-linking sites in type I collagen. J. Biol. 
Chem. 268:25553-25560. 
13.  Gerriets, J.E., Reiser, K.M., and Last, 
J.A. (1996) Lung collagen cross-links in rats 
with experimentally induced pulmonary 
fibrosis. Biochim. Biophys. Acta 1316:121-131. 
14.  Knott, L., Tarlton, J.F., and Bailey, A.J. 
(1997) Chemistry of collagen cross-linking: 
biochemical changes in collagen during the 
partial mineralization of turkey leg tendon. 
Biochem. J. 322:535-542. 
15.  Royce, P.M. and Barnes, M.J. (1985) 
Failure of highly purified lysyl hydroxylase 
to hydroxylate lysyl residues in the non-
helical regions of collagen. Biochem. J. 
230:475-480. 
16.  Steinmann, B., Eyre, D.R., and Shao, 
P. (1995) Urinary pyridinoline cross-links in 
Ehlers-Danlos syndrome type VI. Am. J. 
Hum. Genet. 57:1505-1508. 
17.  Yeowell, H.N. and Walker, L.C. (2000) 
Mutations in the lysyl hydroxylase 1 gene 
that result in enzyme deficiency and the 
clinical phenotype of Ehlers-Danlos 
syndrome type VI. Mol. Genet. Metab. 
71:212-224. 
18.  Bank, R.A., Robins, S.P., Wijmenga, 
C., Breslau-Siderius, L.J., Bardoel, 
A.F., Van Der Sluijs, H.A., Pruijs, H.E., 
and TeKoppele, J.M. (1999) Defective 
collagen crosslinking in bone, but not in 
ligament or cartilage, in Bruck syndrome: 
indications for a bone-specific telopeptide 
lysyl hydroxylase on chromosome 17. Proc. 
Natl. Acad. Sci. USA 96:1054-1058. 
19.  Pornprasertsuk, S., Duarte, W.R., 
Mochida, Y., and Yamauchi, M. (2004) 
Lysyl hydroxylase-2b directs collagen cross-
linking pathways in MC3T3-E1 cells. J. Bone 
Miner. Res. 19:1349-1355. 
20.  Yeowell, H.N. and Walker, L.C. (1999) 
Tissue specificity of a new splice form of 
the human lysyl hydroxylase 2 gene. Matrix 
Biol. 18:179-187. 
21.  Mercer, D.K., Nicol, P.F., Kimbembe, 
C., and Robins, S.P. (2003) Identification, 
expression, and tissue distribution of the 
three rat lysyl hydroxylase isoforms. 
Biochem. Biophys. Res. Commun. 307:803-
809. 
22.  Desmouliere, A. and Gabbiani, G. 
(1995) Myofibroblast differentiation during 
fibrosis. Exp. Nephrol. 3:134-139. 
23.  Gabbiani, G. (2003) The myofibroblast in 
wound healing and fibrocontractive 
diseases. J. Pathol. 200:500-503. 
24.  Branton, M.H. and Kopp, J.B. (1999) 
TGF-beta and fibrosis. Microbes Infect. 
1:1349-1365. 
25.  Shi-Wen, X., Chen, Y., Denton, C.P., 
Eastwood, M., Renzoni, E.A., Bou-
Gharios, G., Pearson, J.D., Dashwood, 
M., du Bois, R.M., Black, C.M., Leask, 
A., and Abraham, D.J. (2004) 
Endothelin-1 promotes myofibroblast 
induction through the ETA receptor via a 
rac/phosphoinositide 3-kinase/Akt-
dependent pathway and is essential for the 
enhanced contractile phenotype of fibrotic 
fibroblasts. Mol. Biol. Cell 15:2707-2719. 
26.  Hofbauer, K.H., Gess, B., Lohaus, C., 
Meyer, H.E., Katschinski, D., and 
Kurtz, A. (2003) Oxygen tension regulates 
the expression of a group of procollagen 
hydroxylases. Eur. J. Biochem. 270:4515-
4522. 
27.  Scheurer, S.B., Raybak, J.N., Rosli, C., 
Neri, D., and Elia, G. (2004) Modulation 
of gene expression by hypoxia in human 
umbilical cord vein endothelial cells: A 
transcriptomic and proteomic study. 
Proteomics. 4:1737-1760. 
28.  Murad, S., Walker, L.C., Tajima, S., 
and Pinnell, S.R. (1994) Minimum 
structural requirements for minoxidil 
inhibition of lysyl hydroxylase in cultured 
fibroblasts. Arch. Biochem. Biophys. 308:42-
47. 
29.  Hautala, T., Heikkinen, J., Kivirikko, 
K.I., and Myllyla, R. (1992) Minoxidil 
specifically decreases the expression of 
lysine hydroxylase in cultured human skin 
fibroblasts. Biochem. J. 283:51-54. 
30.  Murad, S., Tennant, M.C., and Pinnell, 
S.R. (1992) Structure-activity relationship 
of minoxidil analogs as inhibitors of lysyl 
Summary and general discussion 
165 
hydroxylase in cultured fibroblasts. Arch. 
Biochem. Biophys. 292:234-238. 
31.  Pinnell, S.R. and Murad, S. (1987) 
Effects of minoxidil on cultured human skin 
fibroblasts. Dermatologica 175 Suppl. 2:12-
18. 
32.  Pasquali, M., Still, M.J., Vales, T., 
Rosen, R.I., Evinger, J.D., Dembure, 
P.P., Longo, N., and Elsas, L.J. (1997) 
Abnormal formation of collagen cross-links 
in skin fibroblasts cultured from patients 
with Ehlers-Danlos syndrome type VI. Proc. 
Assoc. Am. Physicians 109:33-41. 
33.  Roberts, A.B. and Sporn, M.B. (1993) 
Physiological actions and clinical applications 
of transforming growth factor-beta (TGF-
beta). Growth Factors 8:1-9. 
34.  Eyre, D.R., Koob, T.J., and Van Ness, 
K.P. (1984) Quantitation of 
hydroxypyridinium crosslinks in collagen by 
high-performance liquid chromatography. 
Anal Biochem. 137:380-388. 
35.  Bailey, A.J., Wotton, S.F., Sims, T.J., 
and Thompson, P.W. (1992) Post-
translational modifications in the collagen of 
human osteoporotic femoral head. Biochem. 
Biophys. Res. Commun. 185:801-805. 
36.  Bailey, A.J., Wotton, S.F., Sims, T.J., 
and Thompson, P.W. (1993) 
Biochemical changes in the collagen of 
human osteoporotic bone matrix. 
Connect..Tissue Res. 29:119-132. 
37.  Oxlund, H., Mosekilde, L., and Ortoft, 
G. (1996) Reduced concentration of 
collagen reducible cross links in human 
trabecular bone with respect to age and 
osteoporosis. Bone 19:479-484. 
38.  Eyre, D., Shao, P., Weis, M.A., and 
Steinmann, B. (2002) The kyphoscoliotic 
type of Ehlers-Danlos syndrome (type VI): 
differential effects on the hydroxylation of 
lysine in collagens I and II revealed by 
analysis of cross-linked telopeptides from 
urine. Mol. Genet. Metab. 76:211-216. 
39.  Eyre, D.R. and Glimcher, M.J. (1972) 
Reducible crosslinks in hydroxylysine-
deficient collagens of a heritable disorder of 
connective tissue. Proc. Natl. Acad. Sci. USA 
69:2594-2598. 
40.  Takaluoma, K., Lantto, J., Kivirikko, 
K. I., and Myllyharju, J. (2004) Substrate 
specificity of lysyl hydroxylase isoenzymes.  
In: Programme and Abstracts, XIXth FECTS 
meeting 2004, pp. 66.   
41.  Rautavuoma, K., Takaluoma, K., 
Sormunen, R., Myllyharju, J., 
Kivirikko, K.I., and Soininen, R. (2004) 
Premature aggregation of type IV collagen 
and early lethality in lysyl hydroxylase 3 null 
mice. Proc..Natl. Acad. Sci. USA 101:14120-
14125 
 
  
 
 Appendix 
  
Samenvatting voor de geïnteresseerde leek 
169 
Samenvatting voor de geïnteresseerde leek 
Collageen 
Collageen is een eiwit dat waarschijnlijk iedereen kent van cosmetische 
behandelingen om ingevallen mondhoeken op te vullen en rimpeltjes weg te werken. Er 
zijn echter maar weinig mensen die weten dat ongeveer 30% van de totale eiwit massa 
in ons lichaam collageen is en dat het een zeer belangrijke functie in ons menselijk 
lichaam vervult. Elk weefsel is opgebouwd uit cellen met daaromheen collageen. Dit 
collageen vormt samen met verschillende andere eiwitten de extracellulaire matrix. De 
extracellulaire matrix kan je eigenlijk vergelijken met lijm, het zorgt ervoor dat de cellen 
bij elkaar blijven en dat het weefsel structuur en stevigheid heeft.  
Collageen is opgebouwd uit drie aparte strengen die als een helix opgerold zijn. 
Het deel van het collageen dat deze helix structuur heeft noemen we de triple helix. 
Aan elke kant van deze triple helix zitten rafelige uiteinden. Dit noemen we de 
telopeptiden (Figuur 1A). De bouwstenen van elke collageenstreng zijn aminozuren. 
Nadat het collageen in de cel geproduceerd is, wordt het uitgescheiden. Buiten de cel 
wordt het collageen geordend neergelegd in bundels (fibrillen). Om deze fibrillen 
stevigheid te bieden worden collageenmoleculen uiteindelijk onderling aan elkaar vast 
geknoopt door middel van een verbinding, een cross-link genaamd (Figuur 1B). Er 
bestaan verschillende soorten cross-links en het collageen in elk weefsel is verbonden 
door middel van een specifieke cross-link die precies past bij de structuur en functie van 
het weefsel. Bot bijvoorbeeld moet heel stevig zijn en heeft een hele andere structuur 
dan bijvoorbeeld huid die heel soepel is. Het collageen in deze weefsels is dan ook door 
middel van verschillende cross-links met elkaar verbonden.  
 
Figuur 1. Schematische weergave van een collageenmolecuul (A) en een collageenfibril (B), 
waarin de verschillende collageenmoleculen d.m.v. cross-links met elkaar verbonden zijn. 
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Collageen cross-links 
Zoals eerder vermeld is een cross-link een verbinding tussen meerdere 
collageenmoleculen. Deze verbindingen komen alleen op bepaalde plaatsen binnen het 
collageenmolecuul voor. Zo hebben de telopeptiden aan beide kanten ieder één plaats 
en de triple helix in totaal twee plaatsen die betrokken zijn bij een cross-link. Het hangt 
ervan af welk aminozuur zich er op deze specifieke plaatsen bevindt welke verbinding er 
uiteindelijk ontstaat. Er kunnen twee soorten verbindingen gevormd worden: de allysine 
cross-links en de hydroxyallysine cross-links. Welke van deze twee soorten gevormd 
wordt, is afhankelijk van het aminozuur op de verbindingsplaats in het telopeptide. 
Bevindt zich op deze plek het aminozuur lysine dan zal uiteindelijk een allysine cross-link 
gevormd worden. Is het aminozuur op deze plek een hydroxylysine dan zal er een 
hydroxyallysine cross-link gevormd worden. Als we weer kijken naar bot en huid dan 
zien we dat het collageen in bot met name door middel van hydroxyallysine cross-link 
verbonden is, terwijl in huid deze cross-links nauwelijks voorkomen en het collageen 
voornamelijk door middel van allysine cross-links verbonden is. De verandering van een 
lysine in het telopeptide in een hydroxylysine noemen we hydroxylering en is dus erg 
belangrijk voor de uiteindelijke vorming van het soort cross-links. Als dit niet goed 
gebeurt kan dat grote gevolgen hebben.  
Het Bruck syndroom is hier een goed voorbeeld van. Patiënten met dit syndroom 
hebben een verandering van het soort cross-links in het bot. Men heeft ontdekt dat het 
collageen in het bot van deze patiënten is verbonden door middel van allysine cross-links 
in plaats van hydroxyallysine cross-links zoals het collageen normaal in bot verbonden is. 
Dit is het gevolg van de afwezigheid van hydroxylysines op de verbindingsplaats in de 
collageen telopeptiden. Als we naar de symptomen van dit syndroom kijken zien we dat 
deze verandering in het type cross-link grote gevolgen heeft voor het bot van deze 
patiënten. Bruck syndroom patiënten breken heel snel hun botten. Als we naar de 
structuur van het botweefsel kijken zien we dat de hoeveelheid mineraal, dat in bot 
aanwezig is, sterk verminderd is. Verder zien we dat het botweefsel sneller afgebroken 
wordt dan normaal. Deze bevindingen laten dus zien dat voor de functie en structuur 
van het weefsel het erg belangrijk is dat het collageen op de juiste manier gecross-linkt 
wordt. 
Collageen cross-links in fibrose 
Een ander ziektebeeld, waarin een verandering in het type cross-link ontstaat, is 
fibrose. Fibrose is een algemeen pathologisch (ziekte) proces dat wordt 
gekarakteriseerd door een overmatige ophoping van collageen. Dit proces komt in vele 
weefsels en organen voor en is het eindstadium van vele ziekteprocessen zoals: 
brandwonden, keloid, systemische sclerodermie, en vele long-, lever- en nierziektes. De 
overmatige ophoping van collageen is het resultaat van een verschil tussen de aanmaak 
en afbraak van collageen. In verschillende fibrotische weefsels is een verhoogde aanmaak 
van collageen gevonden, terwijl de activiteit van enzymen die collageen kunnen afbreken 
sterk verlaagd is. Veel therapieën om fibrose aan te pakken richten zich dan ook op de 
verlaging van collageen aanmaak en de verhoging van de activiteit van collageen-
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afbrekende enzymen. Een interessant feit, dat weinig aandacht krijgt, is dat gedurende 
fibrose ook de collageen cross-link soort verandert. Gedurende fibrose ontstaat er een 
verschuiving van allysine naar hydroxyallysine cross-links wat leidt tot een verhoogde 
aanwezigheid van hydroxyallysine cross-links in het collageen. Als we bijvoorbeeld naar 
brandwonden kijken zien we dat het aanwezige collageen in dit weefsel meer 
hydroxyallysine cross-links bevat dan normale huid.  
Hypothese en doel van de studie 
Er zijn veel indirecte aanwijzingen dat collageen dat hydroxyallysine cross-links 
bevat, moeilijker afbreekbaar is door collageen-afbrekende enzymen dan collageen dat 
allysine cross-links bevat. We denken nu dat de verhoogde aanwezigheid van 
hydroxyallysine cross-links in fibrotische weefsels ertoe leidt dat het collageen 
moeilijker afbreekbaar is. Dit zou dan ook een oorzaak kunnen zijn waarom het 
collageen zich uiteindelijk ophoopt in deze weefsels. Direct bewijs hiervoor is echter 
nog nooit geleverd. De studie beschreven in hoofdstuk 2 van dit proefschrift laat zien 
dat collageen dat hydroxyallysine cross-links bevat inderdaad moeilijker afbreekbaar is 
dan collageen dat allysine cross-links bevat. Verder laat een muizenstudie zien dat het 
type cross-link (allysine of hydroxyallysine) de uitkomst van het fibrotisch proces 
beïnvloedt. Wanneer het collageen in fibrotische weefsels geen verhoogde 
hoeveelheden hydroxyallysine cross-links bevat, blijkt de collageen ophoping vanzelf 
weer te verdwijnen en dus omkeerbaar te zijn. Deze studie geeft aanwijzingen dat door 
de verhoogde aanwezigheid van hydroxyallysine cross-links het collageen inderdaad 
minder vatbaar voor afbraak is, wat uiteindelijk leidt tot de ongewenste ophoping van 
collageen in het weefsel. De onomkeerbare collageenophoping gedurende fibrose is dus 
niet alleen het gevolg van verhoogde collageenaanmaak en verlaagde activiteit van 
collageen-afbrekende enzymen, maar de verhoging in hydroxyallysine cross-links heeft 
hierop ook invloed. Therapieën om fibrose tegen te gaan moeten zich daarom niet 
alleen richten op de verlaging van collageenaanmaak en de verhoging van de activiteit van 
collageen-afbrekende enzymen, maar zal zich ook moeten richten op het verlagen van de 
vorming van hydroxyallysine cross-links om zo het collageen makkelijker afbreekbaar te 
maken.  
Methodes om de vorming van hydroxyallysine cross-link specifiek te remmen 
waren tot dusver nog niet beschreven, omdat het precieze mechanisme dat ten 
grondslag ligt aan de vorming van deze cross-link nog niet opgehelderd was. Het doel 
van de verdere studie van dit proefschrift was inzicht te krijgen hoe deze 
hydroxyallysine cross-links gevormd worden om zo een manier te vinden om de 
vorming van deze cross-links in fibrose specifiek aan te pakken. 
 De verschuiving van allysine naar hydroxyallysine cross-links in fibrose wordt 
veroorzaakt door een verhoogde hoeveelheid hydroxylysines in de telopeptiden. Dit 
betekent dus dat er meer lysines in de telopeptiden naar hydroxylysines omgezet zijn. 
Enzymen die ervoor zorgen dat een lysine naar hydroxylysine omgezet wordt zijn lysyl 
hydroxylases. Inmiddels zijn er drie verschillende lysyl hydroxylases beschreven namelijk 
lysyl hydroxylase 1 (LH1), LH2 en LH3. Van LH1 is bekend dat het specifiek de lysine 
residuen in de triple helix van het collageenmolecuul hydroxyleert. Van LH2 en LH3 was 
nog niets bekend. Tot dusver waren er veel aanwijzingen dat er een specifiek enzym 
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moest zijn dat juist alleen de lysine residuen in het telopeptide hydroxyleert maar of dat 
LH2 of LH3 is of juist een ander enzym, wist men nog niet. Omdat de verhoogde 
formatie van hydroxylysines in fibrotische weefsels waarschijnlijk het gevolg is van een 
verhoogde activiteit van een dergelijk telopeptide lysyl hydroxylase was het erg 
interessant om dit enzym te identificeren.  
Bruck syndroom: de identificatie van LH2 als telopeptide lysyl 
hydroxylase 
Zoals eerder gezegd bevat het collageen in bot van Bruck syndroom patiënten 
nauwelijks telopeptide hydroxylysines. Deze patiënten hebben dus een niet goed 
functionerend telopeptide lysyl hydroxylase in het bot. Omdat dit syndroom een 
erfelijke ziekte is zullen deze patiënten een fout in de genetische informatie (DNA) 
hebben dat beschrijft hoe dit enzym eruit moet zien. In hoofdstuk 3 wordt een studie 
beschreven waarin we het DNA van verschillende Bruck syndroom patiënten hebben 
bekeken. Het blijkt dat deze patiënten een fout hebben in het DNA dat beschrijft hoe 
het enzym LH2 eruit moet zien. Deze Bruck syndroom patiënten laten dus zien dat LH2 
een telopeptide lysyl hydroxylase is.  
Interessant is dat er Bruck patiënten zijn die geen fouten hebben in het DNA dat 
beschrijft hoe LH2 eruit moet zien. Deze patiënten zullen geen fouten hebben in de 
opbouw van het LH2 enzym. Toch hebben ze exact hetzelfde probleem als de patiënten 
die wel een fout in het DNA hebben: er kunnen geen telopeptide lysine residuen in het 
bot gehydroxyleerd worden. Het Bruck syndroom blijkt dus verschillende oorzaken te 
hebben. We noemen de patiënten die geen fouten in LH2 hebben Bruck syndroom type 
I en patiënten die wel fouten in LH2 hebben noemen we Bruck syndroom type II.  
Wat er precies mis is met Bruck syndroom type I patiënten blijft een raadsel. Het 
zou kunnen zijn dat in de cellen van deze patiënten veel minder of misschien wel 
helemaal geen LH2 enzym aanwezig is. Dit zou een oorzaak kunnen zijn voor de 
verminderde activiteit van dit enzym. In hoofdstuk 4 wordt een studie beschreven 
waarin we de aanwezigheid van LH2 bekijken in verschillende celtypen van Bruck 
syndroom type I patiënten en de hoeveelheden vergelijken met de hoeveelheden in 
cellen afkomstig van gezonde mensen. Het LH2 enzym komt als twee varianten voor, 
namelijk LH2a en LH2b. Deze varianten zijn bijna identiek aan elkaar. LH2b bevat een 
extra tussenstuk van 21 aminozuren. Beide worden door hetzelfde DNA beschreven. In 
de studies hebben we beide varianten gemeten. Om inzicht  te krijgen in de LH2a en 
LH2b enzym hoeveelheden kun je de hoeveelheden LH2a en LH2b enzym direct meten, 
maar je kunt ook de hoeveelheden voorloper van een enzym, het mRNA, meten. 
Omdat er nog geen methode bestond om LH2a en LH2b enzym hoeveelheden direct te 
meten hebben we in onze studies steeds LH2a en LH2b mRNA hoeveelheden gemeten. 
Onze experimenten lieten zien dat de hoeveelheden LH2a en LH2b in de patiënten 
cellen normaal zijn. Dus er moet een andere oorzaak zijn voor de verlaagde LH2 
activiteit in Bruck syndroom type I patiënten. We denken nu dat LH2 voor het goed 
functioneren nog een hulpfactor nodig heeft en dat Bruck syndroom type I patiënten 
deze hulpfactor missen. Verder onderzoek zal moeten uitwijzen wat deze factor is. 
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Aanwezigheid van LH2b in fibrose  
Toen we aanwijzingen hadden dat LH2 een telopeptide lysyl hydroxylase is, was 
het bijzonder interessant om te onderzoeken of in cellen die afkomstig zijn uit 
fibrotische weefsels dit LH2 enzym verhoogd aanwezig is. Het collageen dat zich in deze 
weefsels bevindt bevat immers meer hydroxylysines in de telopeptiden. Dit wijst op een 
verhoogde aanwezigheid van het telopeptide lysyl hydroxylase. En inderdaad de 
hoeveelheid LH2b mRNA is sterk verhoogd in cellen afkomstig uit fibrotische weefsels 
ten opzichte van cellen uit gezonde huid (hoofdstuk 5). LH2a is nauwelijks aanwezig in 
gezonde en fibrotische cellen. Deze variant van LH2 zal dus niet echt een belangrijke rol 
vervullen in fibrotische processen. Als we deze cellen in een kweekflesje collageen laten 
maken blijkt dat de fibrotische cellen collageen produceren dat een verhoogde 
hoeveelheid hydroxyallysine cross-links bevat en dus meer hydroxylysine residuen heeft 
in de telopeptiden. De gevonden resultaten wijzen erop dat een verhoogde 
aanwezigheid van LH2b verantwoordelijk is voor de verhoogde vorming van 
hydroxylysines en de daarop volgende verhoogde vorming van hydroxyallysine cross-
links. 
De volgende vraag was hoe het komt dat de LH2b mRNA hoeveelheden in 
fibrotische cellen zo verhoogd zijn. Het is bekend dat gedurende het fibrotische proces 
verschillende afweercellen vanuit het bloed zich naar het betreffende weefsel verplaatsen 
en daar verschillende stoffen uitscheiden. Omdat deze stoffen het fibrotisch proces 
versterken, worden ze profibrotische stoffen genoemd. Deze profibrotische stoffen 
zorgen ervoor dat de collageenaanmaak in het weefsel omhoog gaat en dat de activiteit 
van collageen-afbrekende enzymen verlaagd wordt. Of deze profibrotische stoffen de 
hoeveelheid LH2b en zo ook de vorming van hydroxyallysine cross-links kunnen 
verhogen was nog niet beschreven. Om dit te onderzoeken hebben we huidcellen voor 
een bepaalde tijd gekweekt in aan- en afwezigheid van verschillende profibrotische 
stoffen. Vervolgens hebben we gekeken naar de hoeveelheid LH2b mRNA in deze cellen 
(hoofdstuk 6). De LH2b mRNA hoeveelheid bleek inderdaad sterk verhoogd te zijn in 
cellen die behandeld zijn met profibrotische stoffen ten opzichte van onbehandelde 
cellen. Verder hebben we het collageen vergeleken dat geproduceerd werd door cellen 
gekweekt met en zonder profibrotische stoffen. Het bleek dat de profibrotische stoffen 
de formatie van hydroxyallysine cross-links ook verhogen. Deze experimenten laten zien 
dat gedurende het fibrotisch proces, profibrotische stoffen de hoeveelheid LH2b mRNA 
verhogen. Dit leidt tot meer hydroxylysines in het telopeptide en uiteindelijk tot een 
verhoogde vorming van hydroxyallysine cross-links. 
LH2b remmers 
Nu we verschillende aanwijzingen hebben verkregen dat gedurende fibrose een 
verhoogde aanwezigheid van LH2b verantwoordelijk is voor de toename in 
hydroxyallysine cross-links, was het laatste doel van dit proefschrift het zoeken naar 
manieren om de hoeveelheid LH2b enzym omlaag te brengen. Een verlaging van de 
hoeveelheid LH2b enzym zal leiden tot een verlaagde vorming van hydroxyallysine 
cross-links. Dat is immers wat we willen. Minoxidil, een bekend medicijn dat gebruikt 
wordt als bloeddruk verlager, leek een geschikte kandidaat. Van minoxidil was bekend 
dat het de hoeveelheid lysyl hydroxylases in het algemeen verlaagd. Er was echter nog 
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nooit gekeken welk lysyl hydroxylase (LH1, LH2 of LH3) wordt verlaagd. Als minoxidil 
een specifiek remmend effect heeft op LH2b dan zou het een geschikte kandidaat zijn 
voor de behandeling van fibrose. Het was daarom erg interessant om te achterhalen wat 
het effect van minoxidil op de verschillende lysyl hydroxylases is. Helaas was het 
remmend effect van minoxidil het sterkst op LH1 en in mindere maten op LH2b 
hoeveelheid (hoofdstuk 7). Verder was minoxidil ook niet in staat de vorming van 
hydroxyallysine cross-links te verlagen. Minoxidil is dus geen geschikt middel voor de 
behandeling van fibrose.  
Een andere manier om LH2b mRNA te verlagen is door middel van het gebruik 
van small interfering RNA moleculen (siRNA). siRNA moleculen zijn korte moleculen 
die een zeer specifieke opbouw hebben (opgebouwd uit dezelfde bouwstenen als het 
mRNA). Wanneer ze in de cel gebracht worden hechten ze aan een bepaald mRNA 
molecuul. Zodra dit siRNA molecuul is gebonden, vormt het siRNA met het mRNA en 
met een aantal andere eiwitten in de cel een complex. Uiteindelijk zal dit leiden tot de 
specifieke afbraak van het mRNA. Omdat het mRNA de voorloper van een eiwit is kan 
er op deze manier geen eiwit meer gemaakt worden. In ons geval zullen LH2b siRNA’s 
in de cel aan het LH2b mRNA binden wat ertoe leidt dat het LH2b mRNA afgebroken 
wordt. Uiteindelijk zal er geen LH2b enzym gemaakt worden wat uiteindelijk tot gevolg 
heeft dat er minder telopeptide lysine residuen gehydroxyleerd zullen worden. In 
hoofdstuk 8 van dit proefschrift beschrijven we een studie waarin we LH2b-siRNA’s 
hebben ontwikkeld. Deze studie laat zien dat LH2b-siRNA’s in staat zijn om het LH2b 
mRNA in de cel te verlagen. Helaas was dit effect van LH2b-siRNA maar van korte duur 
en zijn we tot op heden nog niet in staat geweest om de duur van dit effect te 
verlengen. Dit betekent dat we ook nog niet in staat zijn geweest om te bekijken wat 
het effect van LH2b-siRNA op de vorming van hydroxyallysine cross-links is. Om genoeg 
collageen te verkrijgen om cross-link metingen uit te voeren moeten de cellen vier 
weken gekweekt worden. Het effect van het LH2b-siRNA moet dan ook ook enkele 
weken aanhouden en dat hebben we tot dusver nog niet voor elkaar gekregen. Maar de 
resultaten van deze studie bieden wel perspectief voor de toekomst. 
Conclusie 
Dit proefschrift beschrijft de identificatie van het enzym LH2b als het telopeptide 
lysyl hydroxylase dat betrokken is bij de vorming van hydroxyallysine cross-links in 
fibrose. Deze studie heeft ons enerzijds een stap dichterbij gebracht in de ontrafeling 
van het fibrotisch proces. Anderzijds heeft het ons nieuwe inzichten gegeven in de 
ontwikkeling van medicijnen die de vorming van hydroxyallysine cross-links specifiek 
kunnen remmen om uiteindelijk de ongewilde collageenophoping in verschillende 
fibrotische ziektes tegen kunnen gaan.  
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List of abbreviations 
ACP adol condensation product  
α-SMA α-smooth muscle actin  
B2M β-2-microglobuline  
BMP-2 bone morphogenetic protein-2 
BS Bruck syndrome 
BSA bovine serum albumin 
COL1A2 collagen type I α2 
CTGF connective tissue growth factor 
deH-DHLNL dehydro-dihydroxylysinonorleucine 
deH-HHMD dehydro-histidinohydroxymerodesmosine 
deH-HLNL dehydro-hydroxylysinorleucine 
deH-LNL dehydrolysinonorleucine 
DHLNL dihydroxylysinonorleucine 
DMEM dulbecco’s modified Eagle’s medium 
EDS VI Ehlers-Danlos syndrome type VI  
ET-1 endothelin-1 
FACIT fibril-associated collagens 
FCS fetal calf serum 
GAPDH glyceraldehyde 3-phosphate dehydrogenase  
Gly glycine 
HHL histidinohydroxylysinonorleucine 
HHMD histidinohydroxymerodesmosine 
HLKNL hydroxylysino-5-keto-norleucine 
HLNL hydroxylysinorleucine 
HP hydroxylysylpyridinoline 
HPS hematoxylin-phloxine-saffron 
HSC  hepatic stellate cell 
HSP47 heat shock protein 47 
Hyl hydroxylysine 
Hylald hydroxyallysine 
Hyp hydroxyproline 
IGF insulin-like growth factor 
IL-4 interleukin-4 
LH lysyl hydroxylase 
LKNL lysino-5-keto-norleucine  
LNL lysinonorleucine 
LOX lysyl oxidase 
LP lysylpyridinoline 
Lys lysine 
Lysald allysine 
MMP matrix metalloproteinase 
OI osteogenesis imperfecta  
PBS phosphate buffered saline 
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PDGF platelet-derived growth factor 
P4HA1 prolyl 4-hydroxylase α1 
PLOD procollagen-lysine, 2-oxoglutarate 5-dioxygenase 
Pro proline 
RER rough endoplasmic reticulum 
RISC RNA-inducing silencing complex 
RP-HPLC reverse-phase high-performance liquid chromatography 
siRNA small interfering RNA 
SSc systemic sclerosis 
TGF-β transforming growth factor-β 
TIMP tissue inhibitor of metalloproteinases 
TLH telopeptide lysyl hydroxylase 
TNF-α tumor necrosis factor-α 
Tsk tight skin 
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Nawoord 
Dit onderdeel van mijn proefschrift wil ik graag gebruiken om mijn waardering en 
dank uit te spreken aan alle mensen die direct en indirect hebben meegeholpen aan dit 
proefschrift. Promoveren doe je tenslotte niet alleen! Allereerst de mensen van het 
“TLH-team”. Ik heb met veel plezier met jullie samengewerkt. Als ik jullie nodig had 
stonden jullie voor me klaar. We vormden de afgelopen 4 jaar een geweldig team. Nico 
en Frits, bedankt voor alle hulp die jullie me bij de HPLC hebben geboden. Ernst, 
bedankt voor alle kweekhulp. Hoeveel flesje het ook waren, het maakte je allemaal niet 
uit. Ik was er erg blij mee. Ik had hierdoor de mogelijkheid om nog meer experimenten 
te doen. Joline en Benno, dank voor alle hulp en gezellige kletspraatjes. Fijn dat jullie me 
ter zijde willen staan als paranimfen! Jeroen, Geesje, Marjan, Ilja, Yvonne, Elly, Maurice, 
Frans, Nicole en Dirk-Jan bedankt voor alle leerzame maar vooral ook gezellige 
momenten. De goede sfeer binnen de matrixbiologie groep zorgde ervoor dat ik altijd 
met plezier naar het lab kwam.  
Martine, bedankt voor alle gezellige “theekransjes” in de trein. Het maakte de lange 
reistijd een stuk aangenamer. Vrienden en vriendinnen, dank voor jullie steun en alle 
ontspannen momenten de afgelopen 4 jaar. Het zorgde ervoor dat ik het harde werken 
kon volhouden. Cor en Lidi, bedankt voor alle interesse die jullie altijd in me hebben en 
alle steun die jullie gaven tijdens het schrijven van dit proefschrift. Nanda en Pieter, dank 
voor alle wijze raad en de hulp bij het zoeken van mijn opleidingsplaats. Saskia, als geen 
ander begreep jij hoe het is om een proefschrift te schrijven. Dank voor alle tips maar 
vooral voor je luisterend oor. Pap en mam, dank voor alle steun. Fijn dat jullie er altijd 
voor me zijn.  
Als laatste lieve Martijn, een proefschrift schrijven doe je niet zonder hulp van 
anderen, maar doe je zeker niet zonder de steun van het thuisfront. Niet alleen je 
praktische hulp, maar vooral het vertrouwen dat je in me hebt en de onvoorwaardelijke 
steun en liefde die je me de afgelopen 10 jaar hebt gegeven, hebben er mede toe geleid 
dat ik sta waar ik nu sta! 
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